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ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. It is an
aggressive cancer, with 50-70% of patients diagnosed at an advanced stage and 30-50% of
patients not cured by chemoimmunotherapy. DLBCL is almost always caused by genetic damage
sustained during the germinal center (GC) reaction. The mechanisms that govern the GC reaction
bear a striking resemblance to those that drive DLBCL. Genomic studies have shown that some
of its most common mutations occur in genes that encode epigenetic modifiers, including the
lysine (histone) acetyltransferases CREBBP and p300. These mutations prevent the acetylation
of multiple histone residues, including H3K27Ac (activating) along the enhancers of genes
whose expression is required for essential functions like GC exit and differentiation. CBP/p300
mutations also prevent the acetylation of p53 (activating) and BCL6 (inhibiting). In light of
recent evidence that -3 fatty acids (-3 FA) can influence histone acetylation in cancer, we
tested the ability of the -3 FA docosahexaenoic acid (DHA) to restore levels of histone and p53
acetylation in three DLBCL cell lines (with different CREBBP/EP300 mutational statuses) and
one line of normal B-cells. After exposure to DHA at clinically attainable doses, we observed
significant changes in the genome-wide levels of histone post-translational modifications (PTMs)
(including acetylated residues H3K9Ac, H4K5Ac, H4K8Ac, H4K12Ac, H4K16Ac) in a cell-line
and dose-dependent manner. Histone acetylation did not uniformly increase as expected, but
levels of p53 acetylation did. We also observed significant changes in the expression of relevant
genes, such as increased expression of CREBBP and PRDM1; the latter is required for the
differentiation of GC B-cells into plasma cells or memory B-cells. Overall, we have performed
(to our knowledge) the first characterization of the epigenetic effects of -3 FA in DLBCL. Our
results highlight their therapeutic potential and emphasize the need for further investigation.
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CHAPTER 1
GENETIC AND EPIGENETIC DETERMINANTS OF DIFFUSE LARGE B-CELL
LYMPHOMA
This manuscript was published in Blood Cancer Journal.
Bakhshi, T. J., & Georgel, P. T. (2020). Genetic and epigenetic determinants of diffuse large Bcell lymphoma. Blood Cancer J, 10(12), 123. doi:10.1038/s41408-020-00389-w
Tanner J. Bakhshi1 & Philippe T. Georgel, Ph.D.1,2
1
2

Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25755, USA
Department of Biological Sciences, Cell Differentiation and Development Center, Byrd
Biotechnology Science Center, Marshall University, Huntington, WV 25755, USA

Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and is
notorious for its heterogeneity, aggressive nature, and the frequent development of resistance
and/or relapse after treatment with standard chemotherapy. To address these problems, a strong
emphasis has been placed on researching the molecular origins and mechanisms of DLBCL to
develop effective treatments. One of the major insights produced by such research is that
DLBCL almost always stems from genetic damage that occurs during the germinal center (GC)
reaction, which is required for the production of high-affinity antibodies. Indeed, there is
significant overlap between the mechanisms that govern the GC reaction and those that drive the
progression of DLBCL. A second important insight is that some of the most frequent genetic
mutations that occur in DLBCL are those related to chromatin and epigenetics, especially those
related to proteins that “write” histone post-translational modifications (PTMs). Mutation or
deletion of these epigenetic writers often renders cells unable to epigenetically “switch on”
critical gene sets that are required to exit the GC reaction, differentiate, repair DNA, and other
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essential cellular functions. Failure to activate these genes locks cells into a genotoxic state that
is conducive to oncogenesis and/or relapse.
Clinical Aspects of DLBCL
1. Definition and Epidemiology
Diffuse large B-cell lymphoma (DLBCL) is a hematological malignancy derived from
mature B-cells that have undergone (or continue to undergo) the germinal center (GC) reaction in
response to antigen and Helper T-cell stimulation. The name “DLBCL” stems from the fact that
it consists of large, neoplastic B-cells that are diffusely spread throughout lymph nodes and, in
some cases, extranodal tissues. The designation of DLBCL as a lymphoma means that it arises
from lymphoid rather myeloid cells and is a solid rather than a “liquid” malignancy (e.g.,
leukemia). Specifically, DLBCL is classified as a type of Non-Hodgkin’s lymphoma (NHL).
For context, in 2019, NHL is estimated to be the seventh-most common type of cancer in
the U.S., with an estimated 74,200 new cases that represent approximately 4.2% of all new
cancer cases (SEER 1, https://seer.cancer.gov/statfacts/html/all.html). Data recorded between
2012 and 2016 in the U.S. show that NHL has an incidence rate of 19.6 per 100,000 persons per
year and, in 2016, had an estimated prevalence of 694,704 patients (SEER 2,
https://seer.cancer.gov/statfacts/html/nhl.html). Specifically, DLBCL is the most common
subtype of NHL, accounting for 25-30% of NHL cases in the U.S. (Morton et al., 2006;
Swerdlow, International Agency for Research on Cancer., & World Health Organization., 2008;
Swerdlow, World Health Organization, & International Agency for Research on Cancer, 2017)
(UpToDate 1, https://www.uptodate.com/contents/epidemiology-clinical-manifestationspathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma), and is also the most
common type of lymphoma overall (Morton et al., 2006) (UpToDate 1,
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https://www.uptodate.com/contents/epidemiology-clinical-manifestations-pathologic-featuresand-diagnosis-of-diffuse-large-b-cell-lymphoma). Based on the same 2012-2016 U.S. dataset,
DLBCL has an incidence rate of 5.6 per 100,000 persons per year overall and is more common
in males (6.7 per 100,000 persons) than in females (4.6 per 100,000 persons) (SEER 3,
https://seer.cancer.gov/statfacts/html/dlbcl.html). While there is no consensus on what causes the
discrepancy between the incidence rates of DLBCL in males and females, there is evidence
suggesting that differences in sex hormones may be partially responsible. Results from multiple
studies indicate that pregnancy, live birth, and oral contraceptives are all associated with a
reduced risk of DLBCL in females. The mechanism by which these effects are achieved is also
unclear, although the direct and indirect effects of estrogen on multiple types of immune cells
have been proposed (Horesh & Horowitz, 2014). DLBCL can occur in people of all ages, but
cases are not evenly distributed amongst different age groups. The median age of diagnosis is 66
years old, with 25.0% of cases occurring between ages 65 and 74, 21.2% of cases between ages
55 and 64, and 20.1% cases between ages 75 and 84. The incidence rates of DLBCL in all other
age groups are lower (e.g., 12.3% of cases between ages 45 and 54 and 8.8% of cases over the
age of 84) (SEER 3, https://seer.cancer.gov/statfacts/html/dlbcl.html). DLBCL is also more
common in Hispanics (i.e., Latinos) and Whites than in Asian/Pacific Islanders, Blacks (i.e.,
African Americans), and Native Americans/Alaskan Natives (SEER 3,
https://seer.cancer.gov/statfacts/html/dlbcl.html). In addition to differences in incidence,
ethnicity can also sometimes be associated with differences in clinical outcome. For instance,
African-American DLBCL patients tend to be younger (mean age 54), are more likely to present
at an advanced stage, and have lower survival and higher mortality rates (Shenoy et al., 2011)
(UpToDate 1, https://www.uptodate.com/contents/epidemiology-clinical-manifestations-
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pathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma). Because epidemiological
data for DLBCL (i.e., not the broader classification of NHL) at the global level are scarce
(Stewart, Wild, International Agency for Research on Cancer, & World Health Organization,
2014), the data presented here are limited to the United States. The most comprehensive
epidemiological database available for DLBCL is the United States’ National Cancer Institute
(NCI) Surveillance, Epidemiology, and End Results (SEER) Program.
2. Clinical Presentation and Diagnostic Workup
Clinically, DLBCL often presents as a fast-growing symptomatic mass in the neck or
abdomen, which is typically indicative of an enlarged lymph node. It most commonly occurs as
an isolated event (de novo), but it can also transform from pre-existing lymphoid malignancies,
such as follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). About 30% of
patients also present with constitutional, or “B” symptoms (e.g., unexplained weight loss, fever,
and night sweats), and over 50% of patients show an increase in their serum level of lactate
dehydrogenase (LDH) (Armitage & Weisenburger, 1998; "A clinical evaluation of the
International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The NonHodgkin's Lymphoma Classification Project," 1997) (UpToDate 1,
https://www.uptodate.com/contents/epidemiology-clinical-manifestations-pathologic-featuresand-diagnosis-of-diffuse-large-b-cell-lymphoma). The typical evaluation of a patient exhibiting
symptoms of NHL includes a complete blood count (CBC) with differential, a comprehensive
metabolic panel (CMP) (including LDH and uric acid), tests for hepatitis B and human
immunodeficiency virus (HIV), the determination of cardiac ejection fraction, a positron
emission tomography with computed tomography (PET/CT) scan, a bone marrow biopsy
(depending on PET/CT results), and an excisional lymph node biopsy (UpToDate 2,
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https://www.uptodate.com/contents/evaluation-staging-and-response-assessment-of-nonhodgkin-lymphoma) (UpToDate 3, https://www.uptodate.com/contents/clinical-presentationand-diagnosis-of-non-hodgkin-lymphoma). The lymph node biopsy is crucial, because
morphological analysis and immunophenotyping of affected tissue(s) are required for accurate
diagnosis of DLBCL (UpToDate 1, https://www.uptodate.com/contents/epidemiology-clinicalmanifestations-pathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma).
Under the microscope, a lymph node that has been infiltrated by DLBCL usually exhibits a
complete loss of normal structures and compartments (e.g., cortex, medulla, and follicles) and

Figure 1. Comparison of normal and DLBCL-infiltrated lymph node histology
(Left) Normal lymph node after hematoxylin and eosin (H&E) staining. Note the complex and
varied architecture. Arrow on the left points to a germinal center within a follicle; both are in the
cortex (outer region). Arrowhead indicates the medulla (inner region). Bottom arrow shows the
hilum, where blood and efferent lymph vessels are connected. [Image Source:
https://www.pathpedia.com/education/eatlas/histology/lymph_node/images.aspx?6 (Slide 1)]
(Right) H&E staining of a lymph node that has been infiltrated by DLBCL. Note the glassy,
uniform surface and complete loss of normal structures. [Image Source:
https://www.webpathology.com/image.asp?case=822&n=3 (Slide 3)]
5

instead consists of diffuse sheets of neoplastic B-cells (Figure 1). Though extensive
morphological variation exists, the cells usually appear large and atypical, with enlarged nuclei,
prominent nucleoli, and have a proliferation fraction (Ki67+) of over 40%.
Immunohistochemistry (IHC) or flow cytometry should also show that the cells express standard
B-cell markers, including cluster of differentiation (CD)19, CD20, CD22, CD45, and
CD79a.Surface or cytoplasmic immunoglobulin [usually immunoglobulin M (IgM)] is expressed
in 50-75% of DLBCL tumors as well (Swerdlow et al., 2008; Swerdlow et al., 2017) (UpToDate
1, https://www.uptodate.com/contents/epidemiology-clinical-manifestations-pathologic-featuresand-diagnosis-of-diffuse-large-b-cell-lymphoma).
3. Staging and Subtyping
The results of a patient’s PET/CT scan are used to stage his/her DLBCL. Since DLBCL
is a type of NHL, staging is conducted according to the Lugano classification (Table 1), which
goes by the number and location of tumor sites (Cheson et al., 2014; Moormeier, Williams, &
Golomb, 1990) (UpToDate 2, https://www.uptodate.com/contents/evaluation-staging-andresponse-assessment-of-non-hodgkin-lymphoma). Stage I involves one lymph node region or
one extralymphatic site without lymph node involvement (Stage IE). Stage II involves two or
more lymph node regions on the same side of the diaphragm, either with (Stage IIE) or without
the localized involvement of an extralymphatic site. Together, Stages I and II constitute limitedstage disease. Stage III involves lymph nodes on both sides of the diaphragm. Stage IV requires
the diffuse involvement of one or more extralymphatic organ(s), with or without the involvement
of lymph nodes. Together, Stages III and IV constitute advanced-stage disease. (Cheson et al.,
2014; Moormeier et al., 1990) (UpToDate 2, https://www.uptodate.com/contents/evaluationstaging-and-response-assessment-of-non-hodgkin-lymphoma). The Lugano classification
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sometimes lacks clinical utility, in part because the staging system from which it was derived
(Ann Arbor) was initially designed for Hodgkin’s lymphoma (HL). Unlike HL, NHL tends to
spread more through the blood than through the lymphatic system, and most patients diagnosed
with aggressive NHL are already at Stage III or IV by the time that they present with symptoms

Table 1. The Lugano classification
This is the system that is used to stage NHLs, including DLBC, based on PET/CT scan results.
Clinical outcomes can be quite different for patients with limited-stage vs. advanced-stage
DLBCL. [Adapted from UpToDate 2 (Table 9) and (Cheson et al., 2014)]
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(50-70% of DLBCL patients, depending on the reference) (Anderson et al., 1982; Armitage &
Weisenburger, 1998; "A clinical evaluation of the International Lymphoma Study Group
classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification
Project," 1997; Rosenberg, 1977; Swerdlow et al., 2008; Swerdlow et al., 2017) (UpToDate 1,
https://www.uptodate.com/contents/epidemiology-clinical-manifestations-pathologic-featuresand-diagnosis-of-diffuse-large-b-cell-lymphoma).
It is now understood that DLBCL also encompasses a variety of subtypes that are
morphologically indistinguishable yet exhibit distinct gene expression profiles and patterns of
genetic and epigenetic aberrations. Though multiple subtyping schemes have been developed
(Caro et al., 2012; Chapuy et al., 2018; Monti et al., 2005; Schmitz et al., 2018), only the original
system published by Alizadeh et al. (Alizadeh et al., 2000) has been officially adopted by the
World Health Organization (WHO) (Swerdlow et al., 2008; Swerdlow et al., 2017). This system
uses information gathered from gene expression profiling (GEP) (Alizadeh et al., 2000), IHC
algorithms (Choi et al., 2009; Hans et al., 2004), or the Lymph2Cx gene expression assay (Scott
et al., 2014) to classify DLBCL into two main subtypes based on its probable cell of origin
(COO): germinal center B-cell (GCB) and activated B-cell (ABC) (UpToDate 4,
https://www.uptodate.com/contents/prognosis-of-diffuse-large-b-cell-lymphoma). A third, minor
subtype consists of cases that cannot be classified as either GCB or ABC. The GCB subtype
accounts for ~40% of de novo DLBCL cases, while the ABC subtype and other non-GCB
DLBCLs account for the other ~60% of de novo cases (Cunningham et al., 2013; Delarue et al.,
2013; Mareschal et al., 2011) (UpToDate 5, https://www.uptodate.com/contents/initialtreatment-of-advanced-stage-diffuse-large-b-cell-lymphoma). Clinically, in addition to COO
classification, DLBCL is also further stratified by the presence of BCL2 (B-cell CLL/lymphoma
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2), BCL6 (B-cell CLL/lymphoma 6), and MYC (Myelocytomatosis) chromosomal translocations
and/or expression, as determined by fluorescent in situ hybridization (FISH) or IHC,
respectively.
4. Standard Treatment and Clinical Outcomes
The standard treatment for DLBCL is the R-CHOP chemoimmunotherapy regimen
[Rituximab, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and
Prednisone]. Rituximab is a monoclonal antibody that binds the CD20 protein on the surface of
B-cells and triggers an innate immune reaction, leading to cellular toxicity (UpToDate 6,
https://www.uptodate.com/contents/rituximab-intravenous-including-biosimilars-of-rituximabdrug-information). Cyclophosphamide is an alkylating agent that cross-links the strands of DNA
and inhibits DNA replication (UpToDate 7,
https://www.uptodate.com/contents/cyclophosphamide-drug-information). Doxorubicin is an
intercalating agent that binds between DNA base pairs and inhibits DNA replication, DNA
repair, and transcription (UpToDate 8, https://www.uptodate.com/contents/doxorubicinconventional-drug-information). Vincristine is a tubulin-binding agent that inhibits the formation
of microtubules and the mitotic spindle, which prevents the completion of mitosis (UpToDate 9,
https://www.uptodate.com/contents/vincristine-conventional-drug-information). And, prednisone
is a corticosteroid (glucocorticoid) that acts as an immunosuppressant and anti-inflammatory
agent (UpToDate 10, https://www.uptodate.com/contents/prednisone-drug-information).
Historically, the CHOP regimen (even before the addition of rituximab) has been the treatment
of choice for DLBCL based on its performance in clinical trials (Coiffier et al., 2002; Coiffier et
al., 2010; Feugier et al., 2005). Other regimens to which CHOP was compared failed to
demonstrate an increase in overall survival (OS), disease-free survival (DFS), or remission rate
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(RR), and some [e.g., m-BACOD (methotrexate with leucovorin, bleomycin, cyclophosphamide,
vincristine, and dexamethasone) and MACOP-B (methotrexate with leucovorin, doxorubicin,
cyclophosphamide, vincristine, prednisone, and bleomycin) (Fisher et al., 1993)] were associated
with an increase in toxicity (Bartlett et al., 2001; Bjorkholm, Andersson, Ahlbom, & Osby, 2008;
Burton et al., 2005; Fisher et al., 1993; Gaynor et al., 2001; Sparano et al., 2002) (UpToDate 5,
https://www.uptodate.com/contents/initial-treatment-of-advanced-stage-diffuse-large-b-celllymphoma).
The specifics of R-CHOP therapy, as well as the extent to which patients respond, vary
depending on the stage and/or molecular subtype of DLBCL. For cases of limited-stage DLBCL
(30-40% of patients) (UpToDate 11, https://www.uptodate.com/contents/initial-treatment-oflimited-stage-diffuse-large-b-cell-lymphoma), molecular subtype can still be clinically relevant,
but it does not guide decisions related to treatment as much as it does for advanced-stage
DLBCL (UpToDate 11, https://www.uptodate.com/contents/initial-treatment-of-limited-stagediffuse-large-b-cell-lymphoma). Instead, an important decision regarding the treatment of
limited-stage DLBCL is whether to use R-CHOP alone or in combination with involved-field
radiation therapy (IFRT). National Comprehensive Cancer Network guidelines published in 2010
(Zelenetz et al., 2010) recommended treating limited-stage DLBCL with either three cycles of RCHOP and subsequent IFRT or six to eight cycles of R-CHOP (with or without subsequent
IFRT). This has been heavily debated due to concerns over potentially unnecessary radiationinduced toxicity. Administration of the former (3 cycles R-CHOP + IFRT) has been associated
with a 5-year OS rate of ~95%, (though individual patient outcomes can vary) (Ballonoff et al.,
2008), as well as lower acute hematologic and cardiac toxicity (UpToDate 11,
https://www.uptodate.com/contents/initial-treatment-of-limited-stage-diffuse-large-b-cell-

10

lymphoma). However, the latter (6-8 cycles R-CHOP – IFRT) is associated with a comparable
long-term survival rate and avoids the risk of long-term radiation toxicity (UpToDate 11,
https://www.uptodate.com/contents/initial-treatment-of-limited-stage-diffuse-large-b-celllymphoma). A recent clinical trial (Lamy et al., 2018) (UpToDate 11,
https://www.uptodate.com/contents/initial-treatment-of-limited-stage-diffuse-large-b-celllymphoma) directly compared the outcomes of R-CHOP (4-6 cycles) with or without subsequent
radiation therapy (RT) in limited-stage (Stage I or II) DLBCL patients. The group that received
RT had a 5-year OS rate of 96%, while the group that did not receive RT had a 5-year OS rate of
92% (i.e., no statistically significant difference between groups). The median time to relapse was
also the same for both groups, as well as cardiac and hematologic toxicity profiles, but three
patients in the RT group exhibited symptoms of radiation-induced toxicity. Therefore, the
authors of the study recommend withholding RT for limited-stage DLBCL patients who show a
complete response (CR) on PET scan after 4-6 cycles of R-CHOP (Lamy et al., 2018)
(UpToDate 11, https://www.uptodate.com/contents/initial-treatment-of-limited-stage-diffuselarge-b-cell-lymphoma). Overall, most patients diagnosed with limited-stage DLBCL have
favorable outcomes when treated with R-CHOP, with or without IFRT.
However, the same cannot always be said for patients diagnosed with advanced-stage
DLBCL (50%-70%, depending on the reference) (Swerdlow et al., 2008; Swerdlow et al., 2017)
(UpToDate 1, https://www.uptodate.com/contents/epidemiology-clinical-manifestationspathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma). There are likely multiple
reasons for this fact. First, advanced-stage DLBCL is disseminated throughout the body,
affecting multiple lymph node regions and/or organs. Second, advanced-stage DLBCL contains
greater genetic and epigenetic (i.e., changes in gene expression that occur without altering the
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actual DNA sequence) heterogeneity than does limited-stage DLBCL. Third, advanced-stage
disease tends to have a higher proportion of patients with ABC-type DLBCL, which is more
aggressive and associated with a worse prognosis than the GCB-type (Scott et al., 2015)
(UpToDate 4, https://www.uptodate.com/contents/prognosis-of-diffuse-large-b-cell-lymphoma).
This makes sense, given that the GCB subtype of DLBCL has instead been observed to be more
enriched in limited-stage disease (Lamy et al., 2018; Scott et al., 2015). And, fourth, the coexpression of MYC and BCL2 (two proto-oncogenes strongly associated with aggressive
lymphomas) is more likely in advanced-stage DLBCL and is independently associated with a
worse prognosis (Scott et al., 2015) (UpToDate 4, https://www.uptodate.com/contents/prognosisof-diffuse-large-b-cell-lymphoma). A study published in 2015 (Scott et al., 2015) (UpToDate 4,
https://www.uptodate.com/contents/prognosis-of-diffuse-large-b-cell-lymphoma) analyzed
biopsies from 344 de novo DLBCL patients (49% limited-stage and 51% advanced-stage) treated
with R-CHOP in order to determine molecular subtype and to assess subtype-specific clinical
outcomes. Limited-stage patients had a 5-year OS rate of 86% for the GCB subtype and 69% for
the ABC subtype, whereas advanced-stage patients’ 5-year OS rates were 74% for the GCB
subtype and 51% for the ABC subtype. Outcomes were also determined based on the coexpression of MYC and BCL2, although these were not stratified by stage. Patients who were not
MYC+/BCL2+ had a 5-year OS rate of 76% (81% for GCB and 62% for ABC), while those who
were MYC+/BCL2+ had a 5-year OS rate of 54% (64% for GCB and 51% for ABC). Taken
together, these findings emphasize the need for molecular subtyping of advanced-stage DLBCL
in order to predict its clinical outcome and choose the most appropriate treatment. Since the GCB
subtype of advanced-stage DLBCL has a relatively good prognosis (5-year OS of 74%) (Scott et
al., 2015) (UpToDate 4, https://www.uptodate.com/contents/prognosis-of-diffuse-large-b-cell-
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lymphoma), R-CHOP (6 cycles; 21 days between each cycle) is still its standard therapy
(UpToDate 5, https://www.uptodate.com/contents/initial-treatment-of-advanced-stage-diffuselarge-b-cell-lymphoma). However, due to the poor outcomes of ABC-type advanced-stage
DLBCL and DLBCLs that co-express MYC and BCL2 (without chromosomal translocations) in
response to R-CHOP, it is often recommended that these patients enroll in a clinical trial
(UpToDate 5, https://www.uptodate.com/contents/initial-treatment-of-advanced-stage-diffuselarge-b-cell-lymphoma).
Overall, while R-CHOP can achieve relatively effective 5-year OS rates in certain subsets
of DLBCL patients (e.g., limited-stage and GCB-type), ~30% of all patients either do not
respond or relapse within five years of treatment (Coiffier et al., 2002; Feugier et al., 2005), and
30-50% of all patients are not cured (Coiffier & Sarkozy, 2016; Coiffier et al., 2010).
Furthermore, while some components of this regimen do exhibit slight specificity (Rituximab
targets the B-cell marker CD20; Prednisone targets inflammatory pathways and immune cells),
even these still affect normal cells, and the regimen as a whole targets rapidly-dividing cells
indiscriminately. Consequently, recipients of R-CHOP often experience many of the side effects
for which chemotherapy is notorious (e.g., hair loss, vomiting, and immune suppression). RCHOP’s lack of specificity is even more problematic in light of DLBCL’s extensive genetic and
epigenetic heterogeneity. In general, as the heterogeneity of a cancer increases, the likelihood
that a given treatment will effectively treat all of its subclones decreases. These conditions can
result in a poor initial response to therapy and/or the selection of chemoresistant subclones that
lead to relapse.
Natural History and Molecular Pathogenesis of DLBCL
1. Normal B-cell Function
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To address the shortcomings of standard DLBCL therapy, researchers in the past couple
of decades have placed greater emphasis on understanding the natural history and molecular
pathogenesis of the disease. Because cancers are derived from normal cells, it would be difficult
to fully comprehend the etiology and behavior of DLBCL without first examining normal B-cells
and the principles that underlie their function. As the cornerstone of humoral immunity, naïve Bcells’ main objectives are to 1.) recognize antigens (from pathogens), 2.) produce B-cell
receptors (BCRs) with high affinity for antigens, and 3.) differentiate into either memory B-cells
(for faster response to future infections) or plasma cells, which actively secrete high-affinity
antibodies. Humoral immunity is essential for fighting infections and is also the biological
process that makes vaccination possible. A recent study of circulating B-cells in a cohort of ten
human subjects found that the human antibody repertoire may contain as many as 10 16-1018
unique heavy/light-chain combinations (Briney, Inderbitzin, Joyce, & Burton, 2019).
Theoretically, this staggering diversity should enable the body to respond to any foreign antigen
that it may encounter. However, B-cells cannot accomplish all of these objectives alone or in
their initial state. They must cooperate with dendritic cells and T-cells, progress through a
coordinated sequence of modifying events, and survive an intense selection environment, all of
which occur during a process known as the germinal center (GC) reaction.
2. The Germinal Center Reaction
The GC reaction (Figure 2) starts when a mature, naive B-cell encounters an antigen in a
secondary lymphoid tissue (e.g., lymph node). Although the BCR of this cell does recognize the
antigen, its baseline affinity for the antigen is low. The B-cell migrates to the edge of a lymphoid
follicle, where it presents a peptide from the antigen to CD4+ T-cells via major
histocompatibility complex II (MHC II). This step is selective, as B-cells with higher baseline
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affinity for antigen than their competitors are preferentially bound by T-cells. After receiving Tcell stimulation, the B-cell starts proliferating and, then, relocates to the center of the follicle,
where it seeds the formation of the GC. Once it has matured, the GC contains two distinct
compartments: the dark zone (DZ) and the light zone (LZ). The DZ consists of highly

Figure 2. The germinal center (GC) reaction
The GC reaction is the foundation of humoral immunity. Its end products are memory B-cells
and plasma cells that encode high-affinity antibodies. However, it also is the source of many
types of B-cell lymphoma, including DLBCL. The time-lapse panels at the top of this figure
depict the sequential steps of the GC reaction, which take place within lymph node follicles. The
large panel at the bottom zooms in to show the mechanisms behind, and outcomes of, the
selection of GC B-cells by TFH cells in the light zone of the germinal center. [Figure Source:
(Victora, 2014). See this reference for a detailed review.]
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proliferative B-cells called centroblasts that divide once every 6-12 hours (Pasqualucci, 2019)
and undergo random somatic hypermutation (SHM) of the genes encoding the variable regions
of immunoglobulins (IgVs). After dividing 1-6 times (Mlynarczyk, Fontan, & Melnick, 2019),
centroblasts can transition to the LZ, where the affinity of their newly-modified BCR for antigen
is tested. The LZ consists of non-replicative B-cells (centrocytes), follicular dendritic cells
(FDCs), and T follicular helper (T FH) cells. A centrocyte first receives some of the antigen from
an FDC, whose tendril-like appendages serve as an antigen reservoir. Once the centrocyte
processes the antigen, it presents MHC II loaded with peptide to T FH cells. TFH cells are limited
in number, which forces centrocytes to compete with one another. Centrocytes have three
potential paths, and each cell’s outcome is entirely dependent upon the affinity of its BCR for
antigen(s). The “default setting” of a centrocyte is to undergo apoptosis in the absence of
sufficient T-cell signal (i.e., low affinity). Thus, only centrocytes whose BCRs have high affinity
for antigen are positively selected by TFH cells. Cells that are positively selected then undergo
class switch recombination (CSR) to switch from the default IgM isotype to IgG, IgA, or IgE
(depending on context), followed by differentiation into memory B-cells or plasma cells.
However, 10-30% of centroctyes (Victora, 2014) have BCRs with intermediate affinity for
antigen, which is enough to interact with T FH cells and avoid apoptosis but not enough for true
positive selection. These cells are instead sent back to the DZ for subsequent cell divisions and
SHM, and they will later be given another opportunity for positive selection in the LZ. [The
above information was adapted from (Basso & Dalla-Favera, 2015; Mlynarczyk et al., 2019;
Pasqualucci, 2019; Victora, 2014). Refer to these for a more detailed discussion of the topic.]
The GC reaction owes much of its “design” to the principles of biological evolution, as it
marries genetic combinatorics (baseline antibody diversity + SHM) with a natural (and clonal)
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selection environment (positive selection by T FH cells) to find the cells that respond best to a
selective pressure (possess BCRs with the highest affinity for an antigen). This strategy also
resembles combinatorial optimization, a process used in mathematics and computer science to
find the optimal solution to a specific problem from a finite number of potential solutions.
Though the number of potential unique antibodies is technically finite, it is so large that it likely
would not be feasible to systematically test all of them. As a compromise, different antibodies
are modified and tested at random until one (or more) is found that binds a specific antigen with
sufficiently high affinity. This mirrors the logic of evolution, by which “survival of the fittest”
does not necessarily guarantee the greatest of all possible fits, but rather one that sufficiently
overcomes a selective pressure and outperforms its competitors. If applied in the appropriate
context and with strict guidelines, these principles can be quite effective for performing a normal
biological function like the GC reaction.
However, as those in the field of cancer biology have known for decades, cancer is also
driven by evolutionary principles and follows a pattern of clonal selection and evolution
(Nowell, 1976). Viewed from this perspective, it is not difficult to imagine how a system that
intentionally recreates a Darwinian microenvironment could 1.) cause or promote oncogenic
events, even under “normal” conditions or 2.) become pathologically dysregulated and
repurposed as a sort of “operating system” for cancer cells. Furthermore, the physiological
mechanisms that the GC reaction requires to function are inherently risky. The transformation
from GC B-cells to DLBCL cells often involves the removal of negative feedback and temporal
restrictions on normal, essential pathways, without any functional alteration of the protein(s)
involved. In other words, simply upregulating the core mechanisms of the GC reaction and/or
increasing their duration can sometimes be enough to initiate oncogenesis (as shown in
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experiments; discussed later). Along these lines, multiple researchers (Hatzi & Melnick, 2014;
Mlynarczyk et al., 2019) have highlighted the fact that B-cells undergoing the GC reaction
naturally exhibit multiple characteristics that resemble the hallmarks of cancer (Hanahan &
Weinberg, 2011).
3. AID and the GC Reaction
The GC reaction is complex and multifaceted, but there are two components in particular
that can explain a great deal about its physiology, the risks inherent to its strategy, and its
sometimes-oncogenic side effects. The first component is activation induced deaminase (AID),
an enzyme that deaminates cytosine residues at specific sites throughout the genome. AID is
required for both SHM and CSR (Muramatsu et al., 2000), which are required for making highaffinity and class-switched antibodies, respectively. This deamination converts cytosines to
uracils, which result in U:G mismatches that trigger DNA repair via the mismatch repair (MMR)
or base excision repair (BER) pathways. For some genes, especially those that encode IgVs,
DNA repair involves an error-prone DNA polymerase (Pol ). This increases the rate of
mutations, insertions, and deletions that fuel SHM and the DNA double-stranded breaks (referred
to as DNA-DSBs) that are required for CSR (although DNA-DSBs can occur during SHM as
well). Perhaps not surprisingly, a mechanism that intentionally causes DNA damage can have
serious side effects, and most B-cell lymphomas can be traced back to cells that come from the
GC and/or have gone through the GC reaction (Kuppers, 2005). The side effects of the GC
reaction primarily include chromosomal translocations and oncogenic mutations. Translocations
(e.g., MYC, BCL2, and BCL6) are quite common in B-cell lymphomas and NHLs in general.
They usually involve the intact coding region of a proto-oncogene being placed under the control
of an immunoglobulin gene regulatory sequence (e.g., enhancer), resulting in constitutive
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expression. While AID is suspected to increase the likelihood of DNA-DSBs and translocations
for multiple genes, it has been most firmly linked to MYC translocations. In a set of in vivo
experiments, Pasqualucci et al. showed that mice engineered to overexpress BCL6 (master
regulator of GCs; see section titled “BCL6 and the GC Reaction”) but which had a knockout of
the gene that encodes AID (AICDA, activation-induced cytidine deaminase) were incapable of
producing MYC-IGH translocations when stimulated to undergo CSR. On the contrary, mice
overexpressing BCL6 and normally expressing AICDA showed an increase in the number of
MYC-IGH translocations of over tenfold when compared with wild-type mice. Furthermore, only
~14% (1/7) of tumors in BCL6-overexpressing/AICDA-knockout mice (tumor incidence = 7/29,
or ~24%) possessed features of DLBCL, compared to ~69% (11/16) of tumors in BCL6overexpressing/AICDA-normal mice (tumor incidence = 16/27, or ~59%) (Pasqualucci et al.,
2008).
As was mentioned previously, SHM of genes encoding IgVs is required for the
generation of high-affinity antibodies. During SHM, the mutation rate at IgV loci is
approximately 106 times higher than the spontaneous mutation rate observed in somatic cells
(Odegard & Schatz, 2006). The B-cells that survive SHM and selection during the GC reaction
benefit from affinity maturation. Each IgV locus obtains approximately nine mutations, and the
affinity of their antibodies increase by about 100-fold (J. Zhang & Shakhnovich, 2010). It has
been known for quite some time that the AID-mediated process of SHM does not always stay
within the confines of IgV loci. This pathological “mistargeting” of SHM is called aberrant SHM
(aSHM). aSHM does not occur in normal GC B-cells and is unique to GC-derived B-cell
lymphomas, especially DLBCL, of which over 50% of cases show evidence of aSHM in multiple
proto-oncogenes (Pasqualucci et al., 2001). It is still not entirely clear how aSHM occurs. An
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interesting study by Liu et al. found that AID actually targets a variety of genes located
throughout the genome in normal GC B-cells, many of which are not IgV loci. While a few of
these genes (e.g., IgVs) are hypermutated due to DNA “repair” with an error-prone DNA
polymerase, many other genes receive high-fidelity repair and are left without a trace of AID
activity. This led Liu et al. to propose that aSHM may be due to a breakdown in the high-fidelity
repair of genes that would otherwise be “protected” under normal circumstances (M. Liu et al.,
2008). Since then, knowledge of the genes that are targeted by AID and/or aSHM has continued
to expand (Alvarez-Prado et al., 2018; Khodabakhshi et al., 2012).
One particular gene that has been studied extensively with regard to both SHM and
aSHM is BCL6 (see above in this section and below in section titled “BCL6 and the GC
Reaction”) (Migliazza et al., 1995; Pasqualucci et al., 1998; Peng et al., 1999; Shen, Peters,
Baron, Zhu, & Storb, 1998). For reasons that are not readily apparent, BCL6 is the most common
non-IgV target of SHM (Khodabakhshi et al., 2012; M. Liu et al., 2008), with 59-73% of
DLBCL cases (Migliazza et al., 1995; Pasqualucci et al., 1998) and even ~30% of normal GC Bcells (Pasqualucci et al., 1998) showing evidence of SHM in the 5’ noncoding region. Liu et al.
showed that, unlike most of the other non-IgV targets of SHM, BCL6 seems to receive the same
error-prone DNA repair as IgV loci. The mutation rate of BCL6 in wild-type B-cells is almost as
high its mutation rate in cells with knockouts of key genes involved in MMR and BER (M. Liu
et al., 2008). Mutations in the 5’ noncoding region can cause the deregulated expression of
BCL6; for instance, in ~13% of DLBCL cases, such mutations interfere with the ability of BCL6
to negatively regulate its own expression (Pasqualucci et al., 2003). Another ~40% of DLBCL
cases involve chromosomal translocations that lead to upregulated BCL6 expression, with
breakpoints typically located in the same 5’ noncoding region (Lo Coco et al., 1994; Ye et al.,
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1993) (UpToDate 12, https://www.uptodate.com/contents/pathobiology-of-diffuse-large-b-celllymphoma-and-primary-mediastinal-large-b-cell-lymphoma). Lastly, the expression and/or
activity of BCL6 can also be indirectly upregulated as a result of mutations in other genes such as
MEF2B (myocyte enhancer factor 2B) and FBXO11 (F-box only protein 11). Regardless of the
specific mechanism by which it occurs, the deregulation of BCL6 expression is very common in
DLBCL.
4. BCL6 and the GC Reaction
Similarly to AID, the actions of BCL6 are strongly associated with both the GC reaction
and the oncogenic transformation of GC B-cells. BCL6 is highly expressed in GC B-cells and is
often referred to as the master regulator of the GC reaction. Results from multiple studies have
shown that the expression of BCL6 is required for GC formation and antibody affinity
maturation (Fukuda et al., 1997; Ye et al., 1997). BCL6 is a transcriptional repressor whose
function is to reduce or prevent the expression of genes whose encoded products would
otherwise interfere with the GC reaction (Figure 3). Recall that GC B-cells must be able to
tolerate an enormous amount of DNA damage in order for the processes of SHM and CSR to
work, despite the fact that cells are ordinarily on high alert for signs of DNA damage. In GC Bcells, this conflict between preserving genomic integrity and creating high-affinity, classswitched antibodies is mediated in large part by BCL6. BCL6 accomplishes this by repressing
the transcription of TP53 (tumor protein 53), ATM (ataxia telangiectasia mutated), ATR (ataxia
telangiectasia and Rad3 related), CHEK1 (checkpoint kinase 1), and CDKN1A (cyclin-dependent
kinase inhibitor 1A, or p21), all of which are critical for signaling and triggering a response to
DNA damage, including stopping the cell cycle, initiating high-fidelity DNA repair, and/or
inducing apoptosis. BCL6 also represses genes involved in other essential aspects of the GC
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reaction. These include PRDM1 (PR/SET domain 1), which is required for the terminal
differentiation of GC B-cells into memory B-cells or plasma cells, and the genes encoding
microRNAs (miRs) miR-155 and miR-361, which negatively regulate the expression of AICDA.
Thus, BCL6 and AID can positively regulate each other. [For a thorough review of BCL6’s
functions, mechanisms, and targets, see Hatzi and Melnick’s review (Hatzi & Melnick, 2014)].
It is not hard to imagine how a system that 1.) increases cells’ tolerance of DNA damage,
2.) permits rapid progression through the cell cycle, and 3.) prevents terminal differentiation,
could be compromised and repurposed as a powerful survival mechanism for cancer cells. Using
a mouse model engineered to constitutively express BCL6, Cattoretti et al. found evidence in
support of BCL6’s role in the pathogenesis of DLBCL (Cattoretti, Pasqualucci, et al., 2005).
Compared to wild type mice, BCL6-overexpressing mice had a significantly greater number of
germinal centers in splenic tissue after immunization and produced ~30% fewer plasmacytoid
cells (mostly post-CSR plasma cells), indicating altered post-GC differentiation. By 6 months of
age, 42% of the BCL6-overexpressing mice developed a benign lymphoproliferative disease,
compared to 11% in wild-type mice. At 13 months of age, the BCL6-overexpressing mice started
to exhibit increased mortality. Between 15-20 months of age, 36-62% of BCL6-overexpressing
mice had developed B-cell lymphoma (compared to 2-8% in wild-type mice), and 75% of these
cases resembled DLBCL. Overall, by 20 months of age, 76-89% of BCL6-overexpressing mice
had either lymphoproliferative disease or lymphoma (compared to 8-14% in wild-type mice), as
well as a significant decrease in survival (Cattoretti, Pasqualucci, et al., 2005).
It is striking that this same protein can be both required for the GC reaction and a driver
of GC-derived lymphoma, simply by deregulating its expression without any functional
alteration. It seems that this system has evolved with an “awareness” of the oncogenic potential
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of BCL6, as it is normally restrained by multiple regulatory mechanisms. BCL6 can inhibit its
own expression via negative feedback (see section titled “AID and the GC Reaction”), and it is
also downregulated and targeted for degradation by multiple signaling pathways in response to
high-affinity BCR-antigen binding and positive selection by TFH cells (Basso & Dalla-Favera,
2015; Niu, Ye, & Dalla-Favera, 1998; M. Saito et al., 2007). The expression of BCL6 must be
shut off and is not normally expressed in post-GC cells, because one of its main targets, PRDM1,

Figure 3. Functional interactions between proteins relevant to GC B-cell and DLBCL
physiology
BCOR BCL6 corepressor; FBXO11 F-box only protein 11; BCL2 B-cell CLL/lymphoma 2;
TP53 Tumor protein 53; CDKN1A Cyclin-dependent kinase inhibitor 1A; CDKN1B Cyclindependent kinase inhibitor 1B; MEF2B Myocyte enhancer factor 2B; BCL6 B-cell
CLL/lymphoma 6; PRDM1 PR/SET domain 1; MYC Myelocytomatosis; ATM Ataxia
telangiectasia mutated; ATR Ataxia telangiectasia and Rad3-related protein; CHEK1
Checkpoint kinase 1; MDM2 Murine double minute 2; IRF4 Interferon regulatory factor 4;
AICDA Activation-induced cytidine deaminase. [Figure Source: Philippe Georgel; STRING
Protein-Protein Interactions Network (https://string-db.org)]
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is required for GC exit and differentiation. Interestingly, BCL6 also represses the transcription of
a number of proto-oncogenes, including MYC and BCL2 (Ci et al., 2009). MYC is critical for
cyclic reentry of light-zone centrocytes back into the dark zone for further replication and SHM.
BCL2 is an anti-apoptotic factor that further increases the threshold for programmed cell death.
In their review of BCL6, Hatzi and Melnick propose that the repression of MYC and BCL2 by
BCL6 may be an attempt to compensate for its repression of tumor suppressor genes (Hatzi &
Melnick, 2014). It may also partly explain why MYC and BCL2 translocations are not uncommon
in DLBCL, as they allow escape from BCL6 repression (Hatzi & Melnick, 2014).
5. The Genetic Heterogeneity of DLBCL
As one might expect of a cancer derived from cells and an environment centered around
combinatorial diversity, heterogeneity is a defining characteristic of DLBCL. This can be
observed all the way from its clinical outcome, to its cellular morphology and phenotype, and
down to its molecular profile, where DLBCL demonstrates a staggering amount of genetic and
epigenetic heterogeneity. Starting at the genetic level, numerous studies over the past decade
have analyzed hundreds of DLBCL patients’ tumor genomes in an effort to better understand the
molecular pathogenesis of the disease (Chapuy et al., 2018; Lohr et al., 2012; Morin et al., 2011;
Morin et al., 2013; Pasqualucci, Dominguez-Sola, et al., 2011; Pasqualucci, Trifonov, et al.,
2011; Reddy et al., 2017; Schmitz et al., 2018). Mutations have been found in more than 700
different genes (Pasqualucci, 2019), with each case of DLBCL having an average of 50-100
genetic lesions in the coding genome (Lohr et al., 2012; Morin et al., 2013; Pasqualucci & DallaFavera, 2015; Pasqualucci, Trifonov, et al., 2011). Approximately 150 of these genes are mutated
in >5% of patients and considered genetic drivers of DLBCL, with an average of ~8 driver
mutations per case (Reddy et al., 2017). A genomic analysis of more than 92,000 cases of over
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100 types of cancer found that DLBCL had the 4th-highest tumor mutational burden (TMB), with
a median of 10 mutations per megabase (Mb) of DNA and ~18% cases with >20 mutations/Mb
(Chalmers et al., 2017). Of the 10 cancer types with the highest TMB in this study, DLBCL (#4)
and follicular lymphoma (FL; #8; can transform into DLBCL) are the only ones which are not
epithelial (i.e., carcinomas) or melanocytic (i.e., melanoma) in nature. Furthermore, all other
cancers in the “top 10” besides DLBCL and FL are derived from the lung, skin, or melanocytes,
all of which are highly associated with exogenous sources of DNA damage (e.g., smoking and
UV light) (Chalmers et al., 2017). This further corroborates the notion that the occurrence of
DLBCL is largely due to endogenous (but still powerful) sources of DNA damage (Tubbs &
Nussenzweig, 2017).
6. Endogenous Sources of Mutation and Their Signatures
Chapuy et al. recently analyzed the mutational signatures in the genomes of 304 DLBCL
patients’ tumors in an attempt to identify the source(s) of mutations in recurrently affected genes
(Chapuy et al., 2018). Approximately 80% of all mutations were linked to the spontaneous
deamination of cytosines at CpGs and a switch from cytosine to thymine (C >T). This type of
mutation is associated with aging and, accordingly, the tumors of older patients in this cohort had
more mutations with this signature than did younger patients’ tumors. This finding also aligns
with the fact that DLBCL patients are usually diagnosed at an older age (median 66 years old)
(SEER3, https://seer.cancer.gov/statfacts/html/dlbcl.html). Two other mutational signatures were
prominent in this study as well. One signature, termed “canonical AID (cAID),” was linked to an
increase in C > T/G mutations at AID hotspots and was associated with both SHM and aSHM
(Alexandrov et al., 2013). The other, termed “AID2,” had similarities to a non-canonical AID
signature that is linked to an increase in A>T/C/G mutations and is associated with error-prone
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DNA repair subsequent to cytosine deamination by AID (Alexandrov et al., 2013). The
contribution of each mutational process varied depending on the particular gene, with some
genes (e.g., BCL2) being mutated mostly by the cAID and AID2 processes, and other genes (e.g.,
NOTCH2) being mutated almost exclusively by “aging”. It is interesting to note that these two
AID mutational signatures are similar to the ones initially described by Liu et al.; one involves
high-fidelity DNA repair, and the other involves error-prone DNA repair (M. Liu et al., 2008). It
should also be noted that mutations caused by spontaneous deamination (C > T) and cAID (C >
T/G) can remove methylated cytosines, thereby reducing DNA methylation and altering cells’
epigenetic profiles. Multiple studies have even implicated AID-induced DNA demethylation as a
means of epigenetic reprogramming that promotes pluripotency (Bhutani et al., 2010; Kumar et
al., 2013; Morgan, Dean, Coker, Reik, & Petersen-Mahrt, 2004; Popp et al., 2010). The
relationship between AID and DNA methylation will be revisited in the section titled
“Connections Between Epigenetic Dysregulation and Relapse in DLBCL”. Presently, however, a
broader discussion of the epigenetic landscape in DLBCL is warranted.
7. Frequent Mutations in Genes Related to Chromatin and Epigenetics
One of the most consistent trends that has emerged from genomic analyses of DLBCL is
the recurrence of mutations in genes whose products are specifically related to chromatin and
epigenetics (Figure 4). Of the 150 genetic drivers of DLBCL described by Reddy et al., 21 (i.e.,
14%) of them fit this description1 (see footnote below) (Reddy et al., 2017). This subset of genes
is skewed towards the top of the list, with 18/21 (86%) located in the “top 75,” 7/21 (33%) in the
“top 20,” and 4/21 (19%) in the “top 10,” including the #1 most commonly altered gene in

1

#1 MLL2; #4 HIST1H1E; #6 CREBBP; #10 ARID1A; #15 ARID1B; #16 SETD1B; #18 SMARCA4; #33 SETD2;
#34 TET2; #37 ARID5B; #38 EZH2; #43 EP300; #44 MLL3; #54 INO80; #55 CHD8; #58 DNMT3A; #71 NCOR1;
#75 CHD1; #88 SETD5; #115 DICER1; #128 HIST1H2BC
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DLBCL: MLL2 [alternative name for KMT2D (lysine methyltransferase 2D)]. The functions of
these genes include regulation of DNA methylation (e.g., DNMT3A) and demethylation
(e.g., TET2), miRNA processing (e.g., DICER1), chromatin remodeling (e.g., ARID1A), linker
histone-mediated chromatin compaction (e.g., HIST1H1E), and post-translational modification

Figure 4. Functional interactions between proteins relevant to GC B-cell and DLBCL
epigenetics
SET SET nuclear proto-oncogene; EP300 E1A binding protein 300; DNMT3A DNA
methyltransferase 3A; NCOR2 Nuclear receptor corepressor 2; ARID1A AT-rich interaction
domain 1A; CREBBP CREB-binding protein; EZH2 Enhancer of zeste 2; DICER1 Dicer 1,
Ribonuclease III; CBX8 Chromobox 8; CBX1 Chromobox 1; HIST1H1E Histone cluster 1 H1
family member E; TET2 Tet methylcytosine deoxygenase 2; KMT2D Lysine methyltransferase
2D. [Figure Source: Philippe Georgel; STRING Protein-Protein Interactions Network
(https://string-db.org)]
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(PTM) of histones (e.g., KMT2D). This last functional category, consisting of histone-modifying
enzymes, are some of the most common mutations in DLBCL (Morin et al., 2011; Pasqualucci,
Trifonov, et al., 2011; Reddy et al., 2017) and are integral to both the physiology of the GC
reaction and the molecular pathogenesis of DLBCL.
As was just stated, KMT2D (sometimes called MLL2 or MLL4) is the most commonly
mutated gene in DLBCL, with ~25% of cases showing genetic alteration (Reddy et al., 2017).
KMT2D is a histone methyltransferase that is primarily responsible for the monomethylation of
lysine 4 of histone H3 (H3K4me1), an epigenetic mark that is associated with active gene
enhancers. CREBBP (CREB-binding protein; ~11%) and EP300 (E1A binding protein 300; ~6%)
are genetically altered in ~17% of DLBCL cases, usually in a mutually exclusive fashion due to
their high structural and functional homology (although CREBBP mutations are more frequent)
(Reddy et al., 2017). These two genes encode the eponymous lysine acetyl transferases [KATs;
previously called histone acetyltransferases (HATs)] that acetylate lysines 18 and 27 of histone
H3 (H3K18Ac and H3K27Ac), the latter of which is required for gene enhancer activation.
CREBBP and EP300 also acetylate a variety of non-histone targets, including BCL6 and p53; the
significance of this will be revisited later (see section titled “The Epigenetic Switch at
Enhancers”).
EZH2 (Enhancer of Zeste 2), the enzymatic subunit of PRC2 (polycomb repressor
complex 2), is a histone methyltransferase that is responsible for the mono-, di-, and
trimethylation of lysine 27 of histone H3 (H3K27me1/2/3), all of which contribute to regulating
promoters’ availability to transcriptional machinery. About 6% of all DLBCL cases feature
mutations in EZH2 (Reddy et al., 2017). However, unlike mutations in KMT2D, CREBBP, and
EP300 (Morin et al., 2011; Pasqualucci, Dominguez-Sola, et al., 2011), mutations in EZH2 only
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occur in the GCB subtype, not the ABC subtype. Within the GCB subtype specifically, as many
as ~22% cases possess an EZH2 mutation (Morin et al., 2010). Mutations in EZH2 are always
heterozygous, and they almost always target tyrosine residue 641 (Y641) within the enzyme’s
catalytic site (Morin et al., 2010). This alters the enzymatic activity of EZH2 and causes it to
favor the trimethylation of H3K27 over mono- or dimethylation. The remaining wild-type EZH2
allele is responsible for providing most of the H3K27 mono- and dimethylation that cells still
require and probably explains why EZH2 mutations are exclusively heterozygous in DLBCL
(Sneeringer et al., 2010).
Gene

Full Gene Name

KMT2D

Lysine
methyltransferase 2D

CREBBP

CREB-binding
protein

EP300

E1A binding protein

EZH2

Enhancer of zeste 2

TET2

Tet methylcytosine
deoxygenase 2

% of DLBCL
Primary
Patients with
Function
Genetic Alteration
[(Reddy et al., 2017)]
24.8%
Monomethylation
of lysine 4 on
histone H3
(H3K4me1)
11.4%
Acetylation of
lysine 27 on
histone H3
(H3K27Ac)
5.7%
Acetylation of
lysine 27 on
histone H3
(H3K27Ac)
6.1%
Mono-, di-, and
trimethylation of
lysine 27 on
histone H3
(H3K27me1/2/3)
6.2%
Stepwise process
of cytosine
demethylation

Relation to
DLBCL

References

Mutated
tumor
suppressor

(Zhang et al., 2015)
(Ortega-Molina et al., 2015)

Mutated
tumor
suppressor

(Jiang et al., 2017)
(Zhang et al., 2017)
(Hashwah et al., 2017)

Mutated
tumor
suppressor

(Jiang et al., 2017)
(Zhang et al., 2017)
(Hashwah et al., 2017)

Mutated
protooncogene

(Velichutina et al., 2010)
(Caganova et al., 2013)
(Beguelin et al., 2016)

Mutated
tumor
suppressor

(Dominguez et al., 2018)

Table 2. Frequently mutated epigenetic modifers in DLBCL
This table lists some of the epigenetic modifiers that are frequently mutated in DLBCL and are
discussed throughout this review. Their proper function is important for regulating enhancer
activity and gene expression in GC B-cells, and mutations in these genes can promote
lymphomagenesis.
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Referring back to the analysis of mutational signatures in DLBCL by Chapuy et al., it is
interesting to note that these mutations in histone-modifying genes are enriched in the “aging”
signature, albeit to varying degrees. Approximately 90% of KMT2D and EP300 mutations in
their dataset were linked to aging, as well as ~70% of CREBBP mutations and >50% of EZH2
mutations (Chapuy et al., 2018). The potential implications of this finding will be discussed later
on in this review. (See sections titled “Endogenous Sources of Mutations and Their Signatures”
and “Connections Between Epigenetic Dysregulation and Relapse in DLBCL.”)
Epigenetics Determinants of DLBCL
1. Epigenetic Switches in GC B-cells
It has been established that B-cells must progress through a specific sequence of steps
during the GC reaction. Some of these steps, such as the transition from naive B-cell to
centroblast in the DZ, are straightforward and proceed only in one direction. Other steps,
however, require decisions to be made and have multiple potential outcomes. For instance, as
centroblasts move from the DZ to the LZ, they face the decision of either going through CSR and
becoming plasmacytes or returning to the DZ for subsequent rounds of cell division and SHM.
Some GC B-cells have to cycle between the DZ and LZ multiple times before they are allowed
to proceed to CSR. Furthermore, once centrocytes go through class-switching and exit the GC
reaction as plasmacytes, they still must commit to differentiation and decide whether to become
memory B-cells or plasma cells. All of these transitions and decisions require specific alterations
in cellular function and identity, which are made possible by rapid and highly coordinated
changes in the expression of particular subsets of genes. This is especially true for GC-B cells
that cycle between the DZ and LZ, as they must be able to switch between the gene expression
patterns that distinguish centroblasts from centrocytes at will, and sometimes repeatedly. GC B-
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cells achieve this level of plasticity using a system of epigenetic “switches” that govern the GC
reaction through the addition or removal of specific histone post-translational modifications
(PTMs) at the promoter or enhancer sequences of genes that require up- or downregulation [for
an in-depth discussion, see Jiang and Melnick’s review (Jiang & Melnick, 2015)].
Critically, the addition and removal of histone PTMs are reversible, which allows cells to
“toggle” between “on” and “poised” (i.e., temporarily off, or paused) states of gene expression
efficiently and without fully repressing genes that may soon be needed again. The two epigenetic
switches, one located at promoters and the other at enhancers, are essential for the normal
physiological function of GC B-cells and are also very commonly dysregulated during the
pathogenesis of DLBCL. In fact, many of the proteins that are responsible for maintaining and
operating the two epigenetic switches are encoded by genes that are some of the most frequently
mutated in DLBCL, including KMT2D, CREBBP, EP300, and EZH2. Additionally, the allimportant BCL6 exerts its repressive effects at the promoters or enhancers of target genes by
forming complexes with histone-modifying enzymes that alter the epigenetic landscape. Thus,
the molecular pathogenesis of DLBCL can be better understood by examining these epigenetic
switches and how they are differentially regulated in normal versus pathological conditions.
2. The Epigenetic Switch at Promoters
During the GC reaction, BCL6 represses the expression of over 1,000 genes in order to
avoid triggering cell-cycle inhibition, apoptosis, or differentiation before the process of affinity
maturation is complete (Hatzi & Melnick, 2014; Mlynarczyk et al., 2019). BCL6 can repress the
expression of a gene by binding either its promoter or enhancer, but the sets of genes that are
affected by binding at either location are largely non-overlapping. The precise mechanism by
which BCL6 represses gene expression also differs depending on whether it is acting at a
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promoter or an enhancer (Hatzi et al., 2013). BCL6 does not act alone. Rather, it must
collaborate (either directly or indirectly) with other proteins in order to exert its repressive
effects, many of which are histone-modifying enzymes. With regard to the epigenetic code, the
promoter of a gene is “on” when the nucleosomes packaging the promoter sequence are
decorated with H3K4me3 but not H3K27me3. Conversely, when these nucleosomes are
decorated with H3K27me3 but not H3K4me3, the promoter is considered “off.” When these
nucleosomes possess both H3K4me3 and H3K27me3 (i.e., bivalent chromatin), the promoter is
“poised” (Figure 5).
Referenced earlier (see section titled “Frequent Mutations in Genes Related to Chromatin
and Epigenetics”), the histone methyltransferase EZH2 is required for GC formation and affinity
maturation (Beguelin et al., 2013). The main role of EZH2 in the GC reaction is the de novo
deposition of H3K27me3 at the promoters of specific target genes that are already marked with
H3K4me3 (i.e., active), thereby forming bivalent promoters. Just like BCL6, some of the key
genes that EZH2 targets include PRDM1 and IRF4, which are required for the differentiation of
GC B-cells into memory B-cells and plasma cells, as well as CDKN1A and CDKN1B, which are
cell-cycle inhibitors (Beguelin et al., 2013; Velichutina et al., 2010). There is significant overlap
between the gene sets that EZH2 and BCL6 target (Beguelin et al., 2016; Caganova et al., 2013).
Based on their experiments, Béguelin et al. recently proposed a model whereby BCL6 and EZH2
collaborate in the repression of common target genes by acting jointly at promoters (Beguelin et
al., 2016). Initially, BCL6 binds its target sequence within the promoter, and EZH2 (as part of
PRC2) independently increases the level of H3K27me3 at the promoter. The CBX8 (chromobox
8) subunit of PRC1 (polycomb repressor complex 1) then binds to H3K27me3, as PRC1 is
typically the protein complex that is responsible for H3K27me3-mediated transcriptional
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Figure 5. Epigenetic switches at promoters and enhancers in GC B-cells
Starting, maintaining, and exiting from the GC reaction requires rapid and coordinated changes
in the expression of specific subsets of genes in response to cell signals. This is achieved by
using epigenetic switches at the promoters and enhancers of these genes. (A) H3K4me3 at a
promoter signifies that it is “on” (green). The addition of H3K27me3 by EZH2 switches it to a
“poised” (yellow) state of transient repression. The Y641 EZH2 mutation increases H3K27me3
deposition and turns the promoter “off” permanently (red). (B) H3K27Ac at an enhancer means
that it is active. Removal of H3K27Ac by HDAC3 (complexed with BCL6-SMRT) leaves only
H3K4me1 marks behind and poises the enhancer. Inactivation of CREBBP switches enhancers
off by preventing their reactivation via H3K27 (and BCL6) acetylation, leaving HDAC3
unopposed. (C) H3K4me1 is also present at active enhancers. The lysine demethylases KDM1
and KDM5 are thought to remove H3K4 methylation and poise enhancers. KMT2D inactivation
silences enhancers by preventing the addition of H3K4me1. (D) TET2 demethylates cytosines at
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enhancers, first by converting 5-methylcytosine (5mC; repressive) to 5-hydroxymethylcytosine
(5hmC; active). TET2 inactivation switches enhancers off by preventing demethylation and,
instead, causing hypermethylation. Genes whose promoter and/or enhancer cannot be reactivated
makes them unresponsive to important cell signals. This locks cells into the GC reaction, which
can lead to lymphomagenesis. [Adapted from (Mlynarczyk et al., 2019)]

repression. However, in GC B-cells, many of the canonical components of PRC1 are
downregulated while other, non-canonical components such as BCOR (BCL6 corepressor) are
upregulated. When CBX8 (as part of PRC1) binds to H3K27me3, it brings the PRC1-BCOR
complex along with it. This promotes the interaction of BCOR and BCL6 to form a BCL6BCOR complex. While BCL6 and EZH2 act on the promoter independently and do not make
physical contact, their simultaneous action allows for a “combinatorial tethering” that is required
for the stable binding of BCOR to BCL6. Stable formation of the BCL6-BCOR complex at
poised promoters is what allows the expression of these genes to be temporarily repressed
(Beguelin et al., 2016).
Previous experiments by Hatzi et al. showed that BCL6 is also capable of forming a
ternary complex with both BCOR and SMRT (silencing mediator of retinoid and thyroid
hormone receptors; also called NCOR2, or nuclear corepressor 2) at the promoters of certain
genes in DLBCL cells (Hatzi et al., 2013). This BCL6-SMRT-BCOR complex was shown to
more strongly repress the expression of target genes than the BCL6-BCOR complex, but it was
bound to the promoters of far fewer genes (n=341) than the BCL6-BCOR complex (n=1783).
Furthermore, a principal component analysis (PCA) determined that BCL6 actively repressed
promoters only when it was bound to BCOR and SMRT (i.e., ternary complex) and when
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accompanied by a particular chromatin signature (decreased H3K4me3, H3K36me3,
H3K79me2, and H3K9Ac; increased H3K27me3 and DNA methylation) that is associated with
pausing of RNA polymerase II elongation (Hatzi et al., 2013).
In cases of DLBCL that feature constitutive expression of BCL6 and a mutation in EZH2
that increases its deposition of H3K27me3 (e.g., Y641), the resulting state of repression becomes
permanent rather than transient. While it is necessary to temporarily repress the expression of
genes whose products would interfere with the GC reaction, prolonging their repression
indefinitely greatly increases the risk of oncogenesis. Béguelin et al. observed this in their
experiments when they bred mice that constitutively express BCL6 and possess the EZH2 Y641
mutant allele (Beguelin et al., 2016). The bone marrow of these mice, as well as that of three
different types of control mice, were then transferred to four separate groups of lethallyirradiated mice. The mice who received bone marrow from the BCL6-overexpressing, EZH2mutant donors experienced a dramatic acceleration in their mortality compared to all of the other
mice. The BCL6-overexpressing, EZH2-mutant recipients also displayed clear evidence of either
lymphoma (10/12; FL or DLBCL) or pre-neoplastic lymphoid neoplasia (2/12) upon both gross
pathological and histopathological inspection, while none of the mice from the other three groups
[wild-type controls (0/4), EZH2-mutant only (0/4), and BCL6-overexpressing only (0/5)] showed
any evidence of disease (Beguelin et al., 2016).
3. The Epigenetic Switch at Enhancers
Just like promoters, enhancers also have an epigenetic code that influences their level of
activity. An enhancer is only considered “on” when nucleosomes are decorated with H3K27Ac,
although H3K4me1 is typically found at active enhancers as well (Creyghton et al., 2010). An
enhancer that loses H3K27Ac but retains H3K4me1 is considered “poised.” And, an enhancer
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that has neither H3K27Ac nor H3K4me1 marks is considered “off” (Figure 5). CREBBP and
P300 are responsible for depositing H3K27Ac at enhancers, which activates them.
CREBBP/P300 and BCL6-SMRT compete with each other at enhancers and can co-occupy
enhancers, and upregulation of BCL6 is associated with a decrease in P300 binding at enhancers
in GC B-cells (Hatzi et al., 2013). BCL6 arguably plays a more direct role in the repression of
enhancers, and it is bound to more enhancers than promoters in GC B-cells (Hatzi et al., 2013).
When BCL6 binds to its target sequence at an enhancer, it must form a complex similar to the
one that it does at promoters in order to enact its repression. However, unlike at promoters,
BCL6 only binds SMRT and does not bind BCOR, which is structurally unrelated to SMRT and
binds through a different peptide sequence (Ahmad et al., 2003; Ghetu et al., 2008; Hatzi et al.,
2013). Critically, the SMRT corepressor is bound to histone deacetylase 3 (HDAC3), which
deacetylates H3K27 and switches active enhancers to a poised state with only H3K4me1 marks
remaining (Hatzi et al., 2013).
Subsequent experiments by Jiang et al. investigated the effects that inactivating CREBBP
mutations have on the “balance of power” between CREBBP/P300 and the BCL6-SMRTHDAC3 complex at the enhancers of certain genes in GC B-cells (Jiang et al., 2017). Their
results show that CREBBP inactivation prevents the deposition of H3K27Ac at enhancers that
are poised (i.e., have had H3K27Ac removed) during the GC reaction, which prevents both
enhancer reactivation and proper expression of the genes that they regulate. Jiang et al. also
show that, due to its removal of CREBBP-mediated acetylation, the action of HDAC3 at
enhancers is required to properly initiate the GC reaction. In the absence of H3K27 acetylation
by CREBBP, HDAC3 activity is left unopposed, and DLBCL cells become HDAC3-dependent
for survival. When DLBCL cells with knocked-down CREBBP expression were treated with a
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selective HDAC3 inhibitor, H3K27 acetylation at the enhancers of multiple MHC II genes was
rescued. The subsequent expression of those MHC II genes was also rescued. It should also be
noted that wild-type CREBBP/P300 can acetylate BCL6 as a form of negative regulation by
preventing its association with HDACs (Bereshchenko, Gu, & Dalla-Favera, 2002). Conversely,
acetylation of p53 by wild-type CREBBP/P300 is a form of positive regulation, as it prevents the
ubiquitination of p53 by murine double minute 2 (MDM2) (M. Li, Luo, Brooks, & Gu, 2002).
The ability of CREBBP/P300 to acetylate both BCL6 and p53 is strongly inhibited by mutations
that inactivate their HAT domain (Bereshchenko et al., 2002; Pasqualucci, Dominguez-Sola, et
al., 2011). Thus, in addition to the loss of regulatory influence at enhancers that accompanies
CREBBP/P300 inactivation, GC B-cells also lose their ability to directly regulate p53 and BCL6,
both of which are integral to GC physiology and DLBCL pathology.
Importantly, the subset of enhancers that are affected by CREBBP inactivation strongly
overlaps with the subset of enhancers that are bound by the BCL6-SMRT-HDAC3 complex.
Some of the most notable genes whose enhancers were affected by CREBBP inactivation (and,
thus, unopposed HDAC3 repression) in these experiments are those involved in GC exit and
termination, plasma cell differentiation, and MHC II antigen processing and presentation (Jiang
et al., 2017). The impact of CREBBP inactivation on these particular pathways is further
corroborated by experiments independently conducted by Zhang et al (J. Zhang et al., 2017).
Their results show that Crebbp deletion in murine GC B-cells results in decreased expression of
certain genes that, in human GC B-cells, are also 1.) expressed, 2.) marked with H3K27Ac, and
3.) bound by CREBBP. Many of these genes are related to signaling pathways (e.g., BCR, CD40,
NF-kB, chemokines, cytokines, and lymphocyte migration) that are activated in the LZ (J. Zhang
et al., 2017). As was reviewed earlier (see section titled “The Germinal Center Reaction”), the
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LZ is where B-cells whose BCR affinity for antigen is sufficiently high can be directed to go
back to the DZ for further modification or to differentiate into memory B-cells or plasma cells.
Furthermore, their data from ChIP-seq (chromatin immunoprecipitation followed by DNA
sequencing) experiments demonstrate the same dynamic of CREBBP and BCL6 opposition at
the promoters and/or enhancers of genes that are strongly related to initiating, maintaining,
and/or exiting the GC reaction. These include genes involved in the cell cycle, responding to
DNA damage, apoptosis, differentiation, and multiple signaling pathways, such as BCR, NF-kB,
Toll-like receptor (TLR), interferon (IFN), and activation by T-cells (J. Zhang et al., 2017).
Taken together, all of these findings depict a scenario in which GC B-cells that possess
inactivating CREBBP/P300 mutations can become locked into the GC reaction and unresponsive
to the signals that would normally terminate the GC reaction and determine their fate. Those
genes whose expression is incompatible with successful affinity maturation, namely those
required for DNA damage response, apoptosis, immune recognition, GC exit, and differentiation,
cannot be switched back on due to an inability to restore proper H3K27 acetylation at enhancers.
In this state, GC B-cells are denied the opportunity to differentiate and perform their intended
biological function, while continuing to be exposed to highly mutagenic and potentially
oncogenic internal conditions.
4. Functional Effects of CREBBP Deficiency
Multiple studies, including some of those discussed above, have documented the
functional effects of CREBBP deficiency and its contribution to lymphomagenesis. For instance,
Zhang et al. (J. Zhang et al., 2017) compared the ability of murine splenic B-cells with wildtype, heterozygous, or homozygous-deleted Crebbp to terminally differentiate ex vivo. After
stimulating cells with lipopolysaccharide (LPS) and interleukin 4 (IL4), flow cytometry showed
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that ~8.5% of wild-type B-cells exhibited a plasmablastic phenotype (pre-plasma cell; high
CD138 and low B220), while only ~3% of B-cells with a heterozygous or homozygous deletion
of Crebbp showed the same plasmablastic flow cytometry signature. Results from qRT-PCR
experiments also showed a significant decrease in Prdm1 (required for terminal differentiation)
expression in Crebbp-deleted (hetero- and homozygous) vs. wild-type cells. Flow cytometry of
splenic B-cells taken from a separate cohort of mice after immunization with sheep red blood
cells (SRBC) also showed a significant decrease in the percentage of high-CD138/low-B220 Bcells in Crebbp-deleted (hetero- and homozygous) vs. wild-type mice. Additional flow cytometry
experiments demonstrated that Crebbp-deleted (hetero- and homozygous) splenic B-cells showed
higher levels of proliferation and viability as well when compared to wild-type cells. Lastly, they
investigated the direct effect of Crebbp deletion on the lymphomagenesis in mice in vivo.
Deletion of Crebbp on its own was not enough to cause a statistically-significant increase in
lymphoma incidence, although 3/22 cases in the heterozygous knockout group [vs. 0/20 in wildtype and 0/24 in homozygous knockout groups] did develop lymphoma (two DLBCL and one
FL). However, in mice with both a heterozygous Crebbp deletion and deregulated Bcl2
expression (which frequently co-occur in FL and DLBCL), there was a significant increase in
lymphoma incidence, with 92% (22/24) of these mice developing some type of FL, compared to
61.5% (16/26) in mice with deregulated Bcl2 expression but wild-type Crebbp (J. Zhang et al.,
2017).
Likewise, Hashwah et al. investigated the effects of CREBBP mutation/deletion on GC
B-cell proliferation and lymphomagenesis (Hashwah et al., 2017). Starting with in vitro
experiments, CRISPR (clustered regularly interspaced short palindromic repeats) was used to
introduce an inactivating mutation to one CREBBP allele in a wild-type human DLBCL cell line.
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While this did result in decreased H3K18 acetylation and changes in gene expression, especially
those involved in MHC II antigen processing and presentation, no significant difference in
growth rate as a function of CREBBP status was observed. However, when human DLBCL cells
with wild-type or heterozygous-mutant CREBBP were subcutaneously xenografted onto mice,
the tumors consisting of CREBBP-mutant cells grew faster and had a greater mass than tumors of
wild-type CREBBP cells. Moreover, orthotopic xenografts established intravenously using the
same human DLBCL cells with wild-type or heterozygous-mutant CREBBP showed a greater
capacity for engraftment in the bone marrow of both immunocompromised mice and mice with a
humanized immune system. In separate experiments, groups of mice were engineered to delete
one or both alleles of Crebbp or Ep300 in response to AID activity after SRBC immunization
(Hashwah et al., 2017). Heterozygous and homozygous Crebbp-deleted mice exhibited
hyperproliferation of GC B-cells while, interestingly, the opposite occurred for mice with
heterozygous and homozygous deletions of Ep300. Histopathological analysis of splenic tissue
showed that the increase or decrease in the number of GC B-cells was due to an increase or
decrease of the size of germinal centers, respectively. Lastly, they also wanted to assess the
extent to which loss of Crebbp contributes to lymphomagenesis. Similar to the findings of Zhang
et al. (J. Zhang et al., 2017), heterozygous Crebbp deletion was not sufficient to induce
lymphomagenesis by itself. However, mice with both a heterozygous deletion of Crebbp and
constitutive expression of Myc developed lymphoma earlier (~20 days post-immunization) and
had worse overall survival (12.5%; 1/8) than mice with wild-type Crebbp and constitutive Myc
expression (~60 days post-immunization; 50%; 2/4) (Hashwah et al., 2017).
Finally, in addition to the more mechanistic experiments described earlier in this section,
Jiang et al. studied the functional effects of Crebbp loss (Jiang et al., 2017). Hematopoietic
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progenitor cells (HPCs) were isolated from mice with deregulated Bcl2 expression, transduced
with either a control retrovirus or one that expresses anti-Crebbp shRNA (short hairpin RNA),
and then transplanted to lethally-irradiated wild-type mice. The lymphomas of mice that received
HPCs with knocked-down expression of Crebbp displayed an earlier onset and a more
aggressive, invasive phenotype than lymphomas with normal Crebbp expression. A similar
phenotype was also observed when the same experiments were performed with Ep300
knockdown (Jiang et al., 2017). In summary, the results of these functional studies support a role
for the loss of CREBBP in promoting increased GC B-cell proliferation, germinal center
expansion, decreased terminal differentiation, greater aggression and invasiveness, and an
increased capacity for lymphomagenesis when combined with the deregulated expression of
known oncogenes. In many instances, the loss of EP300 has similar effects, although this is not
always the case.
5. Functional Effects of KMT2D Deficiency
It was alluded to previously (see section titled “The Epigenetic Switch at Enhancers”)
that, while the presence or absence of H3K27Ac at nucleosomes along an enhancer is what
ultimately distinguishes between its “on” and “off” states, respectively, H3K4me1 is also
typically present at active enhancers. Furthermore, in the absence of H3K27Ac, the presence of
H3K4me1 at an enhancer signifies that it is in a “poised” state rather than completely “off.”
KMT2D is responsible for the mono-, di-, and trimethylation of H3K4, which it accomplishes
through its catalytic SET [Su(var)3-9, Enhancer-of-zeste, and Trithorax] domain. Since KMT2D
is the most commonly mutated gene in DLBCL, multiple investigations have been conducted in
order to better understand the molecular and functional effects of KMT2D mutations, as well as
their impact on lymphomagenesis.
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Zhang et al. compared the in vitro methyltransferase activity of 16 different KMT2D
mutants derived from DLBCL (J. Zhang et al., 2015). Eleven mutants showed a significant
decrease in activity, most of which (9/11) had a mutation close to the SET domain and were
among the most severely affected. These results were validated in vivo by measuring genomewide levels of H3K4me1, H3K4me2, and H3K4me3 in splenic B-cells from mice with wild-type,
heterozygous-deleted, or homozygous-deleted Kmt2d. Heterozygous mice showed a small
increase in all three (H3K4me1/2/3), while those with a complete loss of Kmt2d showed a sharp
decrease in H3K4me1/2/3. A similar pattern was observed in a panel of human DLBCL cell
lines, except that heterozygous cell lines also showed a decrease in H3K4me1/2/3. Mice with
homozygous loss of Kmt2d also experienced changes in B-cell development after SRBC
immunization, including significantly fewer B220+ B-cells in lymphoid tissues, mature B-cells
in the bone marrow, and follicular B-cells in the spleen. The formation of germinal centers was
also affected in SRBC-immunized mice with homozygous loss of Kmt2d. These mice exhibited
significant increases in their GC B-cell population and the number, average size, and total area of
germinal centers. The results in mice with a heterozygous deletion of Kmt2d were similar to
those of mice with complete Kmt2d loss but were generally of lesser magnitude. The relative
depletion of cells that precede GC B-cells (e.g., follicular B-cells) and expansion of GC B-cells
and germinal centers that occur in these mice suggest that loss of Kmt2d encourages mature Bcells to enter the GC reaction more readily. Separate ex vivo experiments also showed that
splenic B220+ B-cells taken from Kmt2d-deficient mice also display a greater proliferative rate
than wild-type cells. This observation fits with results from gene expression analyses showing
that the transcriptional signature in cells that have lost Kmt2d is enriched in genes that are
involved in cell-cycle regulation and apoptosis (J. Zhang et al., 2015). Lastly, the extent to which
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Kmt2d loss directly influences lymphoma incidence and pathogenesis was tested in mice with
wild-type, heterozygous-deleted, and homozygous-deleted Kmt2d. Similar to the findings of
Zhang et al. and Jiang et al. in their studies of CREBBP (Jiang et al., 2017; J. Zhang et al., 2017),
deletion of Kmt2d alone was not enough to significantly increase lymphomagenesis (0/23 wildtype, 0/22 heterozygous-deleted, and 0/15 homozygous-deleted mice). However, in mice with
both loss of Kmt2d and deregulated Bcl2 expression, lymphoma incidence increased from 44.4%
(12/27) in wild-type mice to 62.5% (15/24) in heterozygous mice and 78.6% (22/28) in
homozygous mice, with cases ranging from early FL to DLBCL (J. Zhang et al., 2015).
In an independent study, Ortega-Molina et al. also investigated the influence of Kmt2d
deficiency on lymphomagenesis in multiple mouse models (Ortega-Molina et al., 2015). First,
HPCs obtained from mice with deregulated Bcl2 expression were transduced with either a
control or anti-Kmt2d shRNA-expressing retrovirus and transplanted into lethally-irradiated
wild-type mice. Those who received HPCs with knocked-down Kmt2d expression in addition to
increased Bcl2 expression exhibited early onset of lymphoma, splenomegaly, and
histopathological evidence of high-grade FL. A second mouse model, in which Kmt2d was
knocked out completely, resulted in 58% of them becoming diseased compared to 0% in wildtype controls. The affected mice developed a lymphoma consisting of atypical pre-GC B-cells
that had not undergone SHM or CSR. While the disease was not quite comparable to human
lymphomas (e.g., FL and DLBCL), the results do support a role for KMT2D as a tumor
suppressor. The third mouse model was designed to overexpress Aicda in addition to having a
complete deletion of Kmt2d. Recall from earlier that Aicda encodes AID, which is essential for
both the GC reaction and GC-derived lymphomas. All mice (7/7; 100%) developed lymphoma,
whereas all of the mice overexpressing Aicda without Kmt2d deletion remained lymphoma-free
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(0/14; 0%) (Ortega-Molina et al., 2015). The onset of disease in affected mice was even earlier
than in mice with Kmt2d deletion alone, and tumors displayed greater aggression and wider
dissemination within the spleen and other organs. Evidence of SHM, CSR, and a plasmacytic
phenotype were also present, none of which were observed in mice with Kmt2d deletion only.
Experiments studying the effects of Kmt2d deletion on B-cell development produced results
similar to those of Zhang et al. (J. Zhang et al., 2015). After SRBC immunization, there was a
significant decrease in follicular B-cells and significant increases in transitional B-cells (also
observed before immunization) and GC B-cells in the spleen. Using the same HPC transplant
model described above, recipients of HPCs with knocked-down Kmt2d expression also exhibited
prolonged germinal center formation in the spleen after SRBC immunization compared to wildtype mice. Furthermore, in vivo and in vitro experiments showed evidence of reduced CSR from
IgM to IgG1 after immunization/stimulation in the B-cells of Kmt2d-knockout mice. These
results differ from those of Zhang et al., which found an increase in IgG1+ B-cells but an
approximately 10-fold decrease in antigen affinity (though different antigens were used) (J.
Zhang et al., 2015). Gene expression studies of KMT2D-mutant FL in humans and lymphoma in
Kmt2D-deficient mice revealed a strong overlap between their sets of affected genes (compared
to wild-type), especially those that are down-regulated (Ortega-Molina et al., 2015). Notably, this
overlap included genes involved in immune signaling (e.g., IL and TNF) and plasma cell
differentiation. ChIP-seq experiments were also performed in murine Kmt2d-deficient
lymphomas and human KMT2D-mutant lymphoma cell lines (compared to wild-type) in order to
map changes in H3K4me1/2 distribution and associated changes in gene expression. In both
mouse and human lymphomas, global levels of H3K4me1/2 did not decrease, but losses at
specific loci were detected, especially at enhancers. In mice, some of the genes most affected by
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reduced H3K4me1/2 at promoters and enhancers were those that are induced by immune
signaling (e.g., IL, TNF, NF-kB, and CD40); enhancer-specific H3K4me1/2 loss also overlapped
with a variety of down-regulated tumor suppressor genes. In human cells, genes that lost
H3K4me1/2 and are known KMT2D binding targets were also heavily enriched for immune
signaling pathways (e.g., IL, NF-kB, CD40, and IRF4). Lastly, multiple KMT2D target genes
were studied in order to trace the direct connections between KMT2D mutation/loss and the
functional effects that occur downstream. Many genes, such as tumor necrosis factor alphainduced protein 3 (TNFAIP3), require BCR and CD40 signals for expression in B-cells. TNFAIP3
encodes a protein (A20) that has been shown to negatively regulate NF-kB activity and promote
apoptosis in non-Hodgkin lymphomas (Honma et al., 2009). In human DLBCL cell lines with
knocked-down KMT2D expression, the level of H3K4me1/2 at the enhancer of TNFAIP3
(significantly) and its expression (not significantly) both decreased. Moreover, induction of
TNFAIP3 expression and cell apoptosis by BCR and CD40 signaling were both significantly
decreased; these same results were observed in a comparison of KMT2D-mutant and KMT2Dwild-type human lymphoma cell lines, as was the absence of any significant effect on cell
proliferation (Ortega-Molina et al., 2015). Thus, similar to the results of CREBBP inactivation
that were discussed earlier (see section titled “The Epigenetic Switch at Enhancers”), KMT2D
loss/inactivation appears to make B-cells less responsive to CD40 signaling and less able to
switch on genes that are required for important cell fate decisions.
Overall, the results of these functional studies suggest a multifaceted role for the
loss/inactivation of KMT2D in the progression of lymphoma, especially in FL and DLBCL. The
effects of its loss include increased proliferation, resistance to BCR and CD40 signaling, an
expansion of GC B-cells at the expense of follicular B-cells, increased and prolonged formation
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of germinal centers, greater aggression, wider dissemination, and an increased capacity for
lymphomagenesis when cooperating with other oncogenes. Finally, as an interesting side-note,
although KTM2D is not directly involved in the acetylation or deacetylation of H3K27Ac,
experiments in mouse embryonic stem cells and preadipocytes have shown that KMT2D (i.e., the
protein itself, not H3K4 methylation) is required for CREBBP/P300 to bind and activate
enhancers that regulate the expression of genes involved in terminal differentiation and cell
identity (Froimchuk, Jang, & Ge, 2017; B. Lai et al., 2017; Wang et al., 2016). Without jumping
to conclusions, it would be interesting to know if mutations that result in decreased or lost
KMT2D expression in GC B-cells also result in decreased CREBBP/P300 recruitment to and
activation of enhancers in GC B-cells and/or lymphoma.
6. Connections Between Epigenetic Dysregulation and Relapse in DLBCL
It is clear that mutations in histone-modifying enzymes like KMT2D, CREBBP, P300,
and EZH2 are some of the most common in DLBCL and that they contribute directly to its
molecular pathogenesis. The same can be said for FL, which can transform into and shares many
similarities with DLBCL. There is a growing body of evidence suggesting that, in many
instances, these are driver mutations that occur early on and help create an environment that is
more conducive to oncogenesis. Moreover, these mutations are very commonly present in both
early tumor cells and those that are selected during relapse or transformation from FL to
DLBCL, thus indicating strong evolutionary fitness (Green et al., 2013; Green et al., 2015; Jiang
et al., 2014; Okosun et al., 2014; Pasqualucci et al., 2014).
For example, Jiang et al. compared matched pairs of tumors taken from 14 DLBCL
patients, both at diagnosis and at relapse subsequent to R-CHOP therapy (Jiang et al., 2014).
After analyzing the clonal heterogeneity of each sample and comparing each diagnostic tumor to
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its corresponding relapse tumor(s), two major patterns of clonal evolution were identified. The
first was an “early-divergent” pattern in which the diagnosis and relapse clones were derived
from a common precursor but diverged early on in development and occupied separate branches
of the phylogenetic tree. The second was a “late-divergent” pattern in which the diagnosis and
relapse clones occupied the same branch of the phylogenetic tree and retained a high degree of
similarity. On average, early-divergent tumors had significantly greater entropy (i.e., clonal
heterogeneity) at diagnosis than did late-divergent tumors. Furthermore, while the diagnosis
subclones of early-divergent tumors were almost non-existent in relapse tumors, the diagnosis
subclones of late-divergent tumors largely maintained their presence in relapse tumors. Exome
sequencing was also performed on half of the matched pairs of tumors, including 3/6 from the
early-divergent group. From an epigenetic perspective, the results from early-divergent tumors
were particularly interesting, as all three pairs possessed mutations in histone-modifying
enzymes in both the diagnosis and relapse tumors. Pair 1 had mutations in both KMT2D and
SETDB1 (SET domain bifurcated histone lysine methyltransferase 1), pair 2 had a mutation in
KMT2D as well, and pair 9 had a mutation in EP300. Additionally, some of the relapse tumors
contained additional chromatin-modifying/associated proteins that were not present at diagnosis.
For pair 1, it was a mutation in TET2 (tet methylcytosine deoxygenase 2), pair 2 had a mutation
in EP300, and pair 9 added a mutation in BRD4 (bromodomain-containing protein 4). TET2,
along with TET1 and TET3, comprise the family of ten-eleven translocation (TET) that directs
the convoluted process of cytosine demethylation. They catalyze the successive conversion of
5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5carboxylcytosine (5caC), the latter two of which can trigger DNA repair and replacement with
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unmethylated cytosine (Kohli & Zhang, 2013). Like AID, TET2 initiates a biological process
that leads to reduced DNA methylation (Figure 6) and an altered epigenome (see section titled
“Endogenous Sources of Mutation and Their Signatures”). As a result of TET2 loss,
hematopoietic cells and acute myeloid leukemia (AML) cells displayed selective

Figure 6. DNA repair and de-methylation pathways
Cytosine (C) methylation to 5-methyl cytosine (5-mC) is mediated by DNA-methyltransferases
(DNMT) through direct transfer of CH3. De-methylation is a far more complex process,
involving Ten Eleven Translocation (TET) enzymes, Base Excision Repair (BER) and Thymine
DNA Glycosylase (TDG). Transition from C to Uracil (U) or Thymine (T) can also be involved
in this complex process, through using Activation-Induced Cytidine Deaminase (AID) and
apolipoprotein B mRNA-editing enzyme Catalytic (APOBEC), and Mismatch Repair (MMR).
[Adapted from (Bhutani et al., 2010) and (Dominguez & Shaknovich, 2014)] (5-hmC: 5-hydroxy
methyl Cytosine; 5-fC: 5-formyl Cytosine; 5-caC: 5-carboxyl Cytosine; 5-hmU: 5-hydroxy
methyl Uridine)
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hypermethylation and inactivation of enhancers in one study (Rasmussen et al., 2015).
Additionally, loss of TET2 in GC B-cells was recently shown to mirror many of the mechanistic
and functional effects observed in CREBBP-mutant DLBCL, including enhancer inactivation and
inhibition of GC exit and plasma cell differentiation (Dominguez et al., 2018) (Figure 5).
BRD4 is an epigenetic “reader” that binds to acetylated histones and serves as a general
transcription cofactor and partners with many transcription factors that promote gene expression.
It is heavily involved in the organization and activation of super-enhancers, especially those that
regulate the expression of genes that maintain cell identity. Interestingly, BRD4 is also involved
in DNA repair and is required to complete CSR in B-cells after the introduction of DNA-DSBs
by AID (Donati, Lorenzini, & Ciarrocchi, 2018). Additionally, one of the four late-divergent
matched pairs of tumors (pair 8) also gained a mutation in a histone-modifying enzyme (EZH2)
that was present only at relapse, not at diagnosis. Specifically, it was the Y641 EZH2 mutation,
which disproportionately increases the deposition of H3K27me3 at the expense of H3K27me1/2,
as reviewed earlier (see section titled “Frequent Mutations in Genes Related to Chromatin and
Epigenetics”). These findings, as well as those observed in FL (Green et al., 2013), led Jiang et
al. to propose a model of DLBCL development and relapse in which mutations in epigenetic
modifiers can serve as 1.) early “driver” mutations that disrupt the epigenome in a way that
favors lymphomagenesis and/or 2.) “facilitator” mutations that occur later in development and
introduce characteristics that favor relapse (Jiang et al., 2014). It was mentioned previously that
EZH2, CREBBP, EP300, and KMT2D mutations in DLBCL predominantly have a signature of
spontaneous cytosine deamination (C > T) that is associated with aging (Chapuy et al., 2018).
(See section titled “Frequent Mutations in Genes Related to Chromatin and Epigenetics.”)
Though it would need be shown definitively, this observation may further support the idea that

49

mutations in histone-modifying enzymes can occur early on in the process (as a byproduct of
aging; not sufficient for lymphomagenesis) and “set the stage” for lymphomagenesis later on.
This review of DLBCL epigenetics has focused primarily on histone-modifying enzymes
because of their high mutation rates and their relevance to GC B-cell physiology and pathology.
However, it is important to emphasize the role that DNA methylation plays in DLBCL (Arima et
al., 2018; Chambwe et al., 2014; De et al., 2013; Dominguez & Shaknovich, 2014; Dominguez et
al., 2015; Jiang & Melnick, 2015; Pan et al., 2015; Shaknovich, De, & Michor, 2014;
Shaknovich et al., 2010; Teater et al., 2018). Specifically, Pan et al. found that higher levels of
DNA methylation heterogeneity in DLBCL tumors at the time of diagnosis could predict relapse
subsequent to R-CHOP therapy (Pan et al., 2015). Relapse was also accompanied by a decrease
in intra-tumor DNA methylation heterogeneity, suggesting clonal selection. Furthermore, relapse
was not correlated with clonal genetic heterogeneity, at least with regard to SHM patterns at VDJ
sequences (Pan et al., 2015). Additionally, Teater et al. recently published results from in vivo
experiments in mice showing that AID itself is a driver of DNA methylation heterogeneity
(Teater et al., 2018) (Figure 7). This implicates AID not only in the most essential steps of
affinity maturation in normal GC B-cells, but also in the production of genetic and epigenetic
heterogeneity during lymphomagenesis. The results of these studies make sense in light of what
is known about AID’s involvement in DNA demethylation and epigenetic reprogramming. (See
section titled “Endogenous Sources of Mutation and Their Signatures.”)
7. Viewing DLBCL As a Disease of Epigenetic Dysregulation
When attempting to synthesize all of these disparate findings regarding the epigenetic
dysregulation of DLBCL, it is hard not to notice parallels with the epigenetic progenitor model
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of cancer proposed by Feinberg et al. in 2006 (Feinberg, Koldobskiy, & Gondor, 2016; Feinberg,
Ohlsson, & Henikoff, 2006; Shaknovich et al., 2014; Timp & Feinberg, 2013). Their model
proposes that cancer really begins as a disruption of the epigenome in the stem/progenitor cells

Figure 7. Activation-Induced Cytidine Deaminase (AID), DNA methylation, and epigenetic
heterogeneity in DLBCL and other types of lymphoma
Activation of naïve B-cells (NBC) transitioning to normal Germinal Center B-cells (NGBC).
Changes in DNA methylation patterns during differentiation (GC reaction) involve AID (see
Figure 6), which strongly contributes to creating epigenetic heterogeneity. Ultimately, this leads
to disease progression and, potentially, increased aggression. [Adapted from (Shaknovich et al.,
2014)] [Grey rectangle: Promoter Region; Broken Arrow; Transcription Start Site (TSS); Open
circles: CG Hypo-methylation; Closed circles: CG Hyper-methylation; Grey circles:
Intermediate CG methylation state: 5-hmC, 5-fC, 5-caC Brown oval: CTCF; Green oval: methylDNA binding proteins; ++: high expression; +: medium expression; +/-: Low expression: +/- -:
very low expression; X: Repressed
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of a normal tissue prior to explicit oncogenesis. This produces a polyclonal population of cells
that are epigenetically perturbed and begin gradually drifting towards oncogenesis. Epigenetic
disruption could be caused by “tumor-progenitor genes” that “mediate epigenetic expansion of
progenitor cells… and increase their cancer proneness, …” possibly by prioritizing stemness
over differentiation (Feinberg et al., 2006). Feinberg et al. specifically propose AICDA as a
candidate tumor-progenitor gene because it acts on DNA directly, causes both genetic and
epigenetic changes, and has been linked to B-cell lymphomagenesis. (See sections titled
“Endogenous Sources of Mutation and Their Signatures” and “Connections Between Epigenetic
Dysregulation and Relapse in DLBCL.”) They also point toward genes whose products directly
modify chromatin, such as EZH2. Eventually, chronic epigenetic disruption leads to an initiating
genetic mutation that formally drives oncogenesis, followed by further genetic and epigenetic
aberrations. From then on, the cancer begins to increasingly emphasize the acquisition of genetic
and epigenetic plasticity (Flavahan, Gaskell, & Bernstein, 2017), or “adaptability,” in order to
more readily adapt to any conditions that it may encounter. For example, epigenetic instability is
caused by changes in the expression of genes whose products modify chromatin, like EZH2. One
could plausibly argue that changes in the activity of chromatin-modifying enzymes, including
EZH2, CREBBP, P300 and KMT2D, may also lead to epigenetic instability (Feinberg et al.,
2016; Timp & Feinberg, 2013). Increased plasticity, in turn, fuels tumor heterogeneity and allows
cancer cells to experiment with a diverse array of phenotypes and more aggressive characteristics
(Figure 8). This increases the entropy of the system and decreases the probability that any one
therapy will kill every single subclone, which can lead to chemoresistance (Easwaran, Tsai, &
Baylin, 2014; Shaknovich et al., 2014). Once again, this sequence of events sounds quite similar
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to that which occurs during the development of DLBCL, a cancer notorious for both its
heterogeneity and its resistance to treatment.

Figure 8. Epigenetic heterogeneity promotes the acquisition of aggressive traits in cancer
Classically, cancer has been thought of as a disease that is primarily genetic in nature. However,
it is now known that epigenetic dysregulation in cancer can also be functionally and clinically
relevant. One clear example is its contribution to tumor heterogeneity. When the epigenome is
disrupted, either independently of genetic mutations (e.g., AID-related DNA hypomethylation)
or as a result of them (e.g., in histone-modifying enzymes), tumor cells can start to evolve based
on selection for favorable epigenetic states. This can lead to the production of tumor subclones
that are genetically identical but, in reality, are expressing different combinations of genes and/or
have altered the level at which certain genes are expressed. In addition to producing more
aggressive characteristics, increased tumor heterogeneity decreases the likelihood that any one
treatment will be able to kill every subclone, which can lead to chemoresistance and relapse.
[Adapted from (Easwaran et al., 2014)]
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Additionally, it is evident that DLBCL is closely associated with aging. As was
previously mentioned, the median age of diagnosis is 66 years old, and 66.3% of DLBCL cases
occur between the ages of 55 and 84 (SEER 3, https://seer.cancer.gov/statfacts/html/dlbcl.html).
Furthermore, ~80% of genetic mutations in DLBCL have a signature that is associated with
aging (Chapuy et al., 2018). It should be noted that the aging process itself is known to involve
extensive epigenetic reprogramming. This includes such events as the loss of heterochromatin,
changes in the levels of certain histone variants, alterations in the levels and distributions of
histone PTMs and DNA methylation, and differential expression of noncoding RNAs (Pal &
Tyler, 2016). It seems quite likely that the aging process contributes to the development of
DLBCL in some patients, perhaps acting as an accelerant with regard to large-scale epigenetic
reprogramming.
For all of these reasons, an enormous amount of both basic-science and clinical research
has been devoted to finding alternative strategies for the treatment of DLBCL besides the
standard R-CHOP chemotherapy regimen, especially those that target the epigenome (Camicia,
Winkler, & Hassa, 2015; L. Cerchietti & Leonard, 2013; Guo, Lin, Xiong, Tu, & Chen, 2018;
Kuhnl, Cunningham, & Chau, 2017; Sermer, Pasqualucci, Wendel, Melnick, & Younes, 2019).
Because epigenetic modifications are reversible, the ideas of reprogramming oncogenic
epigenetic changes in DLBCL (Clozel et al., 2013) and preventing the transformation of
precancerous B-cells (Timp & Feinberg, 2013) are very appealing2 (see footnote). Theoretically,
it stands to reason that “resetting” the epigenome of DLBCL cells could also potentially reduce
tumor heterogeneity by eliminating subclones that are genetically identical but epigenetically
distinct. Furthermore, if the drug dose were low enough to alter the epigenome and reduce tumor

This is the logic behind our on-going investigation into the effects of diet (i.e., -3 fatty acids) on the epigenome in
DLBCL.
2
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heterogeneity without killing cells, then perhaps it would be possible to shape the cancer’s
characteristics and overall “trajectory” without promoting natural selection and the development
of resistance. This would not eliminate the tumor mass itself, but if used rationally, perhaps some
of its more aggressive characteristics and/or propensity for relapse could be reduced (Clozel et
al., 2013). Much more research is needed to develop therapies for DLBCL that address its
immense complexity in a way that R-CHOP chemotherapy simply does not.
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CHAPTER 2
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Abstract
Diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma, often
develops resistance and/or relapses in response to immunochemotherapy. Genes encoding
epigenetic modifiers are some of the most frequent targets of mutations in DLBCL, including the
lysine (histone) acetyltransferases CREBBP and EP300. Mutations in CBP/p300 can prevent the
proper acetylation and activation of 1) enhancer sequences that regulate the expression of genes
required for essential functions (e.g., germinal center exit and differentiation) and 2) p53, master
regulator of the cellular response to DNA damage. Based on evidence that -3 fatty acids (-3
FA) can influence histone acetylation in multiple types of cancer, we wanted to know if the -3
FA docosahexaenoic acid (DHA) could partially restore levels of histone and p53 acetylation in
three DLBCL cell lines (each with a different CREBBP/EP300 mutational status) and one line of
normal B-cells. Western blot results showed that exposure to DHA at clinically attainable doses
does significantly alter the genome-wide levels of histone post-translational modifications
(PTMs) in a cell-line and dose-dependent manner, including multiple acetylated residues
(H3K9Ac, H4K5Ac, H4K8Ac, H4K12Ac, H4K16Ac). Although histone acetylation
unexpectedly decreased more often than it increased, levels of p53 acetylation increased
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consistently. qRT-PCR results revealed significant changes in the expression of multiple genes,
including increased expression of CREBBP and of PRDM1, which is required for differentiation
into plasma cells or memory B-cells. Taken together, our results provide (to our knowledge) the
first characterization of the epigenetic effects of -3 fatty acids in DLBCL, as well as a basis for
further investigation into their therapeutic potential.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma
(Morton et al., 2006) (UpToDate 1, https://www.uptodate.com/contents/epidemiology-clinicalmanifestations-pathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma), with an
incidence rate of 5.6 per 100,000 persons per year in the U.S. (SEER 3,
https://seer.cancer.gov/statfacts/html/dlbcl.html). The standard treatment for DLBCL is the RCHOP chemoimmunotherapy regimen (Rituximab, Cyclophosphamide, Hydroxydaunorubicin
(doxorubicin), Oncovin (vincristine), and Prednisone). Although CHOP outperformed other
regimens in clinical trials to become the treatment of choice for DLBCL (Coiffier et al., 2002;
Coiffier et al., 2010; Feugier et al., 2005), response to R-CHOP can be quite variable and is
dependent upon stage and molecular subtype (Scott et al., 2015). Consequently, despite relatively
high 5-year OS rates in certain subsets of DLBCL patients (i.e., limited-stage and germinal
center B-cell (GCB)-type) (Lamy et al., 2018; Scott et al., 2015), ~30% of all patients either do
not respond or relapse within 5 years of treatment with R-CHOP (Coiffier et al., 2002; Feugier et
al., 2005), and 30–50% of all patients are not cured (Coiffier & Sarkozy, 2016; Coiffier et al.,
2010).
In light of R-CHOP’s shortcomings, many researchers have investigated the molecular
pathogenesis of DLBCL to better understand the nature of the disease (Chapuy et al., 2018; Lohr
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et al., 2012; Morin et al., 2011; Morin et al., 2013; Pasqualucci & Dalla-Favera, 2015;
Pasqualucci, Dominguez-Sola, et al., 2011; Pasqualucci, Trifonov, et al., 2011; Reddy et al.,
2017; Schmitz et al., 2018). A consistent trend from genomic analyses of DLBCL is the
recurrence of mutations in genes related to chromatin structure and composition, along with
other epigenetic events. Specifically, mutations in the genes encoding histone-modifying
enzymes are some of the most common in DLBCL (Morin et al., 2011; Pasqualucci, DominguezSola, et al., 2011; Reddy et al., 2017). Two such genes, CREBBP (cAMP response elementbinding protein (CREB) binding protein; ~11%) and EP300 (E1A binding protein 300; ~6%), are
altered in ~17% of DLBCL cases (Reddy et al., 2017). They encode the lysine acetyl transferases
(KATs) CREBBP and p300, whose important targets include lysines 18 and 27 of histone H3
(H3K18Ac and H3K27Ac). The former is usually associated with genes that are actively
expressed, and the latter is required for gene enhancer activation (Creyghton et al., 2010; Raisner
et al., 2018). CREBBP and p300 also target proteins that are not histones, including ones like
BCL6 (“master regulator” of GC reaction; inactivated by acetylation) and p53 (first-line response
to DNA damage; activated by acetylation) that are heavily involved in the physiology of both
normal and cancerous GC B-cells (Bereshchenko et al., 2002; Hatzi et al., 2013; Kim et al.,
2019; M. Li et al., 2002; Pasqualucci, Dominguez-Sola, et al., 2011; Tang, Zhao, Chen, Zhao, &
Gu, 2008). As B-cells progress through the GC reaction, they must repress the expression of
hundreds of genes involved in cell-cycle inhibition [e.g., CDKN1A (Cyclin Dependent Kinase
Inhibitor 1A)], DNA damage response [e.g., TP53 (Tumor Protein P53)], apoptosis,
differentiation [e.g., PRDM1 [PRDF1-RIZ (PR)/[Su(var) 3-9, enhancer-of-zeste, and trithorax]
(SET) Domain 1]], and immune signaling in order for affinity maturation to proceed (Hatzi &
Melnick, 2014; Mlynarczyk et al., 2019). In this context, repression is primarily accomplished
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through the binding of BCL6 and subsequent epigenetic poising or “switching off” of gene
enhancers via the deacetylation of H3K27 residues (Hatzi et al., 2013). The repression is
temporary in normal GC B-cells, but those with CREBBP or EP300 mutations do not reactivate
the affected enhancers and their associated gene(s) (Jiang et al., 2017; Meyer et al., 2019; J.
Zhang et al., 2017). Moreover, BCL6 and p53 fail to be completely inactivated and reactivated,
respectively. This is problematic, because many of these same genes must be expressed in order
to exit the GC reaction, differentiate into plasma cells or memory B-cells, and avoid prolonged
exposure to a potentially oncogenic internal environment (Bakhshi & Georgel, 2020; Jiang &
Melnick, 2015; Mlynarczyk et al., 2019; Pasqualucci, 2019).
Because chemotherapy and radiation do not elicit a partial or complete response in all
patients, there is a constant need for new therapeutic agents and strategies that may improve
cancer treatment. The potential of omega-3 fatty acids (-3 FAs) to prevent and/or treat cancer
has been actively researched for decades. While the question of whether or not -3 FAs can
prevent cancer is heavily debated (Azrad, Turgeon, & Demark-Wahnefried, 2013; Gerber, 2012;
MacLean et al., 2006; Weylandt et al., 2015), their therapeutic effects on extant cancers are welldocumented (D'Eliseo & Velotti, 2016; de Aguiar Pastore Silva, Emilia de Souza Fabre, &
Waitzberg, 2015; Huerta-Yepez, Tirado-Rodriguez, & Hankinson, 2016; Nabavi et al., 2015;
Stephenson et al., 2013), including many types of leukemia and lymphoma (Fahrmann et al.,
2013; Fahrmann & Hardman, 2013; Moloudizargari et al., 2018). Numerous studies have also
demonstrated that -3 fatty acids can alter the epigenome in both normal and cancerous tissues
(Lau, Yu, & Xu, 2019), including the acetylation levels of histones (A. Abbas et al., 2021; Isaac
et al., 2018; Ramaiyan & Talahalli, 2018; Sadli, Ackland, De Mel, Sinclair, & Suphioglu, 2012).
Notably, in their recent work with a mouse model of breast cancer, Abbas et al. showed that the
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F1 offspring of maternal mice that had consumed a diet rich in -3 FAs exhibited significant
(p=0.005) genome-wide increases in acetylation on lysine 18 of histone H3 (H3K18Ac) and
lysines 12 and 16 of histone H4 (H4K12Ac and H4K16Ac) in breast tissue (A. Abbas et al.,
2021). Chromatin immunoprecipitation followed by sequencing (ChIP-seq) revealed significant
enrichment of H3K18Ac at the transcription start sites (TSS) of many genes that were also found
to be overexpressed in a microarray analysis, as well as those of long intergenic noncoding RNA
(lincRNA) genes. Additionally, gene set enrichment analysis (GSEA) revealed significant
upregulation of pathways that are especially relevant in the context of cancer, such as the p53
pathway (p<0.0001), DNA repair (p=0.011), apoptosis (p<0.0001), and the G2/M checkpoint
(p<0.0001). There were also noticeable (though not statistically significant) delays in mortality
and tumor development and reductions in tumor size and lateral growth (A. Abbas et al., 2021).
Despite the large volume of information that is available for DLBCL and -3 FAs as
separate subjects, there is a dearth of literature that specifically describes the effects of -3 FAs
on DLBCL. To our knowledge, the only investigation that has been conducted regarding the
relationship between -3 FAs and DLBCL is a pilot study by Thanarajasingam et al., in which
they indicate a potential association between low plasma levels of -3 FAs and inferior 24month event-free survival (EFS24) (Thanarajasingam et al., 2018). Furthermore, while the
epigenetic effects of -3 FAs have been characterized in multiple types of cancer (A. Abbas et
al., 2021; Lau et al., 2019), we were unable to find an analogous characterization for DLBCL.
The purpose of our investigation, therefore, was to determine the effects of the -3 FA
docosahexaenoic acid (DHA) on viability, gene expression, and genome-wide levels of histone
post-translational modifications (PTMs) in vitro on a series of three DLBCL cell lines and one
normal B-cell line. We hypothesized that exposure to DHA would alter the epigenome of
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DLBCL cells, including a partial restoration of histone acetylation (and acetylation of p53), and
that these epigenetic changes may vary based on the mutational status of CREBBP and/or EP300
in each cell line (Andersen, Asmar, Klausen, Hasselbalch, & Gronbaek, 2012). Along these lines,
and to our knowledge, the results of this study provide the first known characterization of the
epigenetic effects of -3 FAs in DLBCL. They are also the first step towards assessing the ability
of -3 FAs to compensate for pathological epigenetic changes that occur in DLBCL.
Materials and Methods
Cell Culture
The NCI-BL2171 (Cat#CRL-5969), SU-DHL-5 (Cat#CRL-2958), and Toledo
(Cat#CRL-2631) cell lines were obtained from ATCC, while the OCI-Ly7 (Cat#ACC-688) cell
line was obtained from DSMZ. NCI-BL2171, SU-DHL-5, and Toledo were grown in ATCCformulated RPMI-1640 medium (Gibco, Fisher Scientific, Cat#A1049101) supplemented with
10% FBS (Cytiva Hyclone, Fisher Scientific, Cat#SH300880340). OCI-Ly7 was grown in
IMDM medium (Gibco, Fisher Scientific, Cat#12440053) supplemented with 20% FBS (Cytiva
Hyclone, Fisher Scientific, Cat#SH300880340). All cell lines were maintained in T-75 flasks
(CELLTREAT Scientific Products, Fisher Scientific, Cat#50202080) in an incubator set to 37 C
and 5% CO2.
Viability Assays
The Trypan Blue Exclusion method was used to perform viability assays for each cell
line. Assays were conducted in six-well plates (Thermo Scientific, Fisher Scientific,
Cat#12556004) and in biological triplicate (n=3) for 72 hours. Five wells of each plate were used
for different conditions: plain medium, vehicle control, 10-µM DHA, 25-µM DHA, and 50-µM
DHA. 100-mM sub-stock solutions of DHA (Cayman Chemical, Cat#90310) were prepared by
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diluting the stock solution in 100% EtOH (Fisher Scientific, Cat#BP2818500). Working
concentrations of DHA and vehicle control were prepared by serially diluting 100-mM DHA or
100% EtOH, respectively, in the appropriate medium for each cell line. Seeding densities for
each cell line were based on empirical growth rates and suppliers’ guidelines in order to prevent
overgrowth and exhaustion of medium. SU-DHL-5 was seeded at a density of 5x104 viable
cells/mL in 3 mL of control or treatment medium per well (total 1.5x10 5 viable cells). NCIBL2171, OCI-Ly7, and Toledo were seeded at a density of 3x105 viable cells/mL in 3 mL of
control or treatment medium per well (total 9x105 viable cells). After 72 hours, 50 µL from each
well were mixed with 50 µL of Trypan Blue (Gibco, Fisher Scientific, Cat#15250061) before
measuring viability twice and averaging (Invitrogen Countess II FL Automated Cell Counter).
The mean viability of each treatment condition from all three plates was then compared to that of
the vehicle control using a one-way ANOVA, followed by Dunnett’s multiple comparisons test.
The mean viabilities of OCI-Ly7, SU-DHL-5, and Toledo were also compared to that of NCIBL2171 for each treatment condition using a two-way ANOVA, followed by Dunnett’s multiple
comparisons test.
Treatment and Harvesting
100-mM sub-stock solutions of DHA were prepared by diluting the stock solution in
100% EtOH. Working concentrations of DHA and vehicle control were prepared by serially
diluting 100-mM DHA or 100% EtOH, respectively, in the appropriate medium for each cell
line. Treatments with DHA or vehicle control were performed in T-75 flasks (biological
quadruplicate, n=4) for 72 hours. Seeding densities for each cell line were based on empirical
growth rates and suppliers’ guidelines in order to prevent overgrowth and exhaustion of medium.
SU-DHL-5 was seeded at a density of 5x104 viable cells/mL in 30 mL of control or treatment
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medium (total 1.5x106 viable cells). NCI-BL2171, OCI-Ly7, and Toledo were seeded at a
density of 3x105 viable cells/mL in either 15 mL or 30 mL of control or treatment medium (total
4.5x106 or 9x106 viable cells); this was based on the number of cells needed for different
experiments and to account for the suppressive effects of 25-µM DHA on growth and viability.
After 72 hours, cells were collected, centrifuged (Thermo Scientific Sorvall Legend RT) at 125g
for 10 min, rinsed with 1x PBS, and centrifuged again at 125g for 10 min. After aspirating
supernatants, cell pellets were flash-frozen in liquid N2 and then stored at -80°C until needed.
Protein Extraction
Extraction of whole-cell protein from thawed cell pellets began by adding 100 µL of cold
Mammalian Protein Extraction Reagent (M-PER) (Thermo Scientific, ThermoFisher Scientific,
Cat#78501) per 10 µL of packed cell volume and 1 µL of 100X Halt Protease Inhibitor Cocktail
(Thermo Scientific, ThermoFisher Scientific, Cat#87786) per 100 µL of M-PER. After
resuspending cell pellets, lysates were sonicated on high for 5 min with 30-sec on/off intervals at
4°C (Diagenode Bioruptor; Thermo Scientific NESLAB RTE-7) to ensure proper lysis of nuclei.
Samples were then rotated for 10 min at 4°C, followed by centrifugation at 14,000g for 15 min at
4°C (Beckman Coulter Microfuge 22R). Supernatants were transferred to separate tubes and
stored at -80°C for later use. Protein quantification was performed using the Pierce Coomassie
Plus Bradford Assay Kit (Thermo Scientific, ThermoFisher Scientific, Cat#23236) with a
working range of 125-1500 µg/mL and 96-well microplates. Plates were read using a BioTek
Synergy HTX Multi-Mode Microplate Reader, which generated a standard curve and protein
concentrations for all samples in Microsoft Excel.
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Western Blots
Whole-cell protein extracts (20 µg per sample, n=3 or n=4) were separated via
SDS/PAGE (4-20% Mini-PROTEAN TGX Precast Protein Gels, Bio-Rad, Cat#4561095) and
then transferred to PVDF membranes (MilliporeSigma Immobilon-FL, Fisher Scientific,
Cat#IPFL00010). Primary antibodies used were: anti-Histone H3 (Active Motif, Cat#39451,
1:10000), anti-Histone H4 (Active Motif, Cat#61199, 1:1000), anti-H3K4me1 (Active Motif,
Cat#61633, 1:1000), anti-H3K4me2 (Active Motif, Cat#39141, 1:1000), anti-H3K4me3 (Active
Motif, Cat#39159, 1:1000), anti-H3K9me3 (Active Motif, Cat#39765, 1:1000), anti-H3K27me3
(Active Motif, Cat#39155, 1:1000), anti-H3K9Ac (Active Motif, Cat#39917, 1:1000), antiH3K18Ac (Active Motif, Cat#39755, 1:1000), anti-H3K27Ac (Active Motif, Cat#39133,
1:1000), anti-H4K5Ac (Active Motif, Cat#39699, 1:1000), anti-H4K8Ac (Active Motif,
Cat#61103, 1:1000), anti-H4K12Ac (Active Motif, Cat#39927, 1:1000), anti-H4K16Ac
[EPR1004] (Abcam, Cat#ab109463, 1:1000), anti-p53 [DO-1] (Santa Cruz, Cat#sc-126, 1:1000),
and anti-Acetyl-p53 [Lys382] (Cell Signaling, Cat#2525, 1:1000). Secondary antibodies used
were: goat anti-rabbit IgG, HRP-linked (Cell Signaling, Cat#7074, 1:10000) and horse antimouse IgG, HRP-linked (Cell Signaling, Cat#7076, 1:10000). SuperSignal West Dura (Thermo
Scientific, ThermoFisher Scientific, Cat#34075) and SuperSignal West Femto (Thermo
Scientific, ThermoFisher Scientific, Cat#34095) ECL substrates were used to detect target
proteins. Western blots were imaged on either a ProteinSimple FluorChem E imager (analysis
software: AlphaView SA, version 3.4.0.729) or a Bio-Rad ChemiDoc MP Imaging System
(analysis software: Image Lab, version 6.1.0, build 7, standard edition). Numerical values of
signal intensity are shown as the mean of treated samples relative to the mean of control samples,
set at 1, after normalizing all samples to loading control (unmodified Histone H3 or Histone H4).
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The normalized mean signal intensity of treated samples was compared to that of control samples
using an unpaired, two-tailed Welch’s t-test.
RNA Extraction and cDNA Synthesis
Extraction of RNA from thawed cell pellets (~5x106 cells per sample) was done using the
PureLink RNA Mini Kit (Invitrogen, Fisher Scientific, Cat#12183018A) and PureLink DNase
Set (Invitrogen, Fisher Scientific, Cat#12185010). RNA was quantified using the NanoDrop ND1000 (NanoDrop Technologies, Thermo Scientific), and RNA integrity was assessed using an
Agilent 2100 Bioanalyzer RNA 6000 Nano Assay. Only samples with an RNA Integrity Number
(RIN) 7.0 were used for downstream applications. 200ng of total RNA per sample were then
converted to cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Fisher Scientific, Cat#4368814) in a Bio-Rad C1000 Thermal Cycler. Thermal
cycling conditions were as follows: 10 min at 25°C, 120 min at 37°C, and 5 min at 85°C.
qRT-PCR
Real-time qRT-PCR was performed in biological and technical triplicate (n=3) on an
Applied Biosystems StepOnePlus Real-Time PCR System with TaqMan Fast Advanced Master
Mix (Applied Biosystems, ThermoFisher Scientific, Cat#4444557), 2.5 ng of cDNA per reaction,
and TaqMan gene expression assays (ThermoFisher Scientific). All TaqMan probe and primer
sets were selected for best coverage of human target genes and used an FAM-MGB dye: BCL6
(Assay ID#Hs00153368_m1), TP53 (Assay ID#Hs01034249_m1), ATR (Assay ID#
Hs00992123_m1), ATM (Assay ID#Hs00175892_m1), CHEK1 (Assay ID#Hs00967506_m1),
CDKN1A (Assay ID#Hs00355782_m1), AICDA (Assay ID#Hs00757808_m1), PRDM1 (Assay
ID#Hs00153357_m1), MIR155HG (Assay ID#Hs01374569_m1), CREBBP (Assay
ID#Hs00932878_m1), EP300 (Assay ID#Hs00914223_m1), and GAPDH (Assay
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ID#Hs02786624_g1). qRT-PCR conditions were as follows: 2 min at 50°C, 2 min at 95°C, and
40 cycles of 1 sec at 95°C followed by 20 sec at 60°C. Data were analyzed using the 2 -CT
method (Schmittgen & Livak, 2008). Numerical values of gene expression are shown as the
mean of treated samples relative to the mean of control samples, set at 1, after normalizing all
samples to GAPDH as an internal control gene. The normalized mean gene expression of treated
samples was compared to that of control samples using a two-tailed Welch’s t-test.
Statistical Analyses
Differences between control and treatment groups were assessed for statistical
significance using a two-tailed Welch’s t-test for Western blots and qRT-PCR and one-way or
two-way ANOVA followed by Dunnett’s multiple comparisons test for viability assays. Results
were considered statistically significant at p <0.05. Statistical analyses were performed in
GraphPad Prism 9 for macOS, version 9.1.0 (216), GraphPad Software, La Jolla, CA, USA,
www.graphpad.com.
Results
Viability Assays
To determine the concentrations of DHA that would be used to treat cells in downstream
experiments, the effects of DHA on cell viability were tested in three human DLBCL cell lines
(OCI-Ly7, SU-DHL-5, and Toledo) and one line of normal, EBV-transformed human B-cells
(NCI-BL2171). OCI-Ly7 expresses wild-type (WT) CREBBP and EP300 (L. C. Cerchietti et al.,
2010; Jiang et al., 2017) and was originally determined to be Stage IIA at relapse; SU-DHL-5
has a monoallelic deletion of CREBBP and expresses WT EP300 (Hashwah et al., 2017;
Pasqualucci, Dominguez-Sola, et al., 2011) and was originally derived from a metastatic site
(i.e., Stage IV); and Toledo has a 3-bp deletion of CREBBP and a missense mutation in EP300
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(Andersen et al., 2012). All cell lines were treated with plain control medium, medium plus
vehicle (EtOH), and medium supplemented with DHA at concentrations of 10 µM, 25 µM, and
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Figure 9. Cell viability after DHA exposure
Figure 9 shows the mean viability of A) NCI-BL2171, B) OCI-Ly7, C) SU-DHL-5, and D)
Toledo cells after 72-Hr exposure to plain control medium, medium plus vehicle (EtOH control),
and medium supplemented with DHA at concentrations of 10 µM, 25 µM, and 50 µM. Trypan
blue exclusion assays were performed in biological triplicate (n=3). Statistical significance was
assessed by one-way ANOVA, followed by Dunnett’s multiple comparisons test. The mean cell
viability for each treatment condition was compared to that of the EtOH control group. Error bars
represent SEM. 𝛼 = 0.05; ** < 0.0021; *** < 0.0002; **** < 0.0001. Abbreviations: EtOHethanol; DHA- docosahexaenoic acid.
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50 µM. These concentrations are consistent with previous studies in hematological cancer cell
lines (Moloudizargari et al., 2018) and are clinically attainable (Fahrmann et al., 2013). After 72
hours of treatment, viability was assessed using the Trypan Blue Exclusion assay.
In OCI-Ly7, SU-DHL-5, and Toledo cells, no statistically significant changes in viability
occurred at 10-µM DHA compared to vehicle control. In contrast, statistically significant
decreases in the viability of these three cell lines were observed at 25-µM DHA [OCI-Ly7
(p<0.0001); SU-DHL-5 (p=0.0018); Toledo (p<0.0001)] and 50-µM DHA [OCI-Ly7
(p<0.0001); SU-DHL-5 (p=0.0001); Toledo (p<0.0001)] compared to vehicle control (Fig. 9BD). Moreover, OCI-Ly7 and Toledo showed a precipitous drop in viability between the 25-µM
and 50-µM doses (OCI-Ly7 41.2% to 3.4%; Toledo 55.7% to 4.8%) (Fig. 9B and 9D), while the
reduction for SU-DHL-5 was more gradual (32.7% to 15.9%) (Fig. 9C). NCI-BL2171,
meanwhile, only experienced a significant decrease in viability at 50-µM DHA (p<0.0001) (Fig.
9A). Furthermore, the viability of NCI-BL2171 at 50-µM DHA (32.3%) remained significantly
higher than that of other cell lines [vs. OCI-Ly7, 3.4% (p<0.0001); vs. SU-DHL-5, 15.9%
(p=0.0093); vs. Toledo, 4.8% (p<0.0001)] (Fig. 9A-D). Overall, these results indicate that
DLBCL cells have greater sensitivity to DHA than normal B-cells in vitro and that response to
DHA is dose-dependent in both normal B-cells and DLBCL cells.
Western blots
To test our hypothesis that exposure to DHA would alter the epigenome of DLBCL cells,
Western blots were performed to measure genome-wide levels of: methylation at lysines 4, 9,
and 27 of Histone H3 (H3K4me1/2/3, H3K9me3, H3K27me3), acetylation at lysines 9, 18, and
27 of Histone H3 (H3K9Ac, H3K18Ac, H3K27Ac), acetylation at lysines 5, 8, 12, and 16 of
Histone H4 (H4K5Ac, H4K8Ac, H4K12Ac, H4K16Ac), as well as p53 expression and
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acetylation. All four cell lines were treated with either DHA or vehicle control (EtOH) for 72
hours. Based on the results of viability assays, DHA concentrations of 10 µM and 25 µM were
used to determine whether or not changes in histone PTMs were occurring in DLBCL cells in the
context of unaffected (10 µM) or decreased (25 µM) cell viability. We wanted to know if DHA
could induce significant changes in the genome-wide levels of histone PTMs in DLBCL cells in
vitro without significantly affecting viability; this was done to avoid the negative selection of
drug-sensitive cancer cells that can contribute to metastasis and relapse in human DLBCL
patients. Our results show that exposure of DLBCL cells and normal B-cells to DHA in vitro
does lead to statistically significant changes in the genome-wide levels of each histone PTM that
was tested (except H3K9me3), as well as the expression and acetylation of the tumor suppressor
p53, at either one or both doses of DHA. Our results also indicate that the cell lines used in our
experiments responded differently to DHA, both overall and in a dose-dependent manner.
1. Effects of DHA on Histone Methylation
H3K4me1: H3K4me1 is typically associated with transcriptionally active regions of the
genome, particularly along active (i.e., H3K27Ac and H3K4me1) and poised (i.e., H3K4me1
alone) enhancers. DHA exposure had differential effects on genome-wide levels of H3K4me1
based on the cell line being tested.
At the 10-µM dose of DHA, a statistically significant increase in H3K4me1 was observed
in OCI-Ly7 [(p=0.0437); Stage IIA; WT CREBBP and EP300] and Toledo [(p=0.0298); 3-bp
deletion of CREBBP; missense mutation in EP300] cells after 72 hours, compared to vehicle
control [Fig. 10A (top); Supplementary Fig. S1B (top) and S1D (top)]. Interestingly, SU-DHL-5
cells (metastatic; monoallelic deletion of CREBBP; WT EP300) showed a statistically significant
decrease (p=0.0138), and NCI-BL2171 cells showed a statistically nonsignificant 0.5-fold
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decrease (p=0.0563), in H3K4me1 compared to vehicle control [Fig. 10A (top); Supplementary
Fig. S1C (top) and S1A (top)]. At the 25-µM dose of DHA, statistically significant changes in
H3K4me1 were not observed for any cell line [Fig. 10A (bottom); Supplementary Fig. S1A-D
(bottom)].
H3K4me2: H3K4me2 is commonly located at transcriptionally active regions of the
genome as well, specifically along promoters. No statistically significant changes in genomewide levels of H3K4me2 were observed for any cell line at the 10-µM dose of DHA [Fig. 10B
(top); Supplementary Fig. S1E-H (top)]. However, at the 25-µM dose of DHA, H3K4me2
increased significantly (p=0.0203) in SU-DHL-5 cells compared to vehicle control [Fig. 10B
(bottom); Supplementary Fig. S1G (bottom)].
H3K4me3: H3K4me3 is associated with transcriptionally active regions of the genome;
its presence at promoters is often used as a marker of active gene expression. At the 10-µM dose
of DHA, a statistically significant 0.5-fold decrease (p=0.0313) in its genome-wide level was
observed in NCI-BL2171 cells compared to vehicle control [Fig. 10C (top); Supplementary Fig.
S1I (top)]. Meanwhile, at 25-µM DHA, no significant changes in H3K4me3 were detected for
any cell line [Fig. 10C (bottom); Supplementary Fig. S1I-L (bottom)].
H3K9me3: H3K9me3 is a marker of repressed gene expression and is abundant in
heterochromatin (e.g., telomeres and satellite repeats). H3K9me3 is known to be of critical
importance during hematopoiesis and has been implicated in the molecular pathogenesis of acute
myeloid leukemia (AML) (Monaghan et al., 2019). No statistically significant changes in the
genome-wide levels of H3K9me3 were observed in any cell line at either the 10-µM [Fig. 10D
(top); Supplementary Fig. S1M-P (top)] or 25-µM dose [Fig. 10D (bottom) Supplementary Fig.
S1M-P (bottom)] of DHA.

70

Figure 10. Genome-wide levels of histone H3 methylation after DHA exposure
Figure 10 shows the mean genome-wide levels of A) H3K4me1, B) H3K4me2, C) H3K4me3, D)
H3K9me3, and E) H3K27me3 in NCI-BL2171, OCI-Ly7, SU-DHL-5, and Toledo cells after 72Hr exposure to 10-µM DHA (top) or 25-µM DHA (bottom) relative to vehicle (EtOH) control.
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Western blots were performed in biological quadruplicate (n=4) or triplicate (n=3), depending on
sample availability. Numerical values of signal intensity are shown as the mean of treated
samples relative to the mean of control samples, set at 1, after normalizing all samples to total
histone H4. Statistical significance was assessed using an unpaired, two-tailed Welch’s t-test.
Error bars represent SEM. 𝛼 = 0.05; * < 0.0332; ** < 0.0021. Abbreviations: DHAdocosahexaenoic acid; H3K4me1- monomethylation at lysine 4 of histone H3; H3K4me2dimethylation at lysine 4 of histone H3; H3K4me3- trimethylation at lysine 4 of histone H3;
H3K9me3- trimethylation at lysine 9 of histone H3; H3K27me3- trimethylation at lysine 27 of
histone H3.

H3K27me3: H3K27me3 is another marker of gene repression that is enriched at the
promoters of inactive genes or, in combination with H3K4me3, “poised” promoters of genes that
are temporarily repressed. In response to 10-µM DHA, the genome-wide level of H3K27me3
exhibited a statistically significantly decrease in Toledo cells (p=0.0352) compared to vehicle
control [Fig. 10E (top); Supplementary Fig. S1T (top)]. At the 25-µM dose of DHA, H3K27me3
instead increased significantly in Toledo cells (p=0.0394) and decreased significantly in SUDHL-5 cells (p=0.0044) compared to vehicle control [Fig. 10E (bottom); Supplementary Fig.
S1T (bottom) and S1S (bottom)].
2. Effects of DHA on Histone Acetylation
H3K9Ac: H3K9Ac can be found at both promoters and enhancers and is associated with active
gene expression, including the change from transcription initiation to elongation (Gates et al.,
2017). H3K9Ac, along with H3K27Ac, H4K5Ac, and H4K8Ac, are all positively correlated with
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H3K4me3 and active transcription, and they all exhibit a bimodal (“on/off”) distribution (Perner
& Chung, 2013).
When exposed to 10-µM DHA, SU-DHL-5 (p=0.0659) and Toledo (p=0.0524) cells

Figure 11. Genome-wide levels of histone H3 acetylation after DHA exposure
Figure 11 shows the mean genome-wide levels of A) H3K9Ac, B) H3K18Ac, and C) H3K27Ac
in NCI-BL2171, OCI-Ly7, SU-DHL-5, and Toledo cells after 72-Hr exposure to 10-µM DHA
(top) or 25-µM DHA (bottom) relative to vehicle (EtOH) control. Western blots were performed
in biological quadruplicate (n=4) or triplicate (n=3), depending on sample availability.
Numerical values of signal intensity are shown as the mean of treated samples relative to the
mean of control samples, set at 1, after normalizing all samples to total histone H4. Statistical
significance was assessed using an unpaired, two-tailed Welch’s t-test. Error bars represent
SEM. 𝛼 = 0.05; * < 0.0332; ** < 0.0021. Abbreviations: DHA- docosahexaenoic acid; H3K9Acacetylation at lysine 9 of histone H3; H3K18Ac- acetylation at lysine 18 of histone H3;
H3K27Ac- acetylation at lysine 27 of histone H3.
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displayed downward trends, and NCI-BL2171 cells showed a statistically significant 0.6-fold
decrease (p=0.0234), in their genome-wide levels of H3K9Ac compared to vehicle control [Fig.
11A (top); Supplementary Fig. S2C (top), S2D (top), and S2A (top)]. Interestingly, when
exposed to 25-µM DHA, Toledo cells also showed a significant 0.6-fold decrease in H3K9Ac
(p=0.0012) compared to vehicle control [Fig. 11A (bottom); Supplementary Fig. S2D (bottom)].
H3K18Ac: H3K18Ac, another marker of transcriptional activity, did not show any
statistically significant genome-wide changes at the 10-µM dose of DHA [Fig. 11B (top);
Supplementary Fig. S2E-H (top)]. However, after exposure to 25-µM DHA, SU-DHL-5 cells
showed a statistically significant genome-wide increase in H3K18Ac (p=0.0019) compared to
vehicle control [Fig. 11B (bottom); Supplementary Fig. S2G (bottom)].
H3K27Ac: H3K27Ac is associated with the activation of enhancer sequences (Creyghton
et al., 2010). Enhancers positively regulate the expression of one or more genes and can facilitate
the rapid switching of genes between “on,” “poised,” and “off” states. Like H3K18Ac,
H3K27Ac is “written” by CREBBP and p300 (Raisner et al., 2018).
After exposure to 10-µM DHA, a statistically significant increase in the genome-wide
level of H3K27Ac was observed in OCI-Ly7 cells (p=0.0266), as well as a downward trend in
NCI-BL2171 cells (p=0.0552), when compared to vehicle control [Fig. 11C (top);
Supplementary Fig. S2J (top) and S2I (top)]. NCI-BL2171 cells (normal) also showed a
statistically significant 0.5-fold decrease in H3K27Ac (p=0.009) after exposure to 25-µM DHA,
compared to vehicle control [Fig. 11C (bottom); Supplementary Fig. S2I (bottom)].
H4K5Ac: H4K5Ac and H4K8Ac are preferentially bound by BRD4 (BromodomainContaining Protein 4) (W. Zhang et al., 2012). BRD4 both binds acetylated histones and recruits
the transcription factor P-TEFb (Positive Transcription Elongation Factor B) that phosphorylates
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the C-terminal domain (CTD) of RNA Polymerase II (RNA Pol II) during the switch from
transcription initiation to elongation (Perner & Chung, 2013).
At the 10-µM dose of DHA, a statistically significant increase in the genome-wide level
of H4K5Ac in OCI-Ly7 cells (p=0.0085) and a downward trend in Toledo cells (p=0.2685) were
observed compared to vehicle control [Fig. 12A (top); Supplementary Fig. S3B (top) and S3D
(top)]. Similarly, in response to 25-µM DHA, H4K5Ac displayed a statistically significant ~4fold increase in OCI-Ly7 cells (p=0.0043), a significant 0.6-fold decrease in Toledo cells
(p<0.0001), and a significant 0.4-fold decrease in NCI-BL2171 cells (p=0.0003) relative to
vehicle control [Fig. 12A (bottom); Supplementary Fig. S3B (bottom), S3D (bottom), and S3A
(bottom)].
H4K8Ac: H4K8Ac showed a 0.8-fold decrease in Toledo cells (p=0.2215) and a
statistically significant 0.4-fold decrease in NCI-BL2171 cells (p=0.0336) occurred at the 10-µM
dose of DHA compared to vehicle control [Fig. 12B (top); Supplementary Fig. S3H (top) and
S3E (top)]. The results were similar for 25-µM DHA, with a statistically significant 0.4-fold
decrease in H4K8Ac in Toledo cells (p=0.0002) and a significant 0.5-fold decrease in NCIBL2171 cells (p=0.0181) compared to vehicle control [Fig. 12B (bottom); Supplementary Fig.
S3H (bottom) and S3E (bottom)].
H4K12Ac: H4K12Ac has been shown to bind CREBBP (Plotnikov et al., 2014).
Moreover, in response to estrogen in breast cancer cells, a strong correlation between H4K12Ac
and BRD4 occupancy, as well as mRNA expression, was observed at transcription start sites
(TSS) (Nagarajan, Benito, Fischer, & Johnsen, 2015). At enhancers’ loci, H4K12Ac was
correlated with H3K27Ac, BRD4, RNA Pol II, and nascent RNA transcription (Nagarajan et al.,
2015).
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Figure 12. Genome-wide levels of histone H4 acetylation after DHA exposure
Figure 12 shows the mean genome-wide levels of A) H4K5Ac, B) H4K8Ac, C) H4K12Ac, and
D) H4K16Ac in NCI-BL2171, OCI-Ly7, SU-DHL-5, and Toledo cells after 72-Hr exposure to
10-µM DHA (top) or 25-µM DHA (bottom) relative to vehicle (EtOH) control. Western blots
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were performed in biological quadruplicate (n=4) or triplicate (n=3), depending on sample
availability. Numerical values of signal intensity are shown as the mean of treated samples
relative to the mean of control samples, set at 1, after normalizing all samples to total histone H3.
Statistical significance was assessed using an unpaired, two-tailed Welch’s t-test. Error bars
represent SEM. 𝛼 = 0.05; * < 0.0332; ** < 0.0021; *** < 0.0002. Abbreviations: DHAdocosahexaenoic acid; H4K5Ac- acetylation at lysine 5 of histone H4; H4K8Ac- acetylation at
lysine 8 of histone H4; H4K12Ac- acetylation at lysine 12 of histone H4; H4K16Ac- acetylation
at lysine 16 of histone H4.

In response to 10-µM DHA, genome-wide levels of H4K12Ac showed a statistically
significant decrease in SU-DHL-5 cells (p=0.0138) and a downward trend in OCI-Ly7 cells
(p=0.0733) compared to vehicle control [Fig. 12C (top); Supplementary Fig. S3K (top) and S3J
(top)]. Exposure to 25-µM DHA resulted in a statistically significant 1.75-fold increase in
H4K12Ac in NCI-BL2171 cells (p=0.043) compared to vehicle control [Fig. 12C (bottom);
Supplementary Fig. S3I (bottom)].
H4K16Ac: H4K16Ac has a considerable influence on the interaction between
nucleosomes and, therefore, chromatin structure and compaction (R. Zhang, Erler, & Langowski,
2017). Like H4K12Ac, H4K16Ac has been shown to bind CREBBP (Plotnikov et al., 2014).
H4K16Ac has also been shown to recruit BRD4 in combination with other acetylated residues
[e.g., H4K5Ac/H4K8Ac and H3K9Ac/H3S10P (phosphorylation at serine 10 on Histone H3)]
and be involved in transcription elongation (Jung et al., 2014; W. Zhang et al., 2012; Zippo et al.,
2009).
At the 10-µM dose of DHA, the genome-wide level of H4K16Ac increased by 2.6-fold in
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NCI-BL2171 cells (p=0.2832) compared to vehicle control [Fig. 12D (top); Supplementary Fig.
S3M (top)]. At the 25-µM dose of DHA, H4K16Ac increased by 1.8-fold in OCI-Ly7 cells
(p=0.17), showed a statistically significant ~0.9-fold decrease in Toledo cells (p=0.0079), and
decreased 0.4-fold in NCI-BL2171 cells (p=0.1307) compared to vehicle control [Fig. 12D
(bottom); Supplementary Fig. S3N (bottom), S3P (bottom), and S3M (bottom)].
3. Effects of DHA on p53 Expression and Acetylation
The tumor suppressor protein p53 is the master regulator of the DNA damage response
(DDR) and maintaining genomic integrity. As was mentioned previously, p53 is activated via
acetylation by CREBBP and p300. BCL6, the aforementioned master regulator of GC B-cells
and DLBCL cells, represses the expression of both TP53 (Phan & Dalla-Favera, 2004) and
EP300 (L. C. Cerchietti et al., 2010). BCL6 also represses the expression of ATR and CHEK1,
which both encode proteins (of the same name) that are activated (in addition to p53) as part of
the DDR (Nghiem, Park, Kim Ys, Desai, & Schreiber, 2002; Tibbetts et al., 1999; H. Zhao &
Piwnica-Worms, 2001). p53 and BCL6 were recently shown to negatively regulate each other
through physical interaction as well (Kim et al., 2019). Interestingly, p53 is also a key factor in
determining the mechanism of cell death (i.e., apoptosis or autophagy) that cancer cells undergo
in response to treatment with histone deacetylase inhibitors (HDACi’s) (Mrakovcic, Kleinheinz,
& Frohlich, 2019).
p53: In response to 10-µM DHA, OCI-Ly7 cells showed a statistically significant 1.8fold increase in the expression of p53 (p=0.0171), and Toledo cells showed a 0.4-fold decrease in
p53 expression (p=0.0523) compared to vehicle control [Fig. 13A (top); Supplementary Fig. S4B
(top) and S4D (top)]. After exposure to 25-µM DHA, p53 expression showed a downward trend
in SU-DHL-5 cells (p=0.0508), a statistically significant 3-fold increase in Toledo cells
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(p=0.0446), and a noticeable ~8-fold increase in NCI-BL2171 cells (p=0.09) compared to
vehicle control [Fig. 13A (bottom); Supplementary Fig. S4C (bottom), S4D (bottom), and S4A
(bottom)].

Figure 13. p53 protein expression and acetylation after DHA exposure
Figure 13 shows the mean A) p53 protein expression, B) p53 acetylation, and C) ratio of
acetylated p53 to total p53 in NCI-BL2171, OCI-Ly7, SU-DHL-5, and Toledo cells after 72-Hr
exposure to 10-µM DHA (top) or 25-µM DHA (bottom) relative to vehicle (EtOH) control.
Western blots were performed in biological quadruplicate (n=4) or triplicate (n=3), depending on
sample availability. Numerical values of signal intensity are shown as the mean of treated
samples relative to the mean of control samples, set at 1, after normalizing all samples to total
histone H3 or H4. Statistical significance was assessed using an unpaired, two-tailed Welch’s ttest. Error bars represent SEM. 𝛼 = 0.05; * < 0.0332; ** < 0.0021. Abbreviations: DHAdocosahexaenoic acid.
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Acetylated p53: The response profile of acetylated p53 resembled that of p53 expression
for both 10-µM and 25-µM DHA. At the 10-µM DHA dose of DHA, acetylated p53 showed a
noticeable ~4-fold increase in OCI-Ly7 cells (p=0.0665) compared to vehicle control [Fig. 13B
(top); Supplementary Fig. S4F (top)]. At the 25-µM dose of DHA, acetylated p53 exhibited a
noticeable 3.7-fold increase in OCI-Ly7 cells (p=0.1208), a statistically significant ~3-fold
increase in Toledo cells (p=0.035), and a noticeable 2.2-fold increase in NCI-BL2171 cells
(p=0.3036) compared to vehicle control [Fig. 13B (bottom); Supplementary Fig. S4F (bottom),
S4H (bottom), and S4E (bottom)].
4. Summary of Western Blot Results
Despite the variety of changes in genome-wide levels of histone PTMs and protein
expression that were observed, all of them (except H3K9me3) exhibited statistically significant
changes and/or noticeable trends at 10-µM and/or 25-µM DHA. We then narrowed our results
further based on the magnitude of changes that occurred, using 2-fold increases and 0.5-fold
decreases as cutoffs. H3K4me1, H3K4me3, H3K27me3, H3K9Ac, H3K27Ac, H4K5Ac,
H4K8Ac, H4K12Ac, H4K16Ac, p53 expression, and p53 acetylation surpassed these cutoffs at
10-µM and/or 25-µM DHA.
Within this narrower subset, 2-fold increases and 0.5-fold decreases were observed
more commonly in response to 25-µM DHA (59%; 16/27) than in 10-µM DHA (41%; 11/27).
Furthermore, in response to 10-µM DHA, 0.5-fold decreases in expression (73%; 8/11) were
more common than 2-fold increases in expression (27%; 3/11). In contrast, 0.5-fold decreases
and 2-fold increases in expression both occurred at the same frequency in response to 25-µM
DHA (50%; 8/16). Interestingly, changes of this magnitude were only observed in NCI-BL2171
(normal B-cells), OCI-Ly7 (Stage IIA; WT CREBBP and EP300), and Toledo (3-bp deletion of
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CREBBP; missense mutation in EP300) cells, and not SU-DHL-5 cells (metastatic; monoallelic
deletion of CREBBP; WT EP300).
Several other patterns can be discerned from these data. Toledo cells showed 0.5-fold
decreases in H3K9Ac (25-µM DHA), H4K5Ac (10-µM and 25-µM DHA), H4K8Ac (10-µM
and 25-µM DHA), H4K16Ac (25-µM DHA), and p53 (10-µM DHA). Likewise, NCI-BL2171
cells exhibited 0.5-fold decreases in H3K4me1 (10-µM DHA), H3K4me3 (10-µM DHA),
H3K27me3 (10-µM DHA), H3K9Ac (10-µM DHA), H3K27Ac (25-µM DHA), H4K5Ac (25µM DHA), H4K8Ac (10-µM and 25-µM DHA), and H4K16Ac (25-µM DHA). In contrast, OCILy7 cells experienced 2-fold increases in H4K5Ac (25-µM DHA; also a 1.5-fold increase at 10µM DHA), H4K16Ac (25-µM DHA), p53 (10-µM DHA), and acetylated p53 (10-µM and 25µM DHA). NCI-BL2171 cells also showed 2-fold increases in H4K12Ac (25-µM DHA) and
H4K16Ac (10-µM DHA). As was mentioned previously, the response profiles of p53 expression
and p53 acetylation were similar. At 10-µM DHA, p53 expression and acetylation were both
increased in OCI-Ly7. At 25-µM DHA, p53 expression and acetylation were both increased in
Toledo and NCI-BL2171 cells, in addition to increased acetylation at OCI-Ly7. The potential
implications of these findings will be discussed later in further detail.
qRT-PCR
In order to measure the effects of DHA exposure on gene expression in DLBCL cells and
normal B-cells, real-time quantitative reverse transcription polymerase chain reaction (qRTPCR) was used to quantify the expression of a panel of genes that are heavily involved in the
physiology of DLBCL cells. This subset consisted of BCL6 (B-cell CLL/Lymphoma 6) and a
panel of BCL6 target genes, including TP53, ATR (Ataxia Telangiectasia and Rad3-Related
Protein), ATM (Ataxia Telangiectasia Mutated), CHEK1 (Checkpoint Kinase 1), CDKN1A,
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AICDA (Activation-Induced Cytidine Deaminase), MIR155HG [microRNA (MIR) 155 Host
Gene], PRDM1, EP300, and CREBBP (not targeted by - but competes with - BCL6). As was the
case for Western blots, all four cell lines were treated with either DHA or vehicle control for 72
hours. Our results show that exposure of DLBCL cells and normal B-cells to DHA in vitro does
lead to statistically significant changes in the expression of every gene that was examined at 10µM and/or 25-µM DHA, albeit in a cell line- and dose-dependent manner.
1. Effects of DHA on Gene Expression
TP53: In response to 10-µM DHA, the expression of TP53 showed a statistically
significant decrease in Toledo cells (p=0.0255) and an increase in NCI-BL2171 cells (p=0.0917)
compared to vehicle control [Fig. 14A (top)]. At 25-µM DHA, NCI-BL2171 normal B-cells
showed a 0.5-fold decrease in TP53 expression (p=0.0565) compared to vehicle control; this
contrasts with the approximate 8-fold increase in p53 protein expression that was detected by
Western blot [Fig. 14A (bottom)].
ATR: No statistically significant changes in the expression of ATR occurred in response
to 10-µM DHA [Fig. 14B (top)], while ATR expression increased significantly in OCI-Ly7 cells
(p=0.0244) and decreased significantly in NCI-BL2171 cells (p=0.0129) in response to 25-µM
DHA compared to vehicle control [Fig. 14B (bottom)].
ATM: Similar to ATR, ATM encodes a protein (i.e., ATM) that is activated as part of the
DDR. Just as ATR activates CHK1 (checkpoint kinase 1) via phosphorylation, ATM activates
both CHK2 (checkpoint kinase 2) and p53 by phosphorylating them (Banin et al., 1998; Buscemi
et al., 2004; Canman et al., 1998; S. Saito et al., 2002).
At the 10-µM dose of DHA, no statistically significant changes in ATM expression were
observed [Fig. 14C (top)]. At the 25-µM dose of DHA, ATM expression decreased in SU-DHL-5
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Figure 14. Expression of genes related to DNA repair and SHM after DHA exposure
Figure 14 shows the expression of A) TP53, B) ATR, C) ATM, D) CHEK1, E) AICDA, and F)
MIR155HG in NCI-BL2171, OCI-Ly7, SU-DHL-5, and Toledo cells after 72-Hr exposure to 10µM DHA (top) or 25-µM DHA (bottom) relative to vehicle (EtOH) control. qRT-PCR was
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performed in biological and technical triplicate (n=3). Numerical values of signal intensity are
shown as the mean of treated samples relative to the mean of control samples, set at 1, after
normalizing all samples to GAPDH expression and using the 2-CT method of analysis. Statistical
significance was assessed using an unpaired, two-tailed Welch’s t-test. Error bars represent
SEM. 𝛼 = 0.05; * < 0.0332; ** < 0.0021. Abbreviations: DHA- docosahexaenoic acid; TP53tumor protein 53; ATR- ataxia telangiectasia and Rad3 related; ATM- ataxia telangiectasia
mutated; CHEK1- checkpoint kinase 1; AICDA- activation-induced cytidine deaminase;
MIR155HG- microRNA 155 host gene.

cells (p=0.0504) and decreased by ~0.7-fold in NCI-BL2171 cells (p=0.0734) compared to
vehicle control [Fig. 14C (bottom)].
CHEK1: When exposed to 10-µM DHA, a statistically significant decrease in CHEK1
expression was observed in Toledo cells (p=0.0254) compared to vehicle control [Fig. 14D
(top)]. Meanwhile, exposure to 25-µM DHA resulted in a significant increase in CHEK1
expression in OCI-Ly7 cells (p=0.0068) compared to vehicle control [Fig. 14D (bottom)].
AICDA: AICDA encodes Activation-Induced Deaminase (AID), an enzyme that is
required for the processes of somatic hypermutation (SHM) and class switch recombination
(CSR) (Muramatsu et al., 2000) that are responsible for developing high-affinity, class-switched
antibodies. SHM and CSR intentionally cause DNA damage as part of their normal function and,
consequently, the risk of introducing oncogenic mutations and/or chromosomal translocations is
always present. In fact, most B-cell lymphomas originate from GC B-cells (Kuppers, 2005), and
AID has been shown to be required for GC-derived lymphomas (Pasqualucci et al., 2008).
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AICDA expression showed a statistically significant ~1.9-fold increase in OCI-Ly7 cells
(p=0.0117) after exposure to 10-µM DHA, compared to vehicle control [Fig. 14E (top)]. In
Toledo cells, AICDA expression was only detected in one of three tested biological replicates for
both 10-µM DHA and vehicle control; this was likely due to a low level of expression that could
not be sufficiently amplified within 35-40 cycles. In contrast, the expression of every other
assayed gene was detectable in all three biological replicates for both treated and control
samples. At 25-µM DHA, AICDA expression showed a statistically significant ~2.3-fold increase
in OCI-Ly7 cells (p=0.0013) and a statistically significant ~0.5-fold decrease in NCI-BL2171
cells (p=0.0306) compared to vehicle control [Fig. 14E (bottom)].
MIR155HG: MIR155HG is the host gene that encodes miR-155, a miR that is closely
associated with regulation of the immune system, especially adaptive immunity (Vigorito,
Kohlhaas, Lu, & Leyland, 2013). miR-155 has been shown to negatively regulate the expression
of AICDA (Dorsett et al., 2008; Teng et al., 2008) and the post-translational activation of p53
(Bouamar et al., 2015). Interestingly, BCL6 represses MIR155HG (i.e., miR-155) expression,
which then results in the positive regulation of AICDA expression (Basso et al., 2012).
In response to 10-µM DHA, MIR155HG expression decreased in Toledo cells (p=0.0715)
and exhibited a statistically significant ~2-fold increase in NCI-BL2171 normal B-cells
(p=0.0344) compared to vehicle control [Fig. 14F (top)]. In response to 25-µM DHA,
MIR155HG expression also exhibited a downward trend in Toledo cells (p=0.1672), as well as a
0.75-fold decrease in NCI-BL2171 cells (p=0.209) compared to vehicle control [Fig. 14F
(bottom)].
BCL6: After exposure to 10-µM DHA, no statistically significant changes in BCL6
expression were observed in any of the cell lines tested [Fig. 15A (top)]. In contrast, exposure to
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25-µM DHA resulted in a significant increase in BCL6 expression in OCI-Ly7 cells (p=0.0363)
compared to vehicle control [Fig. 15A (bottom)]. As expected, no expression of BCL6 was
detected in NCI-BL2171 cells at either dose of DHA, because BCL6 is normally only expressed
in mature, GC B-cells (Cattoretti et al., 1995).
CREBBP: CREBBP did exhibit a statistically significant ~3-fold increase in expression
in NCI-BL2171 cells (p<0.0001) after exposure to 10-µM DHA, compared to vehicle control
[Fig. 15B (top)]. When exposed to 25-µM DHA, changes in the expression of CREBBP varied
by cell type: a significant ~1.8-fold increase in OCI-Ly7 cells (p=0.0001), a downward trend in
SU-DHL-5 cells (p=0.0869), a significant increase in Toledo cells (p=0.0383), and a 0.4-fold
decrease in NCI-BL2171 cells (p=0.1482) compared to vehicle control [Fig. 15B (bottom)].
EP300: No statistically significant changes in the expression of EP300 were observed in
any cell line at the 10-µM dose of DHA [Fig. 15C (top)]. At the 25-µM dose of DHA, multiple
changes in EP300 expression were observed: a significant increase in OCI-Ly7 cells (p=0.0013),
a 0.4-fold decrease in SU-DHL-5 cells (p=0.1442), an increase in Toledo cells (p=0.1204), and a
significant 0.4-fold decrease in NCI-BL2171 cells (p=0.026) compared to vehicle control [Fig.
15C (bottom)].
PRDM1: PRDM1 expression is required in order for GC B-cells to exit the germinal
center reaction and differentiate into plasma cells, which secrete high-affinity antibodies, or
memory B-cells, which allow faster and stronger immunological responses upon repeated
antigen exposure (Cattoretti, Angelin-Duclos, et al., 2005; Shapiro-Shelef et al., 2003). PRDM1
expression and, therefore, GC B-cell differentiation are repressed by BCL-6 (Alinikula, Nera,
Junttila, & Lassila, 2011; Ochiai, Muto, Tanaka, Takahashi, & Igarashi, 2008; Tunyaplin et al.,
2004).
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Figure 15. Expression of genes related to GC B-cell identity, differentiation, and cell-cycle
control after DHA exposure
Figure 15 shows the expression of A) BCL6, B) CREBBP, C) EP300, D) PRDM1, and E)
CDKN1A in NCI-BL2171, OCI-Ly7, SU-DHL-5, and Toledo cells after 72-Hr exposure to 10-
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µM DHA (top) or 25-µM DHA (bottom) relative to vehicle (EtOH) control. qRT-PCR was
performed in biological and technical triplicate (n=3). Numerical values of signal intensity are
shown as the mean of treated samples relative to the mean of control samples, set at 1, after
normalizing all samples to GAPDH expression and using the 2-CT method of analysis. Statistical
significance was assessed using an unpaired, two-tailed Welch’s t-test. Error bars represent
SEM. 𝛼 = 0.05; * < 0.0332; ** < 0.0021; *** < 0.0002; **** < 0.0001. Abbreviations: DHAdocosahexaenoic acid; BCL6- B-cell CLL/lymphoma 6; CREBBP- CREB-binding protein;
EP300- E1A binding protein 300; PRDM1- PR/SET domain 1; CDKN1A- cyclin-dependent
kinase inhibitor 1A.

Conversely, as part of differentiation into plasma cells, PRDM1 represses many genes that are
expressed in mature B-cells, including BCL6 and AICDA (Shaffer et al., 2002).
PRDM1 experienced changes in expression at both doses of DHA. At the 10-µM dose, a
statistically significant 1.8-fold increase in PRDM1 expression was observed in NCI-BL2171
cells (p=0.0074) compared to vehicle control [Fig. 15D (top)]. At the 25-µM dose, PRDM1
expression showed a significant 2.4-fold increase in OCI-Ly7 cells (p=0.0028), a significant
~2-fold increase in Toledo cells (p=0.0161), and a decrease in NCI-Bl2171 cells (p=0.0832)
compared to vehicle control [Fig. 15D (bottom)].
CDKN1A: CDKN1A encodes the protein CDKN1A, which is also commonly referred to
as “p21.” CDKN1A/p21 is a cell-cycle inhibitor whose expression is upregulated by p53 in order
to promote cell-cycle arrest as part of the DDR (el-Deiry et al., 1993). Interestingly,
CDKN1A/p21 helps facilitate the activation of CREBBP/p300 which, in turn, promotes the
expression of CDKN1A as part of a positive feedback loop (T. Abbas & Dutta, 2009; Snowden,
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Anderson, Webster, & Perkins, 2000). In addition to the aforementioned TP53, ATR, CHEK1,
and EP300, BCL6 also represses the expression of CDKN1A in DLBCL cells (Ranuncolo, Polo,
& Melnick, 2008; Ranuncolo, Wang, et al., 2008).
In response to 10-µM DHA, CDKN1A expression showed a statistically significant ~0.7fold decrease in OCI-Ly7 cells (p=0.0318), an increase in SU-DHL-5 cells (p=0.061), and a
decrease in Toledo cells (p=0.0715) compared to vehicle control [Fig. 15E (top)]. In response to
25-µM DHA, CDKN1A expression significantly increased by 2-fold in OCI-Ly7 cells
(p=0.0149) and decreased by 0.6-fold in NCI-BL2171 normal B-cells (p=0.0883) compared to
vehicle control [Fig. 15E (bottom)].
2. Summary of qRT-PCR Results
Although the changes in gene expression that were observed during our experiments
showed cell-line-dependent and DHA-dose-dependent variability, all of the genes that were
assayed displayed statistically significant changes and/or noticeable trends at 10-µM and/or 25µM DHA. We then narrowed our results further based on the magnitude of changes that
occurred, using 2-fold increases and 0.5-fold decreases as cutoffs. TP53, ATM, CDKN1A,
AICDA, MIR155HG, CREBBP, and PRDM1 surpassed these cutoffs at 10-µM and/or 25-µM
DHA.
Several other patterns emerged from these data. OCI-Ly7 cells exhibited 2-fold
increases in the expression of CDKN1A (25-µM DHA), AICDA (10-µM and 25-µM DHA),
CREBBP (25-µM DHA), and PRDM1 (25-µM DHA). OCI-Ly7 cells also exhibited a 0.5-fold
decrease in CDKN1A expression (10-µM DHA). NCI-BL2171 cells showed 0.5-fold decreases
in the expression of TP53 (25-µM DHA), ATM (25-µM DHA), CDKN1A (25-µM DHA), AICDA
(25-µM DHA), MIR155HG (25-µM DHA), and CREBBP (25-µM DHA). NCI-BL2171 cells
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also showed 2-fold increases in the expression of MIR155HG (10-µM DHA), CREBBP (10-µM
DHA), and PRDM1 (10-µM DHA). Toledo cells displayed a 2-fold increase in the expression
of PRDM1 (25-µM DHA) as well. Interestingly, there is clear overlap in the expression profiles
of CREBBP and PRDM1 in response to both 10-µM and 25-µM DHA; they also have overlap
with the expression profiles of CDKN1A and AICDA at 25-µM DHA. It should also be noted that
EP300 and ATR have similar expression profiles to that of CREBBP and PRDM1 at 25-µM
DHA, although their changes in expression are of lesser magnitude. The potential implications of
these findings will be discussed later in further detail.
Discussion
The purpose of this study was to characterize the epigenetic effects of the -3 fatty acid
DHA on DLBCL cells in vitro. Previous studies have demonstrated that DHA induces epigenetic
changes in multiple types of cancer (Lau et al., 2019), including increased genome-wide levels of
histone acetylation (i.e., H3K18Ac) (A. Abbas et al., 2021). These findings are relevant to
DLBCL, because CREBBP and EP300 are commonly mutated and often result in decreased
levels of H3K18, H3K27, p53, and BCL6 acetylation (Hashwah et al., 2017; Morin et al., 2011;
Pasqualucci, Dominguez-Sola, et al., 2011; Reddy et al., 2017). Reduced acetylation of these
targets in GC B-cells prevents, in part, the activation of enhancers that positively regulate gene
expression, including those that are required for GC exit, differentiation, DDR, and cell-cycle
control (Bakhshi & Georgel, 2020; Hatzi et al., 2013; Jiang & Melnick, 2015; Jiang et al., 2017;
Meyer et al., 2019; Mlynarczyk et al., 2019; Pasqualucci, 2019; J. Zhang et al., 2017). We
hypothesized that DHA would alter the epigenome of DLBCL cells, including a partial
restoration of histone and p53 acetylation, and that these effects may vary depending on
CREBBP and EP300 mutational status. We tested our hypothesis by exposing one line of normal
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B-cells (NCI-BL2171) and three DLBCL cell lines with differing CREBBP/EP300 mutational
statuses (OCI-Ly7, SU-DHL-5, and Toledo) to DHA at doses that are clinically relevant and
within the range used for many hematological cancers (Fahrmann et al., 2013; Moloudizargari et
al., 2018). Our results from viability assays, Western blots, and qRT-PCR experiments showed
that the response to DHA is both dose-dependent and cell-line dependent. We observed
statistically significant changes in the genome-wide levels of histone acetylation in NCI-BL2171
(WT/WT), OCI-Ly7 (WT/WT), and Toledo (CREBBP deletion, EP300 mutation) cells, though
acetylation often decreased instead of increasing as we had predicted based on similar studies
related to DHA’s effects. Statistically significant increases in the expression and acetylation of
p53 were also observed, supporting our hypothesis. The potential implications and relevance of
our results are outlined below.
Viability Assays
We expected the viability of the four cell lines that we exposed to the -3 FA DHA to
decrease as a function of CREBBP/EP300 mutational status, with WT/WT cell lines (NCIBL2171 and OCI-Ly7) maintaining the highest viability and Toledo cells (3-bp deletion of
CREBBP and missense mutation in EP300) having the lowest viability. Our results show that,
while normal NCI-BL2171 B-cells (WT/WT) did maintain the highest viability at all doses of
DHA, Stage IIA OCI-Ly7 DLBCL cells (also WT/WT) instead had unexpectedly low viability at
25-µM and the lowest viability of all cell lines at 50-µM DHA. The viability of Toledo
(CREBBP deletion, EP300 mutation) was similar to that of OCI-Ly7 at 50-µM DHA, but it was
higher than that of both OCI-Ly7 and SU-DHL-5 at 25-µM DHA. Metastatic SU-DHL-5 cells
(CREBBP deletion, WT EP300) had the lowest viability at 25-µM DHA but maintained a higher
viability than both OCI-Ly7 and Toledo at 50-µM DHA. In summary, viability did not seem to
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change in response to DHA strictly as a function of CREBBP/EP300 mutational status or cancer
stage. Rather, the clearest difference in sensitivity to DHA was between normal NCI-BL2171 Bcells and all three DLBCL cell lines. We also observed that DHA affects the viability of DLBCL
cells in a dose-dependent manner, with no statistically significant effect at 10-µM DHA, a
significant decrease at 25-µM DHA and another significant decrease at 50-µM DHA.
Our results contrast with a similar study by Andersen et al. in which four DLBCL cell
lines with different CREBBP/EP300 mutational statuses [including Toledo and U2932
(WT/WT)] were treated with vorinostat, an HDACi (Andersen et al., 2012). They observed
statistically significant differences in the level of apoptosis between WT/WT, single-mutant, and
double-mutant (i.e., Toledo) cell lines. Apoptosis increased in all cell lines in a dose-dependent
manner, and the effect was clearly stronger in Toledo than in all other cell lines (CREBBP
deletion, EP300 mutation). While acknowledging the differences between these two studies, one
possible explanation for the apparent lack of an association between CREBBP/EP300 mutational
status and viability in our study is that -3 FAs likely increase acetylation levels indirectly by
increasing the amount of free acetyl-CoA available to CBP/p300 (Galdieri & Vancura, 2012)
(see below for further discussion of mechanism of action). This would mean that the response of
each cell line is dependent upon the enzymatic activity of CBP/p300; cells with insufficient
CBP/p300 activity may not respond as (we had anticipated). In contrast, HDACi’s act more
directly by preventing the removal of acetyl groups that are already present at specific residues
of histone tails. Under these conditions, the level of acetylation at certain residues (e.g.,
H3K18Ac and H3K27Ac) is less dependent upon CBP/p300 activity. Thus, cells with little
CBP/p300 activity could still show an increase in histone acetylation that would be proportional
to their pre-HDACi level.
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Western Blots
We predicted that exposure to DHA would alter the epigenomes of the four cell lines
tested by increasing and/or decreasing their genome-wide levels of histone PTMs. In particular,
we expected to observe a genome-wide increase in acetylation at multiple residues of Histones
H3 and H4. We also suspected that these changes may vary depending on the CREBBP/EP300
mutational status of each cell line. In partial support of our hypothesis, we did observe
statistically significant changes in the genome-wide levels of every histone PTM that was
measured (except for H3K9me3), the direction and magnitude of which depended on the cell line
and dose of DHA. In response to 10-µM and/or 25-µM DHA, H3K4me1, H3K4me3,
H3K27me3, H3K9Ac, H3K27Ac, H4K5Ac, H4K8Ac, H4K12Ac, and H4K16Ac exhibited 2fold increases and/or 0.5-fold decreases in NCI-BL2171, OCI-Ly7, and Toledo cells (but not
metastatic SU-DHL-5 cells). Changes of this magnitude were observed most frequently at
acetylated residues; however, histone acetylation unexpectedly decreased (H3K9Ac, H3K27Ac,
H4K5Ac, H4K8Ac, H4K16Ac) more often than it increased (H4K5Ac, H4K12Ac, H4K16Ac).
As part of our analysis of the epigenetic changes that were observed in response to DHA
exposure, we searched the literature for known associations between specific histone PTMs and
specific biological functions (Jenuwein & Allis, 2001; Strahl & Allis, 2000; S. Zhao, Allis, &
Wang, 2021). We identified potential connections between acetylated residues that frequently
showed high differential responses to DHA in our experiments (H3K9Ac, H4K5Ac, H4K8Ac,
H4K12Ac, H4K16Ac) and biological processes that occur at the molecular level. These include
transcription (H3K9Ac, H4K5Ac, H4K8Ac, H4K12Ac, H4K16Ac), recruitment of BRD4
(H4K5Ac, H4K8Ac, H4K12Ac, H4K16Ac), recruitment of CREBBP (H4K12Ac, H4K16Ac),
BCL6-mediated promoter repression and RNA Pol II pausing (H3K9Ac), and chromatin
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structure/compaction (H4K16Ac) (Gates et al., 2017; Hatzi et al., 2013; Jung et al., 2014;
Nagarajan et al., 2015; Perner & Chung, 2013; Plotnikov et al., 2014; R. Zhang et al., 2017; W.
Zhang et al., 2012; Zippo et al., 2009). While links to CREBBP and BCL6 would clearly be
relevant to DLBCL, the potential links to BRD4 and transcriptional elongation were unexpected
and warrant further discussion.
BRD4 is a transcriptional activator that commonly targets lineage-specific genes, the
expression of which is required to develop cellular identity (Donati et al., 2018). A relevant
example is the targeting of PRDM1 in multiple myeloma (Loven et al., 2013); as was mentioned
earlier, PRDM1 expression is required for the terminal differentiation of GC B-cells into plasma
cells and memory B-cells. BRD4 functions as an epigenetic “reader” that binds specific histone
acetylated residues (including H4K5Ac, H4K8Ac, H4K12Ac, and H4K16Ac) along regions of
active chromatin. It facilitates transcription initiation (via interaction with Mediator complex at
enhancers) and elongation (via interaction with P-TEFb complex at promoters) by promoting
RNA Pol II activity (Donati et al., 2018; Perner & Chung, 2013). BRD4 can also interact with
chromatin-modifying proteins and transcription factors. For instance, evidence from experiments
with AML suggests that BRD4 works with CBP/p300 and hematopoietic transcription factors to
promote the expression of lineage-specific genes (Roe, Mercan, Rivera, Pappin, & Vakoc, 2015).
Additionally, BRD4 is required to fully repair AID-induced double-stranded DNA breaks [via
nonhomologous end-joining (NHEJ)] during CSR and to complete the process of CSR itself
(Stanlie, Yousif, Akiyama, Honjo, & Begum, 2014). There is evidence that BRD4 is involved in
the pathophysiology of DLBCL as well. Chapuy et al. showed that BRD4 is highly abundant at
super-enhancers that regulate the coordinated expression of genes (including BCL6) that are
required for GC formation and determining B-cell fate (Chapuy et al., 2013). An investigation by
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Jiang et al. suggested that BRD4 may also be implicated in the relapse of DLBCL (Jiang et al.,
2014). They performed deep genome sequencing on pairs of DLBCL tumors matched at
diagnosis and relapse, followed by a phylogenetic analysis based on clonal heterogeneity to
determine the extent to which tumors at diagnosis and relapse were related. Using whole exome
sequencing, they found that early-divergent tumor pairs were enriched for mutations in genes
that encode histone-modifying and chromatin-associated proteins at relapse. These included
KMT2D (lysine methyltransferase 2D), SETDB1 (SET domain bifurcated histone lysine
methyltransferase 1), TET2 (tet methylcytosine deoxygenase 2), EP300, and BRD4 (Jiang et al.,
2014).
In addition to histone acetylation, we predicted that p53 acetylation would increase in
response to DHA exposure and might also depend on the CREBBP/EP300 mutational status of
each cell line. In support of our hypothesis, p53 acetylation increased in OCI-Ly7 cells (~4-fold)
at 10-µM DHA and in normal NCI-BL2171 cells (~2-fold), OCI-Ly7 cells (~4-fold), and Toledo
cells (~3-fold) at 25-µM DHA. Consistent with our observations for viability and histone PTMs,
changes in p53 acetylation were dose-dependent but did not seem to occur strictly as a function
of CREBBP/EP300 mutational status as we had hypothesized. Instead, p53 acetylation was
increased both in the context of wild-type CREBBP and EP300 (NCI-BL2171 and OCI-Ly7)
and, unexpectedly, in the context of mutated/deleted CREBBP and EP300 (Toledo).
Interestingly, we also observed increases in the expression of p53 protein that resembled those of
acetylated p53 in OCI-Ly7 cells at 10-µM DHA and NCI-BL2171 and Toledo cells at 25-µM
DHA. Our results are noteworthy, because they are in line with an emerging trend of
therapeutically targeting p53 and BCL6 acetylation in DLBCL (Amengual et al., 2013; Y. Liu,
Fiorito, Gonzale, et al., 2019; Y. Liu, Fiorito, Gonzalez, et al., 2019; Y. Liu et al., 2018; Sermer
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et al., 2019). One such approach involves the use of deacetylase (DAC) inhibitors in human
DLBCL cell lines, an animal model, and a phase 1 clinical trial (Amengual et al., 2013). In
DLBCL cell lines, increased p53 and BCL6 acetylation correlated with DAC-induced
cytotoxicity and was associated with increased PRDM1 and p21 (i.e., CDKN1A) protein
expression. In a mouse model of aggressive B-cell lymphoma, remission was observed in
response to treatment with DAC inhibitors, as well as increased p53 and BCL6 acetylation and
PRDM1 and p21 protein expression. In a phase 1 clinical trial of 28 relapsed or refractory
lymphoma patients [including 4 DLBCL and 3 follicular lymphoma (FL)], treatment with DAC
inhibitors resulted in an overall response rate (ORR) of 24% and disease stabilization rate of
57% (Amengual et al., 2013). A second approach is the use of a novel HAT-activating
compound, YF2, to increase histone and p53 acetylation (Y. Liu, Fiorito, Gonzale, et al., 2019;
Y. Liu, Fiorito, Gonzalez, et al., 2019; Y. Liu et al., 2018). Early reports demonstrate that YF2 is
capable of increasing p300- and CREBBP-mediated acetylation of H3K18 and H3K27Ac, as
well as p300-mediated acetylation of p53, in DLBCL cell lines. Selective cytotoxicity was
observed in EP300-mutant DLBCL cell lines, and decreased tumor volume was observed in mice
xenografted with EP300-mutant DLBCL. YF2 was also shown to act synergistically with
HDACi’s to increase histone acetylation in DLBCL cell lines and prolong survival in
xenografted mice (Y. Liu, Fiorito, Gonzale, et al., 2019; Y. Liu, Fiorito, Gonzalez, et al., 2019;
Y. Liu et al., 2018). Our experimental evidence, though more preliminary, suggests that -3 FAs
can also cause increased p53 acetylation in DLBCL cells lines, including one with a CREBBP
deletion and EP300 mutation (Toledo). We think that these parallels support our rationale and
would justify further investigation into the potential therapeutic effects of -3 FAs in DLBCL.
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qRT-PCR
We also sought to determine if changes in gene expression were occurring in response to
DHA exposure. We selected a panel of genes that are relevant to the physiology of GC B-cells
and DLBCL, namely BCL6 and its downstream targets. A variety of cellular functions were
represented, including response to DNA damage (TP53, ATR, ATM, CHEK1), cell-cycle control
(CDKN1A), somatic hypermutation and class switch recombination (AICDA, MIR155HG),
histone acetylation (CREBBP, EP300), and differentiation (PRDM1). We observed statistically
significant changes in the expression of every gene that was assayed (except for ATM), the
direction and magnitude of which depended on the cell line and dose of DHA. In response to 10µM and/or 25-µM DHA, TP53, ATM, CDKN1A, AICDA, MIR155HG, CREBBP, and PRDM1
exhibited 2-fold increases and/or 0.5-fold decreases in expression NCI-BL2171, OCI-Ly7,
and Toledo cells (but not metastatic SU-DHL-5 cells).
Although the preliminary nature of our qRT-PCR experiments limits the scope of our
discussion (without veering into speculation), some general conclusions can be derived from the
analysis of our gene expression results. The most significant changes in gene expression that we
observed ( 2-fold increases and 0.5-fold decreases) were in OCI-Ly7 cells (Stage IIA DLBCL;
WT CREBBP and EP300) and NCI-BL2171 cells (normal B-cells; WT CREBBP and EP300).
Similar to that which was observed for changes in histone PTMs and genes monitored by
Western blot), the effects of DHA on gene expression appear to be dose-dependent. Both the
genes affected and the direction of their changes in expression often differed by dose, even for
the same gene in the same cell line. One noticeable pattern in these data is the increased
expression of CREBBP and PRDM1 in NCI-BL2171 cells at 10-µM DHA and in OCI-Ly7 cells
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at 25-µM DHA. PRDM1 expression, but not CREBBP expression, also increased in Toledo cells
(DLBCL; CREBBP deletion and EP300 mutation) at 25-µM.
CREBBP and p300 are intimately related to the molecular mechanisms that govern GC
B-cells’ development and eventual differentiation into plasma cells or memory B-cells. They are
also frequently mutated in DLBCL and serve to “lock in” GC B-cell gene expression programs
that are conducive to oncogenesis. Therefore, the fact that we observed significantly increased
CREBBP expression in DLBCL cells (OCI-Ly7; 25-µM DHA; ~1.8-fold) and normal B-cells
(NCI-BL2171; 10-µM DHA; ~3-fold) is relevant. It should be noted that 1) this only occurred in
cell lines with wild-type CREBBP and 2) there was not a commensurate increase in EP300
expression in any cell line (though a statistically significant ~1.3-fold increase in expression was
observed in OCI-Ly7 cells at 25-µM DHA). Despite having structural and functional homology,
it was recently shown that CREBBP and p300 also have some distinct gene targets and serve
slightly different cellular functions within germinal centers (Meyer et al., 2019). Loss of EP300
resulted in ~50% fewer GC B-cells and reduced expression of genes that are more active in the
dark zone of the GC (i.e., area of active replication and SHM), including those related to the cell
cycle, DNA replication, and DNA repair. Loss of CREBBP resulted in a greater number of GC
B-cells, an increase in the dark zone/light zone ratio, and decreased expression of genes
associated with the light zone of the GC (i.e., area of GC exit and pre-differentiation), including
ones related to B-cell signaling, antigen presentation, and differentiation. These results suggest
that p300 activity is more specific to the dark zone and that CREBBP activity is more specific to
the light zone (Meyer et al., 2019; J. Zhang et al., 2017). While our experiments were conducted
in vitro and in a small number of cell lines, the findings reported by Meyer et al. provide context
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that could potentially help explain the slight emphasis on CREBBP expression that we observed,
as well as the differential response in CREBBP and EP300 expression.
As described earlier, the expression of PRDM1 is necessary for light-zone GC B-cells to
exit the GC reaction and differentiate into either plasma cells or memory B-cells. The GC B-cell
gene expression program directed by BCL6 is incompatible with the gene expression program
orchestrated by PRDM1 (hence the reciprocal inhibition of each other’s expression). For these
reasons, PRDM1 is often used as a marker of B-cell differentiation in studies related to DLBCL
(J. Zhang et al., 2017). Zhang et al. found that heterozygous and homozygous loss of Crebbp in
mice was associated with decreased Prdm1 expression ex vivo, decreased expression of CD138
(surface marker of plasmablastic phenotype) ex vivo and in vivo, and a trend toward decreased
serum IgG1 (class-switched antibody secreted by plasma cells) in vivo. They suggest that
expression of both CREBBP alleles may be required for optimal GC B-cell differentiation (J.
Zhang et al., 2017). Another interesting connection to PRDM1 can be found in the previouslydescribed study of DAC inhibitor-mediated BCL6 and p53 acetylation by Amengual et al.
(Amengual et al., 2013). In both human DLBCL cell lines and a mouse model of aggressive Bcell lymphoma, they observed increased expression of PRDM1 and p21 (i.e., CDKN1A) proteins
after treatment with DAC inhibitors. While we unfortunately did not perform Western blots for
PRDM1 or p21, we did measure their expression at the transcriptional level. We observed a
~1.8-fold increase in PRDM1 expression in NCI-BL2171 cells at 10-µM DHA, as well as a 2.4fold increase in OCI-Ly7 cells and a ~1.9-fold increase in Toledo cells at 25-µM DHA. The
direction and magnitude of CDKN1A expression seemed to be more dose- and cell-line
dependent than PRDM1, but we did observe a 2.1-fold increase in CDKN1A expression in OCILy7 cells at 25-µM DHA (matching increased PRDM1 and CREBBP expression). Amengual et
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al. reported a lack of measurable CDKN1A expression at the protein and transcriptional levels
(Amengual et al., 2013; Shaffer et al., 2002). Though we did not assay the expression of p21
protein, we did measure low levels of CDKN1A gene expression via qRT-PCR (amplified
between 33 and 36 cycles). Overall, we think that these data support our rationale and warrant
further investigation into the potentially beneficial effects of -3 FAs in DLBCL.
Conclusions
The results described in this study are, to our knowledge, the first documented
characterization of the epigenetic effects of -3 FAs in DLBCL. We found that 72-hour
exposure of DLBCL cells to DHA in vitro at doses consistent with the literature (Fahrmann et
al., 2013; Moloudizargari et al., 2018) significantly affected viability, genome-wide levels of
histone PTMs, p53 protein expression and acetylation, and gene expression in a cell-line and
dose-dependent manner. We did not observe a uniform increase in histone acetylation as
expected, but we did observe significant changes in the genome-wide levels of H3K9Ac,
H4K5Ac, H4K8Ac, and H4K16Ac. We suspect that these changes may be related to
transcription elongation and/or the recruitment of the transcriptional activator BRD4. However,
further experiments would be needed to test this idea. Increased levels of p53 acetylation
(between ~2-fold and ~4-fold) were also observed and were similar to changes in p53 protein
expression. This finding is especially relevant, because p53 (and BCL6) acetylation is both an
important component of DLBCL pathophysiology and an emerging therapeutic target. Lastly, we
observed significant changes in the expression of genes that are closely associated with DLBCL,
including recurrent increases in the expression of CREBBP and PRDM1 (between ~2-fold and
~3-fold).

100

Many experiments that were not included in our preliminary study should be performed
in subsequent investigations into the effects of -3 FAs on DLBCL. For example, ChIP-seq
could be performed using antibodies against H3K9Ac, H4K5Ac, H4K8Ac, RNA Pol II, and
BRD4 to test the hypothesis that -3 FAs are affecting transcription elongation and to identify
any associated changes in expression. RNA-seq could also be performed to figure out which
genes experience a change in their expression level in response to DHA. Genes that are
competitively regulated by BCL6 and CBP/p300 would be of particular interest (Jiang et al.,
2017; J. Zhang et al., 2017). Additionally, the specific mechanism by which -3 FAs influence
histone and p53 acetylation should be investigated further. We suspect that -3 FAs add to the
nucleocytoplasmic pool of free acetyl-CoA by modulating acetyl-CoA carboxylase activity
(Galdieri & Vancura, 2012) or via fatty acid oxidation (McDonnell et al., 2016), but we have not
done experiments to test these ideas. The therapeutic potential of -3 FAs in DLBCL should
continue to be investigated. There is a need for agents that can modify the acetylation of histones
and p53 that do not cause the side effects or toxicities that can occur with HDACi’s
(Subramanian, Bates, Wright, Espinoza-Delgado, & Piekarz, 2010).
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CHAPTER 3
CONCLUSIONS
Reflection
The therapeutic effects of omega-3 fatty acids have been demonstrated in a wide variety
of leukemias and lymphomas (Fahrmann et al., 2013; Fahrmann & Hardman, 2013;
Moloudizargari et al., 2018). Additional studies have shown that -3 FAs can alter the
epigenome in multiple cancers (Lau et al., 2019), including genome-wide levels of histone
acetylation at specific loci (A. Abbas et al., 2021; Isaac et al., 2018; Ramaiyan & Talahalli, 2018;
Sadli et al., 2012). Despite the commonality of DLBCL and its frequent epigenetic deficiencies,
information about the effects of -3 FAs on DLBCL is scarce (Thanarajasingam et al., 2018).
Therefore, the objective of our investigation was to characterize the effects of the -3 FA DHA
on viability, gene expression, genome-wide levels of histone PTMs, and p53 acetylation in
DLBCL in vitro.
By the end of our investigation, we accomplished part of our stated objective. We
repeatedly observed significant changes in genome-wide levels of H3K9Ac, H4K5Ac, H4K8Ac,
and H4K16Ac after exposure to DHA at clinically attainable doses consistent with the literature
(Fahrmann et al., 2013; Fahrmann & Hardman, 2013; Moloudizargari et al., 2018). These PTMs
are involved with transcription, recruitment of BRD4 and CREBBP, BCL6-mediated promoter
repression and RNA Pol II pausing, and potential changes in chromatin structure (Gates et al.,
2017; Hatzi et al., 2013; Jung et al., 2014; Nagarajan et al., 2015; Perner & Chung, 2013;
Plotnikov et al., 2014; R. Zhang et al., 2017; W. Zhang et al., 2012; Zippo et al., 2009). We also
observed increased p53 acetylation, which is currently being developed into a therapeutic target
for DLBCL (Amengual et al., 2013; Y. Liu, Fiorito, Gonzale, et al., 2019; Y. Liu, Fiorito,
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Gonzalez, et al., 2019; Y. Liu et al., 2018; Sermer et al., 2019). Lastly, we observed increased
expression of CREBBP and PRDM1, the latter of which is a marker of GC B-cell differentiation.
Taken together, out results show that -3 FAs can induce changes in DLBCL cells in vitro that
are physiologically and, potentially, therapeutically relevant.
Study Limitations
There were some limitations on our study, and they should be considered when analyzing
and interpreting our results. Due to the preliminary nature of our work, we did not perform any
experiments in vivo. It would not have been reasonable to start with an animal model without
first testing our hypothesis and developing a proof of concept in vitro. In no way does this
invalidate our observations; we simply do not know if treatment with -3 FAs would produce
the similar results in an animal model of DLBCL or human DLBCL patients. Next, while the 72hour time frame of our experiments is consistent with that of others’ in vitro experiments with 3 FAs in hematological cancers (Fahrmann et al., 2013; Fahrmann & Hardman, 2013;
Moloudizargari et al., 2018), it may not be directly comparable to the months-long timeframes of
in vivo experiments in CLL (Fahrmann et al., 2013) and breast cancer (A. Abbas et al., 2021).
This is a limit imposed by cell culture, as continuous treatment of cells for weeks or months can
increase variability due to splitting and genetic/epigenetic drift (Franzen et al., 2021). Next, due
to unexpected time and budget constraints, we did not perform any ChIP experiments. Because
our study was focused on epigenetic changes, ChIP-seq would have been the ideal way to
connect changes in genome-wide levels of histone PTMs to any associated changes in the
expression of specific genes. It could have revealed some of the direct consequences of
epigenetic changes, including which gene sets and cellular processes were affected. These
experiments should certainly be performed in the future. Lastly, time constraints also prevented
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us from being able to measure the protein expression of several relevant targets outside of our
core panel of histone PTMs. Western blots targeting CBP, p300, p21, and PRDM1 should be
performed in the future so that their expression at both the transcriptional and translational levels
can be compared. Levels of acetylated BCL6 should also be assayed via Western blot because,
like acetylated p53, it is an emerging therapeutic target in DLBCL (Amengual et al., 2013; Y.
Liu, Fiorito, Gonzale, et al., 2019; Y. Liu, Fiorito, Gonzalez, et al., 2019; Y. Liu et al., 2018;
Sermer et al., 2019).
Impact and Future Directions
The findings of our investigation are relevant to the fields of cancer biology, epigenetics,
and nutrition. DLBCL is a very heterogeneous cancer, both genetically and epigenetically. This
is due in no small part to the nature of the GC reaction, which generates an inordinate amount of
genetic and epigenetic diversity and recapitulates a Darwinian microenvironment (Bakhshi &
Georgel, 2020; Mlynarczyk et al., 2019; Pasqualucci, 2019). While genetic mutations are an
essential component of cancer, they do not fully explain its origins, behavior, or response to
treatment. It is now clear that epigenetic aberrations and heterogeneity are fundamentally
important to these and other aspects of cancer biology (Easwaran et al., 2014; Feinberg &
Irizarry, 2010; Feinberg et al., 2016; Feinberg et al., 2006; Flavahan et al., 2017; Hinohara &
Polyak, 2019; Shaknovich et al., 2014; Suva, Riggi, & Bernstein, 2013; Timp & Feinberg, 2013),
and they have been specifically linked to relapse and poor outcomes in DLBCL (Chambwe et al.,
2014; Pan et al., 2015). Our experiments with -3 FA exposure are part of a recent effort to
improve DLBCL therapy by directly targeting and reprogramming the epigenome (L. C.
Cerchietti et al., 2010; Clozel et al., 2013; Kalac et al., 2011; Pera et al., 2016). Because lysine
(histone) acetyltransferases are sensitive to the amount of acetyl-CoA available in the
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nucleocytoplasmic pool (Pietrocola, Galluzzi, Bravo-San Pedro, Madeo, & Kroemer, 2015) and
mutations/deletions of CREBBP and p300 in DLBCL are typically monoallelic (Pasqualucci,
Dominguez-Sola, et al., 2011), -3 FAs serve as a logical connection between nutrient intake
and modification of the epigenome in DLBCL. Based on the results of our preliminary study and
their support of our rationale, we think that future experiments should be conducted in vivo,
either in a mouse model of DLBCL or a pre-clinical trial of human DLBCL patients.
Final Thoughts
The most important prerequisite for scientific progress is the direct confrontation of the
unknown. It is only after acknowledging a lack of understanding, avoiding the projection of
unwarranted confidence, and setting all assumptions aside that a problem can be laid bare and
solutions addressing the true nature of the problem can be proposed. Having now spent some
time studying cancer biology, I would be remiss not to comment on the reluctance within
mainstream thought to confront the disconnect between our modern understanding of cancer and
the current state of cancer therapy (Wion, Appaix, Burruss, Berger, & van der Sanden, 2015).
It was theorized decades ago, and has since been confirmed, that cancer is a complex
system adhering closely to Darwinian evolutionary principles (Greaves & Maley, 2012; Nowell,
1976; Trigos, Pearson, Papenfuss, & Goode, 2018; Vincent, 2012). This realization caused a
paradigm shift in cancer biology, because it replaced the classical view of cancer as a static,
monolithic neoplasm with one of a heterogeneous, adaptive environment constantly in motion.
Within each tumor, which even to an expert pathologist may appear homogeneous, there exist
countless clonal subpopulations with differences in their genomic, epigenomic, gene expression,
and metabolic profiles, as well as tumor microenvironments. Additionally, variation between
individual tumors, between individual patients, and between different types of cancer must also
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be accounted for (Gerlinger et al., 2012). Upon closer inspection, it immediately becomes clear
that cancer cannot be accurately described as a single disease, but rather a collection of
thousands of different diseases that share certain properties and rules in common (Benz, 2017;
Hanahan & Weinberg, 2011). (As discussed above at length, DLBCL exemplifies this modern
view of cancer.)
This distinction matters because of its implications for cancer therapy and the perennial
hope for a cancer “cure.” With some rare exceptions [e.g., chronic myelogenous leukemia
(CML) and imatinib] (Druker et al., 1996; Greaves & Maley, 2012; Sawyers, 2009), cancers
generally cannot be treated with a single drug that targets a single oncogene or pathway. The
idea that each type of cancer (let alone cancer in general) will eventually be cured through some
yet-to-be-discovered pharmaceutical or vulnerability is unrealistic and overly simplistic (Benz,
2017). Regardless of how effective a given cancer therapy may be initially, there is no guarantee
that the cancer will not develop resistance to that and subsequent therapies (including CML)
(Sawyers, 2009; N. P. Shah et al., 2007). Even chimeric antigen receptor (CAR) T-cell therapy,
which does feel like a true breakthrough in oncology, is not immune to the development of
resistance and relapse (Brown & Mackall, 2019; N. N. Shah & Fry, 2019). As for chemotherapy
and radiation, still the first-line treatments for most cancers, it almost goes without saying that
they are wholly inadequate to the task. While some patients are successfully treated, the side
effects can be nearly intolerable, and there are many instances in which nothing is accomplished
except for the acceleration of resistance and relapse (Benz, 2017). The current unwillingness to
grapple with the evolutionary nature of cancer and its manifestations (e.g., heterogeneity and
treatment resistance) is a severe impediment to the research and development of rational
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therapies (Benz, 2017). It is difficult to imagine any viable cure for cancer that does not feature a
planned response to adaptation as a core component.
If given unlimited time and resources, I would pursue two long-term objectives that could
potentially broaden the scope of cancer therapy and provide a method of escaping the vicious
cycle of chemotherapy and relapse. Drawing inspiration from The Cancer Genome Atlas
(TCGA) created by the National Cancer Institute (Ding et al., 2018; Hoadley et al., 2018;
Sanchez-Vega et al., 2018), a comprehensive database would be assembled that integrates all
available epidemiological data, deidentified patient information, diagnostic information,
molecular and single-cell (Holmes et al., 2020; Yuan et al., 2019) characterizations, treatment
protocols, and treatment outcomes for all types of cancer into one place. This database would
then be made accessible for meta-analysis to a network of supercomputers, quantum computers,
and artificial intelligences capable of sorting through information, finding underlying patterns,
and making connections on a scale that would otherwise not be possible (Azuaje, 2019; Bekisz &
Geris, 2020; X. Lai et al., 2019; R. Y. Li et al., 2021). Moreover, consolidating raw data and
computing power in this fashion would enable the generation of realistic, real-time models of
cancer by comparing present cases to all relevant past cases. Ideally, this computerized system
would be able to predict the cellular and molecular changes that may arise in a patient’s cancer in
response to treatment, recommend a prioritized set of targets to focus on should relapse occur,
and suggest therapies that have been shown empirically to be the most effective. Insights from
systems biology would also be incorporated to provide the biological context for specific genetic
mutations, interactions between genes within genetic networks, and opportunities for synthetic
lethality during treatment (Rauscher et al., 2018).
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The second long-term objective would be the development of next-generation strategies
for treating cancer, especially those that draw from synthetic biology and genetic engineering.
Part of the reason that conventional therapies fail is the expectation that cancer cells will respond
to treatment in a manner similar to that of normal cells. “If pathway X is targeted or the
expression of gene Y or protein Z is modulated, then cancer cells will be killed or forced to
regain homeostasis.” However, this type of thinking fundamentally misidentifies the way that
cancer operates. In the presence of selective pressures, cancer cells regularly shed the constraints
of normal cells (Basanta & Anderson, 2017). Genetic mutations, chromosomal rearrangements,
epigenetic reprogramming, rewiring of gene expression, functional alterations of proteins, and
metabolic changes are all fair game and well-tolerated by cancer cells. One method that could be
used to manage the plasticity of cancer is the design of synthetic gene circuits that 1) can be
programmed to execute any desired biological function(s) within a cancer cell and 2) are logicgated, so that a program runs only under a predetermined set of cancer-specific conditions
(Kitada, DiAndreth, Teague, & Weiss, 2018; Nissim et al., 2017; Wu, Jusiak, & Lu, 2019).
Another possibility is the use of next-generation, programmable CAR T-cells that feature
multiple-antigen recognition and logic gates in order to achieve greater specificity (Cho, Collins,
& Wong, 2018; Wu et al., 2019). These strategies (and others like them) offer a level of
specificity and control that does not currently exist in cancer therapy, and the ability to program
treatments for individual patients’ cancers would represent a significant advancement in
precision oncology. These technologies could also open the door to an iterative model of cancer
therapy in which treatment design and programming are repeated for any subsequent cancers(s)
that may appear (Ranade et al., 2019). Ideally, certain parts of the process could be automated to
improve quality control and accelerate treatment delivery.
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Even under the best circumstances, some form of the objectives that I have proposed
would take decades to accomplish. For now, any research project or clinical initiative that
emphasizes the evolutionary nature of cancer is valuable and worthwhile. There is also much
work to be done in changing the way that medical professionals, scientists, and the public think
about cancer so that a collective vision for the future of cancer care is possible. Lastly, massive
investments in public health institutions are needed to ensure that funding for cancer research is
adequate and widely accessible. The introduction of a single-payer health care system in the U.S.
is also necessary to guarantee that breakthroughs in cancer therapy (e.g., CAR T-cells) are
available to everyone, not just those who can afford their astronomical costs (Leech & Dusetzina,
2019). Differences in socioeconomic status have serious, material effects on cancer incidence,
survival, and mortality in the U.S. (Singh & Jemal, 2017), as well as cancer survivors’ quality of
life (Altice, Banegas, Tucker-Seeley, & Yabroff, 2017; Kale & Carroll, 2016; Yabroff et al.,
2016).
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APPENDIX B
SUPPLEMENTARY FIGURES

Figure S1. Western blot analysis of histone H3 methylation after DHA exposure
Figure S1 shows Western blot analyses of A-D) H3K4me1, E-H) H3K4me2, I-L) H3K4me3,
M-P) H3K9me3, and Q-T) H3K27me3 in NCI-BL2171 (column 1; left), OCI-Ly7 (column 2),
SU-DHL-5 (column 3), and Toledo (column 4; right) cells after 72-Hr exposure to 10-µM DHA
(top) or 25-µM DHA (bottom) relative to vehicle (EtOH) control. Western blots were performed
on whole-cell protein extracts in biological quadruplicate (n=4) or triplicate (n=3), depending on
sample availability. All measurements were normalized to loading control (i.e., total histone H4).
Abbreviations: DHA- docosahexaenoic acid; H3K4me1- monomethylation at lysine 4 of histone
H3; H3K4me2- dimethylation at lysine 4 of histone H3; H3K4me3- trimethylation at lysine 4 of
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histone H3; H3K9me3- trimethylation at lysine 9 of histone H3; H3K27me3- trimethylation at
lysine 27 of histone H3; H4- histone H4.
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Figure S2. Western blot analysis of histone H3 acetylation after DHA exposure
Figure S2 shows Western blot analyses of A-D) H3K9Ac, E-H) H3K18Ac, and I-L) H3K27Ac
in NCI-BL2171 (column 1; left), OCI-Ly7 (column 2), SU-DHL-5 (column 3), and Toledo
(column 4; right) cells after 72-Hr exposure to 10-µM DHA (top) or 25-µM DHA (bottom)
relative to vehicle (EtOH) control. Western blots were performed on whole-cell protein extracts
in biological quadruplicate (n=4) or triplicate (n=3), depending on sample availability. All
measurements were normalized to loading control (i.e., total histone H4). Abbreviations: DHAdocosahexaenoic acid; H3K9Ac- acetylation at lysine 9 of histone H3; H3K18Ac- acetylation at
lysine 18 of histone H3; H3K27Ac- acetylation at lysine 27 of histone H3; H4- histone H4.
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Figure S3. Western blot analysis of histone H4 acetylation after DHA exposure
Figure S3 shows Western blot analyses of A-D) H4K5Ac, E-H) H4K8Ac, I-L) H4K12Ac, and
M-P) H4K16Ac in NCI-BL2171 (column 1; left), OCI-Ly7 (column 2), SU-DHL-5 (column 3),
and Toledo (column 4; right) cells after 72-Hr exposure to 10-µM DHA (top) or 25-µM DHA
(bottom) relative to vehicle (EtOH) control. Western blots were performed on whole-cell protein
extracts in biological quadruplicate (n=4) or triplicate (n=3), depending on sample availability.
All measurements were normalized to loading control (i.e., total histone H3). Abbreviations:
DHA- docosahexaenoic acid; H4K5Ac- acetylation at lysine 5 of histone H4; H4K8Acacetylation at lysine 8 of histone H4; H4K12Ac- acetylation at lysine 12 of histone H4;
H4K16Ac- acetylation at lysine 16 of histone H4; H3- histone H3.
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Figure S4. Western blot analysis of p53 protein expression and acetylation after DHA
exposure
Figure S4 shows Western blot analyses of A-D) total p53 and E-H) acetylated p53 in NCIBL2171 (column 1; left), OCI-Ly7 (column 2), SU-DHL-5 (column 3), and Toledo (column 4;
right) cells after 72-Hr exposure to 10-µM DHA (top) or 25-µM DHA (bottom) relative to
vehicle (EtOH) control. Western blots were performed on whole-cell protein extracts in
biological quadruplicate (n=4) or triplicate (n=3), depending on sample availability. All
measurements were normalized to loading control (i.e., total histone H3 or H4). Abbreviations:
H3- histone H3; H4- histone H4.
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APPENDIX C
ABBREVIATIONS
5caC – 5-carboxylcytosine
5fC – 5-formylcytosine
5hmC – 5-hydroxymethylcytosine
5hmU – 5-hydroxymethyluridine
5mC – 5-methylcytosine
 – significance level
CT – difference in cycle threshold values
µg – microgram; 1/1000000th of a gram
µL – microliter; 1/1000000th of a liter
µM – micromolar; 1/1000000th of a mole
-3 FA – omega-3 fatty acid
A – adenine
A20 – tumor necrosis factor alpha-induced protein 3
ABC – activated B-cell
Acetyl-CoA – acetyl coenzyme A
AICDA – activation-induced cytidine deaminase
AID – activation induced deaminase
AML – acute myeloid leukemia
ANOVA – analysis of variance
APOBEC – apolipoprotein B mRNA-editing enzyme, catalytic polypeptide
ARID1A – AT-rich interaction domain 1A

140

ARID1B – AT-rich interaction domain 1B
ARID5B – AT-rich interaction domain 5B
aSHM – aberrant somatic hypermutation
ATCC – American Type Culture Collection
ATM – ataxia telangiectasia mutated
ATP – adenosine triphosphate
ATR – ataxia telangiectasia and Rad3 related
B220 – CD45R
BCL2 – B-cell CLL/lymphoma 2
BCL6 – B-cell CLL/lymphoma 6
BCOR – BCL6 corepressor
BCR – B-cell receptor
BER – base excision repair
bp – base pair
BRD4 – bromodomain-containing protein 4
C – cytosine
C – degrees Celsius
CA – California
cAID – canonical AID
cAMP – cyclic adenosine monophosphate
CAR – chimeric antigen receptor
CBC – complete blood count
CBP – CREBBP
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CBX1 – chromobox 1
CBX8 – chromobox 8
CD – cluster of differentiation
CDKN1A – cyclin-dependent kinase inhibitor 1A
CDKN1B – cyclin-dependent kinase inhibitor 1B
cDNA – complementary DNA
CH3 – methyl group
CHD1 – chromodomain helicase DNA binding protein 1
CHD8 – chromodomain helicase DNA binding protein 8
CHEK1 – checkpoint kinase 1
ChIP – chromatin immunoprecipitation
ChIP-seq – chromatin immunoprecipitation followed by DNA sequencing
CHK1 – checkpoint kinase 1
CHK2 – checkpoint kinase 2
CHOP – cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine),
prednisone
CLL – chronic lymphocytic leukemia
CML – chronic myelogenous leukemia
CMP – comprehensive metabolic panel
CO2 – carbon dioxide
COO – cell of origin
CR – complete response
CREB – cAMP response element-binding protein
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CREBBP – CREB-binding protein
CRISPR – clustered regularly interspaced short palindromic repeats
CSR – class switch recombination
CTCF – CCCTC-binding factor
CTD – C-terminal domain
DAC – deacetylase
DDR – DNA damage response
DFS – disease-free survival
DHA – docosahexaenoic acid
DHL – diffuse histiocytic lymphoma
DICER1 – dicer 1, ribonuclease III
DLBCL – diffuse large B-cell lymphoma
DNA – deoxyribonucleic acid
DNA-DSB – DNA double-stranded break
DNase – deoxyribonuclease
DNMT – DNA methyltransferase
DNMT3A – DNA methyltransferase 3A
DSMZ – German Collection of Microorganisms and Cell Cultures
DZ – dark zone
E1A – adenovirus early region 1A
EBV – Epstein-Barr virus
ECL – enhanced chemiluminescence
EFS24 – 24-month event-free survival
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EP300 – E1A binding protein 300
EtOH – ethanol
EZH2 – enhancer of zeste 2 polycomb repressive complex 2 subunit
F1 – first filial generation
FAM-MGB – fluorescein amidite-minor groove binder
FBS – fetal bovine serum
FBXO11 – F-box only protein 11
FDC – follicular dendritic cell
FISH – fluorescent in situ hybridization
FL – follicular lymphoma
g – gravitational force; g-force
G – guanine
G2/M – Gap 2/Mitosis
GAPDH – glyceraldehyde 3-phosphage dehydrogenase
GC – germinal center
GCB – germinal center B-cell
GEP – gene expression profiling
GSEA – gene set enrichment analysis
H3 – histone H3
H3K4 – lysine 4 of histone H3
H3K4me1/2/3 – mono-, di-, and trimethylation at lysine 4 of histone H3
H3K9Ac – acetylation at lysine 9 of histone H3
H3K9me3 – trimethylation at lysine 9 of histone H3
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H3K18 – lysine 18 of histone H3
H3K18Ac – acetylation at lysine 18 of histone H3
H3K27 – lysine 27 of histone H3
H3K27Ac – acetylation at lysine 27 of histone H3
H3K27me1/2/3 – mono-, di-, and trimethylation at lysine 27 of histone H3
H3K36me3 – trimethylation at lysine 36 of histone H3
H3K79me2 – dimethylation at lysine 79 of histone H3
H3S10P – phosphorylation at serine 10 on Histone H3
H4 – histone H4
H4K5Ac – acetylation at lysine 5 of histone H4
H4K8Ac – acetylation at lysine 8 of histone H4
H4K12Ac – acetylation at lysine 12 of histone H4
H4K16Ac – acetylation at lysine 16 of histone H4
HAT – histone acetyltransferase
HDAC – histone deacetylase
HDAC3 – histone deacetylase 3
HDACi – histone deacetylase inhibitor
H&E – hematoxylin and eosin
HIST1H1E – histone cluster 1 H1 family member E
HIST1H2BC – histone cluster 1 H2B family member C
HIV – human immunodeficiency virus
HL – Hodgkin’s lymphoma
HPC – hematopoietic progenitor cells
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HRP – horseradish peroxidase
IFN – interferon
IFRT – involved-field radiation therapy
IgA – immunoglobulin A
IgE – immunoglobulin E
IgG – immunoglobulin G
IgM – immunoglobulin M
IgV – variable region of immunoglobulin
IHC – immunohistochemistry
IL – interleukin
IL4 – interleukin 4
IMDM – Iscove’s Modified Dulbecco’s Medium
INO80 – INO80 complex ATPase subunit
IPA – Ingenuity Pathway Analysis
IRF4 – interferon regulatory factor 4
KAT – lysine acetyltransferase
KDM1 – lysine-specific histone demethylase 1
KDM5 – lysine-specific demethylase 5
KMT2D – lysine methyltransferase 2D
LDH – lactate dehydrogenase
lincRNA – long intergenic noncoding RNA
LPS – lipopolysaccharide
LZ – light zone
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MACOP-B – methotrexate, leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone,
bleomycin
Mb – megabase
m-BACOD – methotrexate, leucovorin, bleomycin, doxorubicin, cyclophosphamide, vincristine,
dexamethasone
MDM2 – murine double minute 2
MEF2B – myocyte enhancer factor 2B
MHC – major histocompatibility complex
min – minutes
miR – microRNA
MIR155HG – microRNA 155 host gene
mL – milliliter; 1/1000th of a liter
MLL2 – myeloid/lymphoid or mixed-lineage leukemia 2
MLL3 – myeloid/lymphoid or mixed-lineage leukemia 3
MLL4 – myeloid/lymphoid or mixed-lineage leukemia 4
mM – millimolar; 1/1000th of a mole
MMR – mismatch repair
M-PER – Mammalian Protein Extraction Reagent
mRNA – messenger RNA
MU – Marshall University
MYC – myelocytomatosis
n – sample size
N2 – nitrogen
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NBC – naïve B-cells
NCI – National Cancer Institute
NCOR1 – nuclear receptor corepressor 1
NCOR2 – nuclear receptor corepressor 2
NF-kB – nuclear factor kappa B
ng – nanogram; 1/1000000000th of a gram
NGBC – normal germinal center B-cells
NHEJ – nonhomologous end-joining
NHL – Non-Hodgkin’s lymphoma
NIGMS – National Institute of General Medical Sciences
NIH – National Institutes of Health
NOTCH2 – Notch receptor 2
OCI – Ontario Cancer Institute
ORCID – Open Researcher and Contributor ID
ORR – overall response rate
OS – overall survival
p – p-value
p21 – CDKN1A
p53 – tumor protein 53
p300 – E1A binding protein 300
PCA – principal component analysis
PCR – polymerase chain reaction
PET – positron emission tomography
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PET/CT – positron emission tomography with computed tomography
Pol  – DNA polymerase eta
PR – PRDF1-RIZ homology domain
PRC1 – polycomb repressor complex 1
PRC2 – polycomb repressor complex 2
PRDM1 – PR/SET domain 1
P-TEFb – positive transcription elongation factor B
PTM – post-translational modifications
PVDF – polyvinylidene fluoride
qRT-PCR – real-time quantitative reverse transcription polymerase chain reaction
R-CHOP – rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin
(vincristine), prednisone
RII – research infrastructure improvement
RNA – ribonucleic acid
RNA Pol II – RNA Polymerase II
RNA-seq – RNA sequencing
RPMI – Roswell Park Memorial Institute
RR – remission rate
RT – radiation therapy
SDS/PAGE – sodium dodecyl sulfate/polyacrylamide gel electrophoresis
sec – seconds
SEER – Surveillance, Epidemiology, and End Results Program
SEM – standard error of the mean
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SET – Su(var) 3-9, enhancer-of-zeste, and Trithorax
SETD1B – SET domain containing 1B, histone lysine methyltransferase
SETD2 – SET domain containing 2, histone lysine methyltransferase
SETD5 – SET domain containing 5
SETDB1 – SET domain bifurcated histone lysine methyltransferase 1
SHM – somatic hypermutation
shRNA – short hairpin RNA
SMARCA4 – SWI/SNF Related, Matrix Associated, Actin Dependent
SMRT – silencing mediator of retinoid and thyroid hormone receptors
SRBC – sheep red blood cells
SWI/SNF – switch/sucrose non-fermentable
T – thymine
TCGA – The Cancer Genome Atlas
TDG – thymine DNA glycosylase
TET – ten-eleven translocation
TET2 – tet methylcytosine deoxygenase 2
TFH – T follicular helper
TLR – Toll-like receptor
TMB – tumor mutational burden
TNF – tumor necrosis factor
TNFAIP3 – tumor necrosis factor alpha-induced protein 3
TP53 – tumor protein 53
TSS – transcription start site
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U – uracil
US – United States
USA – United States of America
UV – ultraviolet
VDJ – variable diversity joining
WHO – World Health Organization
WT – wild-type
WV-INBRE – West Virginia IDeA Network of Biomedical Research Excellence
x – fold concentration
Y641 – tyrosine residue 641
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